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Stel/ingen behorende tot het p;oeftc'hrift: 
THE PERIODONTAL INFLAMED SURFACE AREA AS INFLAMMATORY BURDEN 
IN DIABETES AND RHEUMATOID ARTHRITIS PATIENTS 
1. De chronische infectie- en ontstekingslast veroorzaakt door parodontitis vormt een risico voor 
de algemene gezondheid. (dit proefschrift} 
2. De 'Periodontal Inflamed Surface Area' (kortweg PISA} geeft de hoeveelheid ontstoken 
parodontaal weefsel weer en is daarom het best beschikbare instrument om de ontstekingslast 
die door parodontitis wordt veroorzaakt te kwantificeren. (dit proefschrift) 
3. Om een goede mond- en algemene gezondheid te handhaven, zullen maatregelen om de 
parodontale gezondheid te bewaken onderdeel uit moeten gaan maken van de zorg voor 
mensen met type-2 diabetes. (dit proefschrift} 
4. Parodontitis komt vaker voor bij patienten met reumato'ide artritis en de behandeling van 
parodontitis kan bijdragen aan het verlagen van de ziekteactiviteit van reumato'ide artritis. (dit 
proefschrift) 
5. De aanwezigheid van gecitrullineerde eiwitten in parodontitisweefsel zou een rol kunnen 
spelen bij de vorming van auto-antistoffen tegen gecitrullineerde eiwitten, welk mechanisme 
vermoedelijk een rol speelt in de etiologie van reumato'ide artritis. (dit proefschrift} 
6. Leren begint met nederigheid, erkennen dat je iets nog niet weet of kunt. De grootste uitdaging 
van 'life long learning' is daarom je !even lang nederig te blijven. 
7. Gezien onderzoek grotendeels met publiek geld gefinancierd wordt, is het vreemd dat er, 
zeker in verhouding tot het toegankelijk maken van onderzoeksresultaten voor vakgenoten, 
weinig aandacht wordt besteed aan het toegankelijk maken van onderzoeksresultaten voor het 
publiek. 
8. Ook in de wetenschap kun je naar hetzelfde kijken, maar het toch verschillend zien. 
g. Computervirussen vormen een steeds groter gevaar voor de volksgezondheid. 
10. Het woord 'langs-elkaar-heen-leving' doet meer recht aan de manier waarop we !even dan het 
woord 'samenleving'. 
11. Gezien de substantiele bijdrage van de Islam aan 'de Verlichting', is het ridicuul om de wortels 
van onze Westerse beschaving als een !outer Joods-Christelijke erfenis te beschouwen. 
12. "There are only two ways to live your life. One is as though nothing is a miracle. The other is as 
though everything is a miracle." - Albert Einstein 
13. "Truly, God does not change the condition of a people, until they change what is in themselves." 
Quran 13=11 
14. Men moet geen spelletje spelen met het spelletjes spelen. 
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Past Presumptions, Present Knowledge 
B{, Future Puzzles 
I Past Presumptions The concept of oral health being closely linked to overall health has stood the test of time. Perhaps the oldest known report of this association originates from an 
Egyptian medical text dating back over 4000 years (2100 BC), in which a relation­
ship between toothache and diseases of the female genital system is described 
[1]. In a text dating back 2700 years, a physician at the court of King Ashurbanipal 
of Assyria, blamed the king's headache and the pain in his arms and feet on the 
condition of the king's teeth, consequently removal of these teeth was advised 
[2]. Hippocrates (460 -370 BC) wrote of an association between periodontitis and 
rheumatoid arthritis. He described a patient with 'rheumatism' being cured after 
extraction of a single tooth. Anthonie van Leeuwenhoek (1683) was the first to 
draw attention to the presence of many "tiny little creatures" living in the mouth 
(Fig. 1). He thought that a lack of oral hygiene promoted the growth of these 
micro-organisms. 
In 1891, the American dentist Miller drew attention to a large variety of diseases 
that might be caused by micro-organisms inhabiting the mouth [3]. He assumed 
that oral micro-organisms could spread elsewhere through the human body and 
could thereby be a source of infection and a major cause of many diseases. Bill­
ings [4] coined the term "focal infection theory" for Miller's postulation, and rec­
ommended rigorous removal of any potential oral source of infection in order 
to safeguard overall health. As the theory of focal infection gained support, con­
servative dental treatment was abandoned in favor of extractions. However, it 
quickly became apparent that removal of potential sources of infection by extract­
ing teeth, rarely cured illnesses. Around 1940 the practice of extracting teeth to 
root out sources of infection was quickly dropped. 
Present Knowledge 
Periodontitis Poses an Inflammatory Burden 
With the appearance of two Finnish studies in 1989, showing periodontitis was 
associated with myocardial and cerebral infarction, the theory of focal infection 
gained new interest [5,6]. Although the spread of bacteria through the rest of 
the body is now no longer considered as being a major cause of diseases, the 
chronic low grade systemic infection and inflammation associated with periodon­
titis are thought to contribute to the development and deterioration of diseases 
like cardiovascular diseases [7,8] and diabetes mellitus [9,10]. On the one hand, 
circulating oral bacteria might provoke distant infections, i.e. beyond the oral 
cavity, thus posing an inflammatory burden [11-13]. On the other hand, periodon­
titis may pose an inflammatory burden directly, through the production of local 
inflammatory mediators entering the circulation [14,15]. Periodontitis increases 
serum levels of CRP, I L-6 and TN Fa, which may for example lead to insulin res is-
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Figure 1 "I have had several gentle women in my house, who were keen on seeing the little eels 
in vinegar; butsome of 'em were so disgusted that they vowed they'd ne'er use vinegar again. But 
what if one should tell such people in future that there are more animals living in the scum on the 
teeth in a man's mouth, than there are men in a whole kingdom?" Anthonie van Leeuwenhoek 
tance and thereby to poor control of blood glucose in patients with type 2 diabe­
tes mellitus (DM2) as well as healthy individuals [16-18]. In addition to CRP, IL-6 
and TN Fa, periodontitis increases serum levels of fibrinogen. Increased serum 
levels of these substances have been associated with an increased risk of cardio­
vascular diseases [5,19-21]. In other words, periodontitis appears to be a chronic 
low-grade source of infection and inflammation that may endanger overall health 
by contributing to development and deterioration of diseases like diabetes mel­
litus and cardiovascular diseases. 
Strength of Evidence of Periodontitis as a Health Hazard 
The strength of scientific evidence is often rated according to the design of the 
study. Although there are different systems rating the strength of evidence, the 
highest level of evidence (level I) is usually given to randomized controlled clini­
cal trials or meta-analyses of such studies, while the lowest level of evidence 
(level Ill) is given to expert opinions and case reports [22] (Table 1). In addition 
to this hierarchy based on study design, how well the study design is executed 
11 
I 
I is also graded. Although there are again different systems to grade how well the study design is executed, one of the most straigthforward ways is grading the execution of study design as "good", "fair" or "poor". A study meeting all criteria 
appropriate for the study design is judged as "good", a "fair" study does not 
meet all criteria, but contains no fatal fiaws, while a "poor" study contains fatal 
fiaws [22]. Thus, the highest possible level of evidence, randomized controlled 
trials that are executed according to all criteria appropriate for the study design, 
is graded as level I-good, while the lowest possible level of evidence, e.g. a case 
report that has fatal flaws in it's study design, is graded level I I I-poor. 
Periodontitis has been implicated as a risk factor for a large variety of diseases. 
Of these, most evidence has accumulated on periodontitis as a risk factor for 
diabetes, cardiovascular diseases and preterm low birth weight delivery. There is 
strong evidence (level I-fair to good) from meta-analyses of randomized control­
led clinical trials that treatment of periodontitis in patients with diabetes mellitus 
type 2 reduces HbA1c by 0-4% [9,10]. A reduction in HbA1c of 0.9% is associated 
with a 10% decrease in the chance of dying from diabetes associated cardiovas­
cular complications [23]. Thus, although the effect on HbA1c is small, prevention 
and treatment of periodontitis may contribute substantially to an improved over­
all health and reduced mortality in diabetes mellitus type 2 patients. 
Recent meta-analyses of observational studies have shown there is level I l-2-
good evidence of a periodontitis associated increased risk of cardiovascular dis­
ease, estimated relative risks being 1.1 and 1.3 [7,8]. With cardiovascular disease 
still being the number one cause of death worldwide, such a small increase may 
be highly relevant in preventing morbidity and mortality. However, whether perio­
dontitis prevention and treatment reduces this risk, remains to be investigated . 
There is level I l-2-fair evidence of periodontitis being associated with an in­
creased risk of preterm low birth weight delivery with odds ratios of 4 to 8 [24]. 
Again, the potential of treating periodontitis to reduce this risk remains to be in­
vestigated. Pre-eclampsia, a pregnancy complication characterized by hyperten­
sion and proteinuria, has also been reported to be associated with periodontitis 
(level ll-2 fair). However, randomized controlled trials do not report a reduction 
in the incidence of pre-eclampsia after periodontitis treatment (level I-fair) [25]. 
Therefore, it appears the observed epidemiological association between pre-ec­
lampsia and periodontitis is non-causal in nature, i.e. caused by a third, or multi­
ple third, factor(s): confounding. 
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Table 1. Hierarchy of research design 
Evidence obtained from at least one properly randomized controlled trial or 
systematic reviews and meta-analyses of such studies. 
11-r Evidence obtained from well-designed controlled trials without randomization. 
II-2 Evidence obtained from well-designed cohort or case- control analytic studies, 
p1eferably frum more than one center or research group. 
II-3 Evidence obtained from multiple time series with or without the intervention. 
Dramatic results in uncontrolled experiments (such as the results of the intro­
duction of penicillin treatment in the 1940s) could also be regarded as this type 
of evidence. 
III Opinions of respected authorities, based on clinical experience, descriptive stud­
ies anci case reports, or reports of expert committees. 
Epidemiological associations have been reported between a large spectrum of 
other diseases and periodontitis, ranging from oral cancer to decreased fertility 
and sleep apnoea [26-28]. Obviously, these are not all causally related. Rather, 
these associations are at least in part based on confounding: periodontitis pres­
ence partly reflects poor overall health status. Factors like lifestyle (e.g. smoking 
and diet), socio-economic status, psychosocial factors and genes, cluster togeth­
er and exert a negative effect on oral as well as overall health [29]. Thus, causal 
and non-causal associations between periodontitis and other diseases appear to 
exist. Therefore, careful exploration of the existence and nature of these associa­
tions should take place. 
Future Puzzles 
Rheumatoid Arthritis 
One association that is in need of careful exploration is the association between 
periodontitis and rheumatoid arthritis as both epidemiologic associations and 
plausible mechanisms underlying the association have been reported. Studies 
appearing from 1990 report an increased prevalence and severity of periodontitis 
associated with rheumatoid arthritis [29-37]. Apart from the potentially increased 
prevalence and severity, some studies have implicated periodontitis as being an 
inducer of anti-citrullinated protein antibody formation [38-42]. Since anti-citrulli­
nated protein antibodies are suspected of playing an important role in the aetiol­
ogy of rheumatoid arthritis, by causing their formation, periodontitis might play a 
role in the aetiology of rheumatoid arthritis. 
Challenges facing the field of periodontal medicine 
Although the evidence from systematic reviews and meta-analyses lends support 
to periodontitis as a risk factor for other diseases, the same studies also point 
13 
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I out the need for more, larger, well-designed observational and experimental stud­ies to be performed [7-10,43-46]. Only few methodologically sound studies, with relatively small sample sizes, could be included in meta-analyses, as is evidenced 
by the large confidence intervals. Moreover, there appears to be a lack of consist­
ent results across different studies, as evidenced by statistical and clinical het­
erogeneity observed in meta-analyses. Thus, additional methodologically sound 
studies are needed to shed light on the magnitude, consistency and nature of the 
observed associations between periodontitis and other diseases. These studies 
should meet some of the following challenges still facing the field of periodontal 
medicine: 
1. Most studies assessing periodontitis as a risk factor for other diseases 
assessed periodontal status in a group of patients with a particular dis­
ease. Such case control studies are prone to selection bias. Selected 
populations, and observed associations, may not be representative 
of the general population. Furthermore, if proper blinding is not per­
formed, observer bias may occur. Knowledge of disease status may 
influence observers' measurements of periodontal status in favour of 
finding an increased prevalence of periodontitis among diseased versus 
control subjects. 
2. A great variety of definitions are used for periodontitis as a risk factor 
for other diseases. This poses major problems when trying to summa­
rize the available evidence in order to reach decisive conclusions. Many 
studies use a threshold value, separating the population into partici­
pants with and without periodontitis. Thresholds by their nature create 
dichotomous, (yes or no), or at best ordinal (mild, moderate, severe) 
results. This may be problematic since the current model for the bio­
logic plausibility of periodontitis as a risk factor for other diseases holds 
that the inflamed periodontium poses an inflammatory and infectious 
burden consisting of inflammatory mediators and / or oral bacteria en­
tering the systemic circulation. The larger the amount of inflamed perio­
dontium, the larger the inflammatory and infectious burdens may be. 
Therefore, it is crucial to have access to a tool that quantifies the amount 
of inflamed periodontal tissue, which diagnostic thresholds, by their na­
ture, fail to do. 
3- Two additional challenges facing the field of periodontal medicine are 
confounding and effect modification. As already mentioned above, perio­
dontitis and other diseases share many common risk factors like smoking 
and increasing age. Such factors may confound an observed association 
between periodontitis and other diseases, i.e. the observed association 
is caused solely by this third confounding factor. To complicate matters, 
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such a third factor may be an effect modifier instead of a confounder. In 
other words, a third factor effects the magnitude of the association be­
tween periodontitis and another disease. 
An example of an effect modifier that may exert an influence on associa­
tions between periodontitis and other diseases is nationality or ethnicity. 
Studies performed in different countries and among different ethnic pop­
ulations show different results as to the magnitude [47,48], and some­
times the very existence, of associations between periodontitis and other 
diseases [49]. Differences in environment, life-style and genes associated 
with differences in nationality and ethnicity are known to affect the sus­
ceptibility to certain diseases and may therefore also affect the associa­
tions between periodontitis and other diseases. Therefore, results from 
one study cannot automatically be generalized to another population. 
SCOPE OF THE THESIS 
Studies performed in this thesis aimed to tackle some of these challenges. Conse­
quently, the overall aim of this thesis was to assess the effects of the inflammatory 
burden posed by periodontitis on overall health, and more specifically on overall 
health of diabetes type-2 and rheumatoid arthritis patients. 
The aim of the study presented in chapter 2 was to explore associations be­
tween periodontitis and a broad range of other diseases in a sample of the general 
population living in the North of the Netherlands, while controlling for the most 
important confounders. This study aimed to meet the challenges of selection and 
information bias, confounding and the inability to generalize results from other 
studies to the Dutch population. 
The aim of the study presented in chapter 3 was to create a continuous meas­
ure reflecting the amount of inflamed periodontal tissue that might be universally 
applied. This study aimed to meet the major challenge of finding a definition of 
periodontitis that quantified the amount of inflamed periodontal tissue. Thereby, 
this measure could be assumed to quantify the inflammatory burden posed by 
periodontitis and, simultaneously quantify the risk periodontitis poses to overall 
health. To meet the challenge of the incomparability of research results created 
by the great variety of definitions used for periodontitis as a risk factor for other 
diseases, this study additionally aimed to create a tool that would make this new 
definition easily and broadly applicable. 
The aim of the study described in chapter 4 was to compare the prevalence and 
severity of periodontitis between patients with diabetes type-2 and healthy sub-
15 
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I jects in Indonesia. To assess the effect of using different measures to define peri­odontitis on differences in the prevalence and severity of periodontitis between Indonesians with diabetes type-2 and healthy controls, many different methods 
to define periodontitis were used, including the newly developed measure that 
quantified the amount of inflamed periodontal tissue. 
In conjunction with the previous study performed in the Netherlands an ad­
ditional aim was to assess the influence of nationality and ethnicity on observed 
associations between periodontitis and diabetes. This specific population was 
chosen since Asians constitute 60% of the world's population, Indonesia is the 
4th most populous country in the world, and Indonesia is in the top ten of coun­
tries with the highest number of diabetes patients in the world. 
The study described in chapter 5 assessed whether the amount of inflamed per­
iodontal tissue was associated with HbA, c (glycosylated hemoglobin, as a meas­
ure of blood glucose control over a prolonged period of time), while controlling 
for confounding and effect modification, in a group of Indonesian type-2 diabetes 
patients and healthy controls. This study sought to meet the challenge of finding 
the underlying nature of an association between periodontitis and blood glucose 
control, by assessing the amount of inflamed periodontal tissue and relating it 
to both measures of systemic inflammation (e.g. CRP) as well as to HbA1c, while 
controlling for a broad range of potential confounders (age, sex, BMI, socio eco­
nomic status, smoking and plaque control). 
The aim of the study described in chapter 6 was to assess whether a dose re­
sponse relationship existed between the amount of inflamed periodontal tissue 
and HbA1c in a group of African American diabetes type-2 patients. This study 
aimed to meet the challenge of validating the new continuous variable reflect­
ing the amount of inflamed periodontal tissue, by assessing convergent validity 
i.e. the degree to which a measure correlates with a measure it is supposed to 
predict. The validation process was performed in this specific population since 
strong evidence is accumulating on periodontitis as a risk factor for diabetes 
type-2, and African-Americans are known for their increased susceptibility to dia­
betes type-2. 
The aim of the study described in chapter 7 was to systematically review the 
current literature to answer the following questions: I) is periodontitis prevalence 
and severity increased in rheumatoid arthritis patients and 1 1 ) does treatment 
of periodontitis reduce rheumatoid arthritis disease activity? This study aimed 
to summarize the best available evidence on the observed epidemiological as­
sociation between periodontitis and rheumatoid arthritis quantitatively, in a non-
1 6  
biased, reproducible way. Since a few randomized controlled trials indicated that 
treatment of periodontitis reduces disease activity of rheumatoid arthritis, the 
best available evidence on this topic was summarized in a similar fashion. 
The aim of the study described in chapter 8 was to explore the potential pres­
ence of citrullinated proteins in periodontal tissue of patients with periodontitis. 
This study sought to meet the challenge of exploring the nature underlying the 
observed association between periodontitis and rheumatoid arthritis. Anti-citrull­
inated protein antibodies are suspected of playing an important role in the aetiol­
ogy of rheumatoid arthritis. Some studies reported that periodontitis contains all 
of the ingredients necessary to induce anti-citrullinated protein antibody produc­
tion. However, whether the most basic ingredient needed for anti- citrullinated 
protein antibody formation, i.e. citrullinated proteins, was present in periodonti­
tis tissue remained unknown. This study sought to address this important issue. 
1 7  
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Increased Prevalence of Cardiovascular 
and Auto-immune Diseases in Periodontitis 




Background: Associations between periodontitis and cardiovascular and autoim­
mune diseases are most often assessed in patients with a particular cardiovas­
cular or autoimmune disease. To prevent selection bias, this study assessed the 
existence of associations between periodontitis and cardiovascular and autoim­
mune diseases in patients attending a dental or periodontal clinic. 
Methods: Data were collected from 1276 randomly selected dental records from 
patients attending a dental (n=588) or periodontal (n=688) clinic. Data on the 
prevalence of cardiovascular and autoimmune diseases were obtained from a 
validated health questionnaire. Data on the presence of periodontitis were taken 
from patients' dental records. 
Results: In uncontrolled analyses, the prevalence of hypertension, diabetes melli­
tus (DM) and rheumatoid arthritis (RA) is significantly increased in periodontitis 
patients. Controlled for confounding, periodontitis was associated with DM, with 
an Odds Ratio of 4.0 (1.03-15.3), in the dental clinic. DM was not associated with 
periodontitis in periodontal clinics. Hypertension does not appear to be associ­
ated with periodontitis when controlling for confounders. Periodontitis might be 
associated with RA in both clinics types. 
Conclusions: The increased prevalence of cardiovascular and auto-immune dis­
eases among periodontitis patients attending dental or periodontal clinics may, 
at least in part, be influenced by confounding. However, the increased prevalence 




Periodontitis is a chronic infiammatory disease of the teeth supporting tissues. 
Severe generalized periodontitis affects 5 to 15% of any population worldwide and 
is a major cause of tooth loss 1. However, periodontitis appears to affect more than 
just the teeth supporting tissues. Studies have reported associations between 
periodontitis and cardiovascular and autoimmune diseases2•5 like myocardial 
infarction6•7, hypertension8, stroke9·1 0, diabetes mel litus (DM)1 ,., 6 and rheumatoid 
arthritis (RA)17•20• 
The underlying causes of such associations could be fourfold. First, a disease 
may predispose to the development of periodontitis. Second, the reverse may be 
true, periodontitis may predispose to the development of certain diseases. Third, 
there may be no effect of a disease on periodontitis and no effect of periodontitis 
on that disease. The association between periodontitis and that disease would 
then be a coincidental finding caused by a "third" confounding factor. Fourth, peri­
odontitis may indeed cause certain diseases, but only in the presence of a "third" 
modifying factor. It is also possible that al l these mechanisms col lectively cause 
association between periodontitis and a certain disease. Whatsoever the nature of 
associations between periodontitis and cardiovascular and autoimmune diseases 
may be, the existence of such associations may be relevant to the prevention of 
both periodontitis as well as other diseases. 
Since several studies did not find a significant association between periodonti­
tis and cardiovascular or autoimmune diseases21 -26, the existence of associations 
between periodontitis and cardiovascular and autoimmune diseases is still not 
proven beyond doubt. Furthermore, studies that did find a significant associa­
tion, most often assessed periodontal status within groups of patients with a par­
ticular cardiovascular or autoimmune disease. Selecting groups of patients with a 
particular cardiovascular or autoimmune disease may lead to selection bias. The 
selected patients may not be representative for al l patients with a cardiovascular 
or autoimmune disease, nor of patients attending a dental or periodontal clinic. 
Therefore, it is unknown whether associations between periodontitis and cardio­
vascular and autoimmune diseases exist in patients attending a dental or peri­
odontal clinic. The aim of this study was to assess the existence of associations 
between periodontitis and cardiovascular and autoimmune diseases in a random 
selection of patients attending a dental or periodontal clinic. 
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SUBJECTS AN D METHODS 
Subjects 
Data were collected from a convenient sample of 1276 randomly selected dental 
records, 588 patients attending a dental clinic and 688 patients attending two peri­
odontal clinics. Selection was performed by randomly picking letters and including 
all patients whose family name started with randomly selected characters. 
The dental clinic was located in the northern part of the Netherlands (Leeu­
warden). Patients attended this clinic for regular dental check-ups once or twice a 
year. The periodontal clinics were located in the northern (Groningen) and west­
ern (Amsterdam) part of the Netherlands, respectively. These periodontal clinics 
treated patients who were referred for specialist periodontal care. 
All patients attending the dental clinic were routinely screened for periodontitis 
using a Community Periodontal Index of Treatment Needs (CPITN)-based scor­
ing system27·28 in which Probing pocket depths (PPD) were measured on six sites 
per tooth, on all teeth, and the highest CPITN-score per sextant was recorded. In 
case all CPITN-scores were <3 in all sextants, indicating no PPD �4mm (defined 
as health to gingivitis), only CPITN scores per sextant were recorded. In case of 
any CPITN-score of a3, indicating PPD �4mm (defined as periodontitis), all PPD 
measurements, full mouth at six sites per tooth, were recorded. All patients at­
tending the specialist periodontal clinics underwent full mouth PPD measurement 
on six sites per tooth, all of which were recorded. Hence, full mouth PPD data were 
available for all patients with periodontitis. These data were used to calculate the 
number of sites affected by PPD �4 as a percentage of the total amount of probed 
sites (extend) and the mean PPD (severity). 
All patients in dental and periodontal clinics completed the same, extensively vali­
dated, self-reported health questionnaire29·30·31. Patients' responses to this question­
naire have previously been compared with the results of a verbal history, taken by an 
experienced physician (the 'gold standard'). The sensitivity, specificity and Cohen's 
Kappa of the medical questionnaire were shown to be o.88, 0.98 and 0.87 respective­
ly32. Information on the prevalence of cardiovascular and autoimmune diseases was 
obtained from this questionnaire. Additionally, use of medication was also available 
from the same health questionnaire. This information was used to verify patients' an­
swers regarding the presence or absence of cardiovascular or autoimmune diseases. 
Information on age, sex and smoking was obtained from patients' dental records. 
Inclusion criteria 
Records were included of dentate patients who were at least 18 years old, who 
completed the health questionnaire, and of whom a full mouth CPITN-based 
screening or full mouth PPD recording was available. When the interval between 
date of periodontal screening and date of completion of the health questionnaire 
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exceeded one year, records were excluded. 
This study was approved by the Medical Ethics Committee of the University Medi­
cal Center Groningen. 
Selection of other diseases and possible confounders 
In the current study cardiovascular (i.e. hypertension, myocardial infarction and 
stroke) and autoimmune diseases (i.e. DM, hypothyroidism and RA) were chosen 
from the health questionnaire for analysis on the basis of their reported associa­
tions with periodontitis2•20• The selection of these diseases from the health questi­
onnaire was performed prior to analysis. As potential confounders in the relation­
ship between periodontitis and cardiovascular and autoimmune diseases, sex, age 
and smoking habits were also assessed; these variables were also selected prior to 
analysis of their potential association with periodontitis. 
Statistical analyses 
Group 1 consisted of controls, viz. subjects attending the dental clinic without peri­
odontitis. Group 2 and 3 consisted of periodontitis patients attending, respectively, 
the dental clinic (group 2) and periodontal clinics (group 3) (tables 1 & 2). First, 
differences in the prevalence of cardiovascular and autoimmune diseases between 
three groups of patients were compared (groups 1, 2, and 3). In case of a significant 
difference between the 3 groups, pairwise comparisons were made (group 1 with 
group 2 and group 1 with group 3). Differences in the prevalence of cardiovascular 
and autoimmune diseases were tested for significance using the Chi-square test. 
Differences in potential confounders, age, sex and smoking, between patients were 
tested likewise; firstly overall (groups 1, 2 and 3), and in case of a significant differ­
ence, secondly pairwise using Chi-square tests and independent sample t-test as 
appropriate. Additionally, differences in confounders and disease prevalence be­
tween periodontitis patients attending dental or periodontal clinics (groups 2 and 
3) were tested for significance. For all pairwise comparisons, a Bonferroni-Holm 
correction for multiple statistical tests was used; adjusting the significance level of 
0.05 appropriately. 
Diseases that were found to be significantly more prevalent among patients 
with periodontitis in the univariate analyses were further analyzed using logistic 
regression (method: backward stepwise). On the basis of the outcomes of the 
logistic regression, the associations were expressed as Odds Ratios while control­
ling for potential confounding by age, sex and smoking. Smoking was entered into 
the model as o, for currently not smoking, or 1, for currently smoking. Age was 
entered as a continuous variable. Effect modification, i.e. interactions between 





R ES U LTS 
Patients' characteristics 
In the dental clinic, 91% of 588 randomly selected dental records met inclusion 
criteria (n=537, table 1, p24). The remaining 9% of the selected records (n=51) 
was mainly excluded because the interval between the date of periodontal screen­
ing and the date of completion of the health questionnaire exceeded one year. 
Full mouth PPD recordings were available for 72% (n=163) of all patients with a 
CPITN-score of �3 (n=225). In the remaining 28% of the patients with a CPITN­
score � 3 (n=62), full mouth PPD recordings were unavailable due to objection 
to full mouth screening for financial or other reasons. On average, 36% (median, 
with interquartile range: 21 to 52%) of all probed sites of patients with periodonti­
tis in the dental clinic were affected by median PPD of 4.9mm (interquartile range 
4.6 to 5.3mm). 
In the specialist periodontal clinics, 98% of 688 randomly selected records met 
the inclusion criteria (n=671). On average, 49% (median, with interquartile range 
30 to 72%) of all probed sites of patients with periodontitis in periodontal clinics 
were affected by median PPD of 5.2mm (interquartile range 4.8 to 5.7mm). Table 1 
shows patients' characteristics. 
Results of univariate, unadjusted analyses 
The prevalence of periodontitis in the dental clinic was 40% (table 1, group 2). 
Age and sex differed significantly among groups 1, 2 and 3 (p-values respectively 
<0.001 and 0.003). Patients with periodontitis in the dental clinic (group 2) were 
significantly older than controls (group 1; mean difference 8 years, p<o.001). Pa­
tients with periodontitis in the periodontal clinics (group 3) were on average 16 
years older than patients without periodontitis in the control group (p<o.001). 
Periodontitis patients from periodontal clinics were more often female (61 vs. 
48%, p<o.001), and were on average 8 years older (p<o.008) than periodontitis 
patients in the dental clinic. Data on smoking habits was available for 50% of 
patients attending the general dental clinic. In specialist periodontal clinics, data 
on smoking was present in 99% of cases (663 out of 671). Smoking differed sig­
nificantly between all groups and between groups 2 and 3 (p-values respectively 
0.018 and 0.026). 
Periodontitis patients from periodontal clinics had significantly more sit.es af­
fected by significantly deeper PPD (both p-values <0.001). 
Prevalence of hypertension, DM and RA differed significantly between all 3 
groups (table 2, p26, p-values respectively <0.001, 0.023 and 0.025). In the dental 
clinic the prevalence of hypertension was significantly higher in periodontitis pa­
tients compared to controls (p= 0.001). In periodontal clinics, the prevalence of 
hypertension, DM and RA was significantly higher than controls (p-values respec-
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Table 3. Odds ratios (95% Confidence Intervals) for cardiovascular- and autoimmune 
diseases associated with periodontitis. -
Dental Clinic, OR (95CI) o.6 (0.2 to 2.r) 4.0 (r.03 to 15.3)* 4.4 (0.5 to 39.6)** Periodontal Clinics, OR (95CI) r.2 (o.6 to 2.8) r.o (0.3 to 3.8) 4.1 (0.5 to 32.8)** 
Presented Odds ratio's (0 R) are from binary logistic regression analyses with age, sex and smoking included in the model. * The neutral value of I (no effect) is not included in the 95% confidence interval (95 CI), indi­cating a significantly increased OR (p<o.05) ** Periodontitis was kept in the final model to predict RA when controlling for age, sex and smoking. However, this yielded unrealistically high ORs. Therefore, presented ORs are from regression analyses not corrected for smoking. 
DM = Diabetes Mellitus, HT = Hypertension, RA =  Rheumatoid Arthritis 
tively <0.001, 0.008 and 0.004). There was no significant difference in the preva­
lence of any diseases between periodontitis patients from dental and periodontal 
clinics (groups 2 and 3, data not shown). 
Resu Its of logistic regression analyses 
When controlling for age, sex and smoking, the Odds Ratio (OR) of diabetes mel­
litus associated with having periodontitis was 4.0 (1.03 to 15.5) in the dental clinic 
(table 3). 
Periodontitis was kept in the regression models predicting RA presence in both 
dental and periodontal clinics, since the probability for stepwise removal was set 
at 0.10 (significance of change 0.060 and 0.063 for dental and periodontal clinics 
respectively, with change in -2 log Likelihood both 3.5). In dental clinic periodon­
titis was the only predictor that was kept in the model. In periodontal clinics, age 
and sex were additional predictors of RA. However, the OR of RA associated with 
having periodontitis in both clinic types was unrealistically large, as were confi­
dence intervals, when controlling for smoking. The OR of RA associated with hav­
ing periodontitis without controlling for smoking was 4.4 (0.5 to 39.6) and 4.1 (0.5 
to 32.8) in dental and periodontal clinics respectively (table 3). 
Other diseases didn 't show a significantly in- or decreased OR, nor was peri­
odontitis ever kept in the final regression model on the basis of which the presence 
of these diseases was predicted. 




troducing them as confounders) did not result in a significantly better regression 
model, nor in significant regression coefficients of these effect modifiers. 
DISCUSSION 
Most studies on associations between periodontitis and cardiovascular and au­
toimmune diseases, assessed periodontal status within a group of patients with 
a particular cardiovascular or autoimmune disease. To avoid selection bias, this 
study assessed these associations in a large random sample of patients attending 
general dental (n=537) and periodontal (n=671) clinics. Several conclusions can be 
drawn from the results. 
First, in univariate, unadjusted analyses, hypertension (HT) was significantly 
more prevalent among periodontitis patients in the dental clinic. DM was almost 
significantly more prevelant (p value 0.012, with significance level 0.010 using 
Bonferroni-Holm correction). HT, DM and RA were significantly more prevalent 
among periodontitis patients in the periodontal clinics. Given the random selec­
tion of patients attending these clinics, the increased prevalence of these cardio­
vascular and autoimmune diseases among periodontitis patients is probably not 
the result of selection bias. 
Second, when controlling for age, sex and smoking as potential confounders, 
the OR of DM was significantly increased (4.0, 95%CI: 1 .03 to 15.3) in periodontitis 
patients in the dental clinic. 
Third, the significantly increased prevalence of HT among periodontitis pa­
tients, may have been the result of confounding by age, sex and smoking, since no 
significantly increased OR's were found after controlling for these factors. 
Fourth, attempts to elucidate the nature of associations between periodontitis 
and RA, by controlling for the potential confounders age, sex and smoking, were 
hampered by the low prevalence of RA. There was only one RA patient without 
periodontitis (table 2). Smoking status of this RA patient without periodontitis 
was unfortunately unknown. When logistic regression analyses were performed 
controlling for smoking, periodontitis was kept in the final regression models pre­
dicting RA in dental and periodontal clinics. However, results from logistic regres­
sion analyses yielded unrealistically large ORs and confidence intervals (hence 
why ORs for RA were presented without controlling for smoking; table 3). 
Given the relatively low prevalence of some cardiovascular and autoimmune 
diseases, including RA, a case control study might have been more appropriate. 
However, the latter is highly susceptible to selection bias. In conclusion, the na­
ture of the observed association between periodontitis and RA remains unclear, 
but may be caused by more than just confounding. 
The relevance of the significantly increased OR of DM, controlled for confound­
ing, in the dental clinic, depends on whether this association can be generalized 
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to the general population, and on the nature of this association. Regarding gener­
alization, we did not use a population based sampling scheme to capture a repre­
sentative sample of the general population. Rather, a random sample of patients 
attending a dental clinic was taken, from an area of which 74% of the general pop­
ulation attends a dental clinic for a yearly check-up33 • Therefore, our sample might 
be representative of the general population in the North of the Netherlands. 
Regarding the nature of the association between DM and periodontitis, there 
may be a bilateral causal association between periodontitis and DM. On the one 
hand, DM may lead to periodontitis. Increased levels of blood glucose leads to 
altered local immune responses, delayed wound healing and increased chance 
of infections34• On the other hand, periodontitis may lead to DM. An inflamma­
tory burden, consisting of inflammatory mediators as TN F-a, I L-6 and I L-1 in the 
systemic circulation, alters lipid and glucose metabolism35, and induces insulin 
resistance36·37,38• This inflammatory burden posed by periodontitis may be quan­
tified by means of the Periodontal Inflamed Surface Area (P ISA)39• On a group 
level an increase in PISA has been shown to be associated with an increase in 
HbA1c in type-2 diabetics15• Finally, treatment of periodontitis has been shown to 
improve glycemic control in type 2 diabetics40·47• Therefore this association could 
be relevant to public health. However, this study by it's nature couldn't establish 
causality. 
The use of the CPITN to diagnose periodontitis in the dental clinic may be con­
sidered as a weakness of this study. However, full mouth PPD recording were avail­
able for 72% of patients with CPITN-score � 3. The results of these 72% show that, 
with an average number of 26 teeth, around which a median of 36% of probed 
sites exhibited median PPD of 4.9mm, patients with CPITN-score � 3 may, at least 
in our study, safely be regarded as having periodontitis48 • 
The use of questionnaires to assess general health might be considered as an­
other point of weakness of this study. However, all clinics used the same validated 
health assessment questionnaires. Previous studies have shown that this ques­
tionnaire had a sensitivity, specificity and Cohen's  Kappa of o.88, 0.98 and 0.87, 
respectively32• Thus, the questionnaire applied in this study may be considered as 
a sound indicator of the presence of cardiovascular and autoimmune diseases. 
A weakness of this study is that smoking status was available for only 50% of 
patients attending the dental clinic. Fortunately, there is no reason to assume any 
form of bias in the availability of data on smoking status, since data on smoking 
was available in approximately 50% of both periodontitis patients and healthy con­
trols. However, binary logistic regression analyses controlling for smoking (and 
age and sex) could only make use of those patients of which smoking status was 
known. Thus, sample size was reduced by 50%, thereby decreasing statistical pow­




diseases with a low prevalence. Furthermore, we could unfortunately not control 
for smoking duration and dose (packyears). 
In conclusion, there is an increased prevalence of cardiovascular and auto-im­
mune diseases among patients with periodontitis attending dental or periodontal 
clinics. The increased prevalence of DM and RA in periodontitis patients could 
not be explained by confounding. The increased prevalence of other diseases are, 
at least in part, caused by confounding (smoking, age, sex). Nevertheless, these 
findings might be relevant in safeguarding oral health, as these diseases may be 
regarded as risk indicators of periodontitis. 
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Periodontal Inflamed Suiface Area (PISA) : 




Background: Currently, a large variety of classifications is used for periodontitis 
as a risk factor for other diseases. None of these classifications quantifies the 
amount of inflamed periodontal tissue, while this information is needed to as­
sess the inflammatory burden posed by periodontitis. 
Aim: To develop a classification of periodontitis that quantifies the amount of 
inflamed periodontal tissue, which can be easily and broadly applied. 
Materials and methods: A literature search was conducted to look for a classifica­
tion of periodontitis that quantified the amount of inflamed periodontal tissue. 
A classification that quantified the root surface area affected by attachment loss 
was found. This classification did not quantify the surface area of inflamed peri­
odontal tissue, however. Therefore, an Excel spreadsheet was developed in which 
the Periodontal Inflamed Surface Area (PISA) is calculated using Clinical Attach­
ment Level (CAL), recessions and bleeding on probing (BOP). 
Results: The PISA reflects the surface area of bleeding pocket epithelium in square 
millimetres. The surface area of bleeding pocket epithelium quantifies the amount 
of inflamed periodontal tissue. A freely downloadable spreadsheet is available to 
calculate the P ISA. 
Conclusion: PISA quantifies the inflammatory burden posed by periodontitis and 
can be easily and broadly applied. 
I NTRODUCTION 
Periodontitis is a chronic inflammatory disease of the supporting tissues around 
the teeth. Severe generalised periodontitis affects 5 to 15% of any population 
worldwide and is a major cause of teeth loss (Burt 2005, AI-Shammari et al. 2005, 
Yoshida et al. 2001). Periodontitis may, however, affect more than teeth and their 
surrounding structures. Periodontitis is claimed to be a risk factor for a broad 
range of diseases such as cardiovascular diseases and stroke (Bahekar et al. 
2007, Janket et al. 2003, Khader et al. 2004, Scannapieco et al. 2003a) diabetes 
(Khader et al. 2006, Saremi et al. 2005), pneumonia (Scannapieco et al. 2003b) 
and preterm low birth weight ( Khader & Ta'ani 2005; Scannapieco et al. 2003c). 
The biological model for the plausibility of periodontitis as a risk factor for 
other diseases holds that periodontitis causes an inflammatory burden by elicit­
ing bacteraemia (Chiu 1999, Madianos et al. 2001), systemic inflammatory re­
sponses (Beck et al. 2005, D'Aiuto et al. 2004, Kweider et al. 1993, Montebugnoli 
et al. 2005, Southerland et al. 2006), or cross-reactivity leading to auto-immune 
reactions (Rosenstein et al. 2004, Bartold et al. 2005). This inflammatory burden 
in turn causes damage to the human body far beyond the oral cavity. Following 
this biological model, the larger the amount of inflamed periodontal tissue is, the 
larger the chances are of periodontitis eliciting bacteraemia, systemic inflamma­
tory responses or cross-reactivity. Therefore, any classification of periodontitis as 
a risk factor for other diseases should quantify the amount of inflamed periodon­
tal tissue in order to quantify the inflammatory burden. 
Many studies express periodontitis as a non-continuous variable. These stud­
ies use cut-off points to classify patients as being either unaffected or affected by 
mild, moderate or severe periodontitis. By definition, these classifications do not 
quantify the amount of inflamed periodontal tissue (Bahekar et al. 2007, Janket et 
al. 2003, Khader et al. 2004, Khader & Ta'ani 2005, Khader et al. 2006, Merchant 
& Pitiphat 2007, Scannapieco et al. 2003a, Scannapieco et al. 2003b, Scannapie­
co et al. 2003c). Some studies linking periodontitis to other diseases do quantify 
periodontitis as a continuous variable, i.e. using mean probing pocket depth or 
mean clinical attachment level (Bahekar et al. 2007, Janket et al. 2003, Khader et 
al. 2004, Khader & Ta'ani 2005, Khader et al. 2006, Merchant & Pitiphat 2007, 
Scannapieco et al. 2003a, Scannapieco et al. 2003b, Scannapieco et al. 2003c). 
Although these are continuous variables, this does not necessarily mean that 
these outcome measures quantify the amount of inflamed periodontal tissue. 
Thus, none of the classifications currently used expresses periodontitis as a con­
tinuous variable that is a measure of the amount of inflamed periodontal tissue. 
Hence these classifications may not quantify the inflammatory burden posed by 
periodontitis. 




tis as a risk factor for preterm low birth weight for example, 13 different classifica­
tions of periodontitis are being used (Khader & Ta'ani 2005, Scannapieco et al. 
2003c, Vettore et al. 2008). Broad application of just one classification of peri­
odontitis would allow for a better comparison of these studies, which may in turn 
provide decisive conclusions on periodontitis as a risk factor for other diseases. 
The goal of this paper was to develop a classification of periodontitis that 
quantifies the amount of inflamed periodontal tissue and which can be easily and 
broadly applied. 
MATERIALS AN D M ETH ODS 
Periodontal Inflamed Surface Area (PISA) 
Since no gold standard for periodontitis as a risk factor for other diseases exists, 
a list of demands was assembled for the construction of a new classification 
of periodontitis. The first and foremost demand was that the new classification 
should adequately quantify the amount of inflamed periodontal tissue. Second, 
the classification should be easy to use and broadly applicable. This means that 
the classification should make use of clinical measurements commonly used to 
establish periodontitis, i.e. Clinical Attachment Level (CAL), recession and Bleed­
ing On Probing (BO P) measurements. A literature search was performed to look 
for a classification of periodontitis that met these demands. 
A classification that quantified the total surface area of attachment loss was 
found (Hujoel et al. 2001). We will refer to this classification as the Attachment 
Loss Surface Area (ALSA). To calculate the ALSA, formulas were generated where­
by linear probing measurements, from the Cemento-Enemal Junction (CEJ) to the 
bottom of the pocket (i.e. CAL), around a particular tooth are transformed into 
the ALSA for that particular tooth (Despeignes 1979, Hujoel 1994, Hujoel et al. 
2001). 
The ALSA quantifies the root surface area that has become exposed due to 
attachment loss. However, the ALSA cannot be used to quantify the amount of 
inflamed periodontal tissue. ALSA does not quantify the Periodontal Epithelial 
Surface Area (PESA), because CAL instead of PPD measurements are used to 
calculate ALSA (fig 1, p42). To calculate the Periodontal Epithelial Surface Area 
(PESA), the Recession Surface Area (RSA) has to be subtracted from Attachment 
Loss Surface Area (ALSA) (fig. 1a and 16). Since ALSA = PESA + RSA, it can be de­
ducted that ALSA - RSA = PESA. To calculate the PESA there are three arithmetical 
possibilities, depending on the Location of the Gingival Margin (LGM): 
1 .  The LGM is below the CEJ so the Recession Surface Area (RSA) > o. In this 
case, PPD < CAL and thus PESA < ALSA. Therefore PESA = ALSA- RSA (fig 
1a) 
2. The Location of Gingival Margin (LGM) is exactly at the CEJ .  In this case, 
Probing Pocket Depth (PPD) = Clinical Attachment Level (CAL), RSA = o. 
Therefore PESA = ALSA (fig 1 b) 
3. The LGM is above the CEJ .  Since PPD > CAL, PESA > ALSA. Using CAL will 
lead to an underestimation of PESA. Calculating the PESA is only possible by 
using PPD instead of CAL, i.e. entering PPD as CAL in the formula transform­
ing linear measurements to surface area. This will still lead to an underesti­
mation of PESA (fig i c). 
Thus, PESA accurately quantifies the surface area of pocket epithelium if LGM 
is at or below the CEJ .  However, PESA does still not quantify the surface area 
of inflamed pocket epithelium. After all, the PESA also includes healthy pocket 
epithelium. Healthy pocket epithelium contains relatively few inflammatory cells 
and may pose an effective barrier against bacteria trying to enter the circulation 
(Amato et al. 1986, Caton et al. 1988, Thilo et al. 1986). Therefore, part of the 
PESA that consists of healthy epithelium may not contribute to the inflammatory 
burden. 
The inflamed part of the PESA on the other hand, does theoretically pose an 
inflammatory burden. To calculate the inflamed part of the PESA we propose 
calculating part of the PESA that is affected by Bleeding On Probing (BOP). After 
all, BOP reflects decreased collagen density, increased blood vessel density and 
fragility and a reduction of epithelial thickness and epithelial integrity (Amato 
et al. 1986, Davenport, J r. et al. 1982, Greenstein et al. 1981, Muller-Glauser & 
Schroeder 1982, Polson et al. 1981). Thin, fragile or even discontinuous pocket 
epithelium, may serve as an entrance for oral bacteria into the systemic circula­
tion. Furthermore, BOP is characterised by a dense infiltration of inflammatory 
cells (Caton et al. 1988, Thilo et al. 1986). These inflammatory cells may play a 
key role in eliciting a systemic inflammatory response or cross-reactivity. Thus, 
the bleeding surface area, the Periodontal Inflamed Surface Area (PISA), may be 
thought of as the main contributor to any systemic inflammatory burden posed 
by periodontitis. Therefore, the PISA is proposed as a classification of periodonti­
tis that quantifies the amount of inflamed periodontal tissue and as such, quanti­
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RESULTS 
Calculating Periodontal Inflamed Surface Area 
Using the formulas described by Hujoel et al. (2001), a Microsoft Excel spread­
sheet was constructed to facilitate PISA calculation. P ISA is calculated in seven 
steps: 
1. After completing the CAL measurements at six sites per tooth, the computer 
calculates the mean CAL for each particular tooth. 
2. The mean CAL around a particular tooth is entered into the appropriate for­
mula for the translation of linear CAL measurements to the ALSA for that 
specific tooth (Hujoel et al. 2001). 
3. After filling in recession measurements at six sites per tooth, the computer 
calculates the mean recession for each particular tooth. 
4. The mean recession around a particular tooth is entered into the appropriate 
formula for the translation of linear recession measurements to the RSA for 
that specific tooth (Hujoel et al. 2001). 
5. The RSA for a particular tooth is subtracted from the ALSA of that particu­
lar tooth, rendering the PESA for that specific tooth; i.e. PESA= ALSA- RSA 
(fig.,a and 1b} 
6. The PESA for a particular tooth is then multiplied by the proportion of sites 
around that tooth that was affected by BOP. For example, if three out of the 
maximum of six sites were affected by BOP, the PESA of that particular tooth 
was multiplied by 3/6, thereby rendering the Periodontal Inflamed Surface 
Area for that specific tooth. 
7. The sum of all individual PISA 's around individual teeth is calculated, 
amounting to the total P ISA within a patient's mouth. 
Next, PISA was calculated for three different patients. Patient 1 has a healthy 
periodontium; exhibiting limited BOP with CAL not exceeding 3mm (fig 2a, p44). 
Patient 2 has severe local periodontitis; exhibiting BOP with CAL ranging from 
6-1omm locally (fig 2b, p45). Patient 3 has severe generalised periodontitis; exhib­
iting widespread BOP with PPD ranging from 3 to 10mm (fig 2c, p46). PISA may 
thus range from 28.6 mm2 (::::: 0.3 cm2) in healthy individuals, to 3,899 mm2 (::::: 39 
cm2) in patients with severe generalised periodontitis (fig. 2). 
Spreadsheets are freely available from our website; www.parsprototo.info. All it 
takes to calculate PISA is filling in CAL, recessions and BOP on six sites per tooth 
in this freely downloadable spreadsheet. In addition to research purposes, the 
spreadsheet might also be used to show patients their surface area of bleeding 
pocket epithelium in square mm, illustrating the inflammatory burden periodon­
titis potentially poses to their body. 
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D I SCUSS I O N  
The great variation in  periodontal classifications used in the various studies and 
the lack of a tool that adequately assesses the inflammatory burden of periodon­
titis is a major drawback of the studies published on the periodontal inflamma­
tion - systemic disease interaction. Therefore, a new measure of periodontitis as 
a risk factor for other diseases was developed, the P ISA. P ISA reflects the surface 
area of bleeding pocket epithelium in square millimetres. P ISA is calculated us­
ing conventional CAL, recession and bleeding on probing measurements. PISA 
quantifies the amount of inflamed periodontal tissue, thereby quantifying the in­
flammatory burden posed by periodontitis. A freely downloadable spreadsheet 
is available to calculate PISA, therefore P ISA can be easily and broadly applied. 
Broad application of P ISA may provide decisive conclusions on periodontitis as a 
risk factor for other diseases. An additional advantage of the P ISA is that it can be 
retrospectively calculated using existing research data containing CAL, recession 
and BOP measurements. 
Although PISA is thought to be the best tool for assessment of the amount of 
periodontal inflamed tissue that is currently available, for several reasons PISA 
might not precisely quantify the amount of inflamed tissue. First, CAL, recession 
and BOP measurements used for the calculation of P ISA always include meas­
urement errors related to observer, instrument, teeth, patients and their inter­
actions. Second, the formulas transforming CAL and recession to surface area, 
use population based mean values of both root surface areas and root lengths. 
Thus, individual variations in root surface area and root length are not taken 
into account when calculating PISA. Third, P ISA quantifies the amount of in­
flamed periodontal tissue in two dimensions, whereas in fact periodontitis is a 
three dimensional inflammatory process, i.e. extending into the connective tissue 
around the root. For these reasons, P ISA may not precisely quantify the amount 
of inflammatory tissue. However, PISA likely quantifies the amount of inflamed 
periodontal tissue for each individual patient more accurately than any classifica­
tion currently used. 
PISA is, however, unable to accurately quantify the amount of inflamed peri­
odontal tissue in case of pseudo-pockets or gingival overgrowth, i.e. when the 
gingival margin is located above the CEJ (fig 1c) . In these cases, CAL will be 
smaller than PPD and ALSA will consequently be smaller than PESA. Therefore, 
using only CAL will underestimate the true PESA and thereby underestimate true 
PISA. Using PPD instead of CAL, i.e. entering PPD into the formula for CAL, will 
diminish this underestimation. However, given the conical shape of a root, it will 
still lead to a slight underestimation of true PISA. Fortunately, cases of gingival 
overgrowth are relatively rare, and often due to usage of mediation (e.g. anti­




certain diseases (e.g. leukaemia). These cases are not representative for the gen­
eral population. Therefore, PISA can be used in the majority of cases, i.e. when 
the gingival margin is located at or below the CEJ. In case the gingival margin is 
located above the CEJ, PISA might still be used by replacing PPD with CAL, taking 
into account that it will result in an underestimation of true PISA. 
Finally, PISA might not adequately predict the probability of periodontitis 
to cause other diseases, even if it would be possible to measure precisely the 
amount of inflamed periodontal tissue. For example, the type of inflammation 
might be more important in causing other diseases than the amount of inflam­
mation. Certain cells, proteins or inflammatory mediators might play a key role 
in causing other diseases. Furthermore, there might be a critical level of inflam­
mation that functions as a threshold. When the threshold is passed, a response 
is initiated that causes damage to the human body beyond the oral cavity. Finally, 
PISA does not take into account the type of microbiological flora. Certain oral mi­
cro organisms might play a key role in causing other diseases, e.g. Campylobacter 
rectus, Prevotella intermedia, Porphyromonas gingivalis and Peptostreptococcus mi­
cros (Beck et al. 2005, Chiu 1999, Madianos et al. 2001) . For these reasons, the 
PISA might not be the only determinant in predicting the probability of periodon­
titis to cause other diseases. When additional information on the role of certain 
inflammatory mediators or micro organisms in causing other diseases becomes 
available, this information and the PISA can be incorporated in a new model 
that predicts the probability of periodontitis to cause other diseases even more 
accurately. 
Although the PISA still has shortcomings, theoretically it appears to be a far 
better classification of periodontitis as a risk factor for other diseases than any 
classification currently used (face validity). The next step is to perform studies 
to analyse construct validity by means of correlating PISA with measures of the 
activity, severity or presence of other diseases. 
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Periodontitis prevalence and severity 




Background: The prevalence of diabetes mellitus type 2 (DM2) in Indonesia is high 
and still rising. Periodontitis is associated with DM2. No study has investigated 
this association in Indonesia, nor has any study investigated this association 
using a variety of methods to operationalize periodontitis. Therefore this study 
compared prevalence and severity of periodontitis in DM2 patients to healthy 
controls, using different methods to operationalize periodontitis. 
Methods: 78 DM2 and 76 healthy subjects underwent a full mouth periodontal 
screening assessing probing pocket depth, gingival recession, plaque index and 
bleeding on probing. Using these measurements, periodontitis prevalence and 
severity was operationalized in various ways. Differences in periodontitis preva­
lence and severity between DM2 and healthy subjects were analyzed using univar­
iate analyses. In regression analyses, periodontitis prevalence and severity were 
predicted on the basis of DM2 presence, controlling for confounders and effect 
modification. 
Results: Prevalence of periodontitis was significantly higher in DM2 patients com­
pared to healthy subjects, showing odds ratios of 5.0 and 6.1 . Likewise, periodon­
titis severity was significantly higher in DM2 subjects. 
Conclusion: Indonesian DM2 subjects had more prevalent and more severe perio­
dontitis than Indonesian healthy subjects, independent of confounding factors or 
the methods used to operationalize periodontitis. 
54 
I NTRODUCTION 
Diabetes mellitus (DM) is a chronic disease characterized by dysregulation of 
carbohydrate, protein and lipid metabolism. An elevation of blood glucose level 
(hyperglycemia) is the primary feature of DM and results from either a defect in 
insulin secretion by pancreatic beta cells, a decrease in insulin sensitivity, or a 
combination of both. The most common form of DM is DM type 2 (DM2), which 
accounts for 85% of all diabetes patients. 1 The estimated world wide prevalence 
of DM is 220.5 million, or 2.8 % of the world's population. DM currently is the 
twelfth leading cause of death in the world. The prevalence is estimated to rise 
up to 4.4%, putting DM in the top ten leading causes of death by 2030. 2• 3 With 
the increasing prevalence of DM, this already vast and world wide epidemic will 
increasingly pose serious problems to public health. These problems mostly arise 
from the complications associated with DM like myocardial infarction, cerebro­
vascular disease, retinopathy, nephropathy and neuropathy. 4 
Periodontitis is more prevalent and severe among patients with DM2 than 
among healthy controls. 5-7 Thus, DM2 may initiate or deteriorate periodontitis. 
However, the reverse could also be true, i.e. periodontitis may initiate or deterio­
rate DM2. The strongest support for this comes from studies showing that treat­
ment of periodontitis improves glycaemic control in DM2 patients. 8•13 Thus, there 
is an association between DM2 and periodontitis that appears to be bilateral 
causal in nature (i.e. one causes or deteriorates the other and vice-versa). 
The strength of associations between periodontitis and DM2 appears to differ 
geographically. Studies performed in different locations, i.e. performed among dif­
ferent ethnic groups, show different associations between periodontitis and DM2. 
5, 14·1 7 These differences in the strength of associations may, apart from differences 
in study design and data analysis, be based on genetic, dietary, cultural and other 
differences between ethnic groups. 18 Therefore, findings among one ethnic popu­
lation cannot automatically be generalized to another ethnic population. 
South East Asia hosts approximately 10% of the world's current population. 
With 240 million inhabitants, Indonesia is the 4th most populous country in the 
world. The prevalence of DM in South East Asia is 5.3%. 19 In Indonesia, the preva­
lence of DM in 2008 was 5.7%, 20 putting Indonesia in the top ten of countries with 
the highest number of DM patients in the world. By the year 2030, the estimated 
number of patients with DM in Indonesia will be over 20 million (approximately 
10% of the population). 2 With this high and rising prevalence of DM2 in Indone­
sia, periodontitis prevalence and severity may also rise. To the best of our knowl­
edge, only three studies report on the association between periodontitis and DM2 
in South East Asia; one in Thailand, 21 one is Singapore, 22 and one in Indonesia. 23 
Unfortunately, in the latter study, the way in which periodontitis was measured and 




type 1 and DM type 2 patients, leaving many questions unanswered. 
Another question that remains unanswered is the influence of using a par­
ticular method to operationalize periodontitis on the strength of an association 
between periodontitis and DM2. The use of different methods to operationalize 
periodontitis prevalence and severity may influence not only the strength of the 
associations between a given disease and periodontitis, but may even influence 
whether an association is observed at all. For example, in research linking peri­
odontitis to preterm low birth weight, 13 different methods have been used to op­
erationalize periodontitis. Depending on the method used, either an association 
24• 25 or no association 26 between periodontitis and preterm low birth weight was 
observed. The same may be true for periodontitis and D M2. 
Therefore, this study assessed prevalence and severity of periodontitis among 
D M2 patients in Indonesia, using multiple, commonly used methods to opera­
tionalize both periodontitis prevalence and severity. 
S U BJ ECTS AN D M ETHODS 
DM2 patients were recruited at three different sites, namely 1) Internal Medicine 
Dept. of the Dr. Sardjito Hospital, 2) Prof. Soedomo Dental Hospital, Faculty of 
Dentistry, Gadjah Mada University and 3) Diabetes Center of Yogjakarta Inter­
national Hospital, Indonesia. DM2 patients were diagnosed according to World 
Health Organization criteria: fasting blood glucose level �.126 mg/di and/or a post­
prandial blood glucose level �200 mg/di. 27 Healthy controls were recruited in Prof. 
Soedomo Dental Hospital. Inclusion criteria for all subjects in this study were an 
age 18 years or over, and having �8 remaining teeth. This study was approved by the 
Ethical Committee for Research of the Medical Faculty of Gadjah Mada University, 
Yogjakarta, Indonesia and was conducted from July 2008 until February 2009. 
To assess whether periodontitis prevalence and severity differed between DM2 
patients and healthy controls, 78 DM2 patients and 76 healthy controls, who gave 
informed consent, underwent a full mouth periodontal examination. Full mouth 
periodontal probing pocket depth (PPD), gingival recession, plaque score and 
bleeding on probing (BOP) measurements were performed on all teeth, on six 
sites per tooth. All permanent fully erupted teeth were examined with a manual 
periodontal colour coded standard probe (Dentsply, London, UK). Measurements 
were made in millimetres and were rounded to the nearest whole millimetre. CAL 
was defined as the distance from the cementa enamel junction (CEJ)  to the bot­
tom of the pocket/sulcus, and calculated as the mathematical sum of the PPD 
and gingival recession measurements 28• BOP was recorded as either present or 
absent within 30 seconds after probing at 6 sites per tooth. The number of miss­
ing teeth was also recorded. Plaque score was defined as being present or absent 
at 6 points on each tooth. 29 
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mean (SD) yr 
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26 (33%) 15% (0.3% to 29%) <0.05*:j: 
IO (13%) 0.182* 
o (0%) o.n9* 
3 (4%) o.no* 
*Results of Chi-square test, other results are the results of the independent samples t test 
tOnly diseases with a prevalence of at least 1% (i.e. 2 patients) were analyzed 
�:statistically significant difference (p < 0.05) between DM2 and controls 
95%CI: 95% Confidence Interval 
BMI: Body Mass Index 
DM2: Diabetes Mellitus type 2 
Education: (low: elementary & junior school, middle: high school, high: university) 
HbA1c: Glycosilated/Glycated Hemoglobin 
n: number of participants 





Periodontitis prevalence, extent and severity were operationalized using a variety 
of methods, all of which are currently used in literature studying the association 
between periodontitis and other diseases. All methods used to operationalize peri­
odontitis prevalence and severity were calculated using conventional clinical meas­
urements obtained during the full mouth periodontal examination. Periodontitis 
prevalence was operationalized by using two diagnostic threshold values; 1) having 
one site with PPD � mm and CAL �3 mm, 26 and 2) having one site with PPD �5 
mm and CAL �2 mm. 30 The following methods to operationalize periodontitis ex­
tent and severity were calculated using a freely accessible online spreadsheet (www. 
parsprototo.info, Microsoft Excel 2003 spreadsheet for Windows): the number of 
sites with PPD �. �5 and �6 mm, the numbers of sites with CAL �3, �. �5 and �6 
mm, mean PPD, mean CAL and the percentage of sites with BOP. 26 
Additionally, two recently introduced measures of periodontitis severity, the 
Periodontal Epithelial Surface Area (PESA) and the Periodontal Inflamed Surface 
Area (P ISA) 31 were both calculated using another freely downloadable spread­
sheet (www.parsprototo.info). PESA reflects the surface area of all pocket epi­
thelium in square millimetres, whereas PISA reflects the surface area of bleed­
ing pocket epithelium in square millimetres. PESA and P ISA are calculated using 
conventional CAL, gingival recession and BOP measurements. P ISA quantifies 
the amount of inflamed periodontal tissue and it is suggested that PISA thereby 
quantifies the inflammatory burden posed by periodontitis. 
Furthermore, all participants completed a validated general health assessment 
questionnaire, 32·34 to check for other medical conditions that might be a risk fac­
tor for periodontitis. The original questionnaire was translated from English into 
Indonesian, a reverse translation to English was made to check for potential dif­
ferences. No substantial differences were found. Additionally, ethnicity35, Body 
Mass Index (BMl)36, dental plaque, age, gender, smoking (pack years), and Socio 
Economic Status (SES, operationalized using level of education) were recorded 
for each participant, since these are potential determinants of periodontitis. 37 
To assure that healthy controls were not undiagnosed diabetes patients, all 
participants underwent venepuncture to obtain a blood sample. Blood glucose 
and glycosilated (glycated) haemoglobin (HbA1c) were determined for both DM2 
patient and healthy controls. Controls with a blood HbA1c level of 2!:6.5% were 
excluded from the analysis, to exclude latent DM2 status. 
Statistical analysis 
Differences in periodontitis prevalence, extent and severity between DM2 and 
healthy subjects were analyzed first using univariate analyses (i.e. the indepen­
dent sample t-test or Chi-square test as appropriate). Likewise, differences in 
potential predictors of periodontitis (namely: age, gender, BMI, SES, smoking, 
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Table 2. Differences in periodontitis p reva lence between hea lthy and DM2 subjects. 
Periodontitis 
prevalence -- -
46(71%) 72(92%) 21% 5.0 0.001* (9% to 32%) (1.8 to 13.3) 
PPD5&CAL2 20(31%) 57(73%) 42% 6.1 <0.001* 
(26% to 55%) (2.9 to 12.6) 
* Result of Chi-square test 
tstatistically significant difference (p < 0.05) between DM2 and controls 
OR: Odds Ratio's were calculated using binary logistic regression analyses controlling for 
confounders 
95%CI: 95% Confidence Interval 
DM2: Diabetes Mellitus type 2 
PPD: Probing Pocket Depth 
CAL: Clinical Attachment Loss 
PPD4&CAL3: participants with one site exhibiting both PPD 4 mm & CAL 3 mm, 
PPD5&CAL2: participants with one site exhibiting both PPD 5 mm & CAL 2 mm 
plaque score, number of teeth, ethnicity and other medical conditions) between 
DM2 patients and healthy controls were tested for significance using univariate 
analyses. In case both periodontitis prevalence, extent and severity and any of the 
potential predictors of periodontitis differed significantly between DM2 patients 
and healthy controls, the predictors of periodontitis other than DM2 might act as 
confounders or effect modifiers. 
Since periodontitis severity was operationalized as several interval variables 
(i.e. P ISA, or number of sites with PPD �mm), linear regression analyses (meth­
od: backward stepwise) were performed to predict periodontitis extent and sever­
ity on the basis of DM2 presence and the other potential predictors (age, gender, 
BMI, SES, smoking, plaque score, number of teeth, ethnicity and other medical 
conditions). To facilitate clinical interpretation of presented analyses, age was 
centered to it's mean (age -53.86). Since periodontitis prevalence was operation­
alized as two dichotomous variables, logistic regression analyses were performed 
in a similar way. Odds ratios and 95% confidence intervals were calculated us­
ing these logistic regression analyses. Interaction between different predictors of 
periodontitis was explored. Statistics were calculated using SPSS 16.0. 
R ES U LTS 
Of the original 76 healthy controls, 1 1  subjects were excluded because of HbA, c 
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T a b l e  3 .  D i ff e r e n c e s  i n  p e r i o d o n t i t i s  s e v e r i t y  b e t w e e n  D M 2  a n d  h e a l t h y  s u b j e c t s  
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The prevalence of periodontitis in DM2 subjects was significantly higher than 
healthy controls, regardless of the definition used (table 2, p59). The extend and 
severity of periodontitis was also significantly higher in participants with DM2 
when compared to controls, again independent of the method used to operation­
alize periodontitis severity (table 3, p6o). 
Age and hypertension were the only potential predictors of periodontitis preva­
lence and severity that differed significantly between DM2 and healthy subjects 
in the univariate analysis (table 1). In the multiple linear regression analyses, 
controlling for age and hypertension as potential confounders, DM2 remained a 
significant predictor of all measures of periodontitis severity (table 4, p62). Age 
was an additional predictor of periodontitis severity, together with DM2, when­
ever periodontitis severity was operationalized using CAL. Age did not modify 
the effect of DM2 on periodontitis severity. Hypertension was not a predictor of 
periodontitis prevalence or severity. 
D I SCUSS I O N  
This study revealed that Indonesian DM2 subjects had significantly increased 
prevalence, extent and severity of periodontitis compared to healthy Indonesian 
subjects. Moreover, the increased prevalence, extent and severity of periodonti­
tis among Indonesian DM2 subjects were independent of the methods used to 
operationalize periodontitis. Furthermore, the increased prevalence, extent and 
severity of periodontitis appeared independent of confounding factors (i.e.: age, 
gender, smoking, BM I, ethnicity, SES and other medical conditions). 
Age was an additional predictor of all methods that used CAL to operationalize 
periodontitis severity. This could have been expected since CAL reflects the accu­
mulation of damage sustained by the periodontium over time. In other words, with 
increasing age, CAL increases. Nevertheless, DM2 remained a significant predic­
tor of every method used to operationalize periodontitis prevalence and severity. 
Prior to the study we did not perform a formal sample size calculation al­
though this study is the second on periodontitis and DM2 in Indonesia. From 
the first study on this topic it is not clear how periodontitis was measured and 
defined.23 Neither was a distinction made between DM type 1 and DM2 patients 
in that study. In a post-hoc power analysis it appeared that we had a power of 
.92 to find a difference in prevalence of periodontitis of 21%, between controls 
(n=65, prevalence=71%) and DM2 patients (n=78, prevalence=91%). A sample of 
50 DM2 patients and 50 controls would have been enough to detect this differ­
ence (Power: 0.80). 
A limitation of this study is that we did not use a population based sampling 
scheme to select DM2 patients. However, Indonesian DM2 patients regularly 




Table 4. DM2 and age as statistical pred ictors of periodontitis extent and severity: 
Resu lts of mu lt ip le  l i near regress ion ana lyses with periodontiti s operationa l ized accord­
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0.03 
327-49 0.18 <0.05 
863-04 <0.001 
0.04 
275-29 0.19 <0.05 
154.06 0.089 
0.II 
I0.65 o.34 <0.001 
14.23 <0.001 
0.12 
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4·92 <0.05 
0.10 
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1.35 0.254 
0.07 
3-70 0.26 0.002 
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0.43 to 8.56 
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1.36 to 6.03 
-0.97 to 2.47 
0.19 to 0.54 
qo to 1.96 
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t a p-value of so.05 was considered statistically significant 
p = probability 
�: unstandardized coefficient 
95%CI: 95% Confidence Interval 
Independent variables: 
Age centered = Age- Mean age 
Constant and 






Dependent variables (periodontitis severity measures) are underlined: 
BOP: Bleeding On Probing 
Number of sites with CAL: Clinical Attachment Loss �. �4. �5 & �6 mm 
CAL mean 
PESA: Periodontal Epithelial Surface Area 
PISA: Periodontal Inflamed Surface Area 




14.99 to 33-49 
O.IO to 0.98 
31.0 to 44.4 
13.31 to 28.40 
0.28 to r.oo 
9.0 to 19.9 
8.31 to 19.94 
0.18 to 0.74 
3.26 to n.68 
4.42 to 13.22 
0.08 to 0.50 
0.85 to 7.22 
0.33 to 1.09 
0.01 to 0.05 
2.00 to 2.54 
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I 
at two hospitals does not mean a subset of patients with more severe DM2 pa­
tients was selected. Rather, these DM2 patients may be thought to represent a 
sample of diagnosed and treated Indonesian DM2 patients. However, 'true' DM2 
associated increased periodontitis risk may be underestimated, since a substan­
tial portion of DM2 patients often goes undiagnosed. Likely, these patients have 
worse blood sugar control and consequently worse periodontal status. On the 
other hand, the DM2 patients that were recruited from a dental hospital may have 
visited this hospital for periodontitis, overestimating DM2 associated periodon­
titis prevalence in this subgroup. Likewise, since controls were all selected from 
the same dental hospital, the prevalence of periodontitis in controls may also 
have been overestimated. Since the prevalence in both groups might be overes­
timated, the overall effect on calculated DM2 associated periodontitis risk may 
have been small. Finally, selection of healthy controls at a dental hospital may 
not be representative of the general Indonesian population without DM2. Thus, 
although some threats to the generalizability of our results remain, the increased 
DM2 associated periodontitis risk does appear to have sufficient generalizability 
and might sooner have been underestimated rather than overestimated. 
The finding that DM2 subjects have an increased prevalence and severity of 
periodontitis is in line with other studies. 30• 38• 39 A major achievement of the cur­
rent study is that a large variety of methods to operationalize periodontitis preva­
lence and severity has been applied, and that the conclusions that could be drawn 
from the results were irrespective of the measures used. This indicates that this 
association is robust. As the prevalence of DM2 in Indonesia, and South East 
Asia, is already high and is predicted to rise further, the prevalence and severity 
of periodontitis may also rise. Due the vast number of people living in Indonesia, 
and South East Asia, and the proposed bilateral association between DM2 and 
periodontitis, this will increasingly pose serious problems to public health. 
Two main mechanisms are thought to underlie the proposed bilateral associa­
t ion between DM2 and periodontitis. One underlying mechanism is that DM2 
may alter local immune responses within periodontal tissue. DM2 may result 
in small vessel damage within the periodontium, resulting in poor nutrient deli­
very, decreased oxygen diffusion and decreased elimination of metabolic waste 
products. 4° Furthermore, hyperglycaemia alters collagen metabolism which pre­
disposes to impaired wound healing. In general, hyperglycemia results in the 
formation of proteins known as Advanced Glycation End products (AG Es). AG Es 
may be associated with a state of enhanced oxidative stress, thereby accelerat­
ing tissue injury. AGEs also function as a chemotactic for monocytes, thereby 
magnifying the inflammatory response, delaying wound healing and tissue repair 
and inducing connective-tissue damage and bone resorption. Finally, hypergly­
caemia and the imbalance in lipid metabolism impair neutrophil and monocyte 
functioning. 41 • 42·44 All of these factors may contribute to DM2 predisposing to 
periodontitis. 
The second underlying mechanism of the association between DM2 and perio­
dontitis is that periodontitis may play a role in initiating, or exacerbating DM2. 7• 
43• 45 Periodontitis poses an inflammatory burden consisting of increased serum 
levels of inflammatory mediators, like (-reactive protein and lnterleukin-6. 46 This 
inflammatory burden in turn leads to deteriorating blood glucose control in DM2 
patients. 43 The higher the amount of inflamed periodontal tissue, the higher the 
inflammatory burden, and the poorer blood glucose control in DM2 patients may 
be thought to be. 
P ISA quantifies the amount of inflamed periodontal tissue (representing it as 
the surface area of inflamed periodontal epithelium in mm2) ,  and it is suggested 
that P ISA thereby quantifies the inflammatory burden posed by periodontitis. 31 It 
was shown that there is indeed a dose-response relationship between P ISA and 
HbA1c in DM2 patients in the Dutch Caribbean. 47 Likewise, the present study 
finding of a significantly higher P ISA among DM2 subjects, may mean that perio­
dontitis is a risk factor for poor glucose control. Treating periodontitis might im­
prove blood glucose control, 8•13 and prevention and treatment of periodontitis in 
DM2 patients might contribute to better general health in DM2 patients. 48· 49 
In conclusion, this study shows that periodontitis prevalence is significantly 
higher in a group of Indonesian DM2 patients compared to a group of healthy 
Indonesians. Furthermore, Indonesian DM2 subjects have more extended and 
more severe periodontitis than healthy Indonesian subjects. Given the already 
high and increasing prevalence of DM2 in Indonesia, DM2 patients should be 
screened for periodontitis and oral (preventive) health care should become part 
of the regular care provided to Indonesian DM2 patients. Given the proposed 
bilateral association between DM2 and periodontitis, such care may contribute 
to better oral and overall health. 
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Periodontal inflamed suiface area as a predictor 




Background: Periodontitis may pose an infectious and inflammatory burden, evi­
denced by increased (-reactive protein (CRP). This burden may impair blood glu­
cose regulation. 
Aim: To assess whether periodontitis severity and CRP predict HbA1c levels in a 
group of healthy Indonesians and a group of Indonesians treated for type 2 dia­
betes mellitus (DM2), while controlling for confounders. 
Methods: A full mouth periodontal examination including probing pocket depth, 
gingival recession, plaque index and bleeding on probing was performed in 132 
healthy Indonesians and 101 Indonesians treated for DM2. In addition, HbA1c 
and CRP were assessed. A validated questionnaire was used to assess smok­
ing, body mass index (BMI), education and medical conditions. In regression 
analyses, it was assessed whether periodontitis severity and CRP predict HbA1c, 
controlling for confounding and effect modification. 
Results: In healthy Indonesians, the periodontal inflamed surface area (PISA) pre­
dicts HbA1c together with CRP, age, sex and smoking. In Indonesians treated for 
DM2, PISA did not predict HbA1c. 
Conclusion: Periodontitis may impair blood glucose regulation in healthy Indone­
sians in conjunction with elevated CRP levels. The potential effect of periodontitis 
on glucose control in DM2 patients may be masked by DM2 treatment. 
70 
I NTRODUCT ION 
The periodontal inflamed surface area (PISA) quantifies the amount of  inflamed 
periodontal tissue and is supposed to quantify the inflammatory and infectious 
burden posed by periodontitis 1 . Periodontitis may pose an inflammatory burden 
through the production of local inflammatory mediators entering the circulation. 
This inflammatory burden is evidenced by increased serum C-reactive protein 
(CRP) levels associated with periodontitis 2•7• 
Periodontitis may also pose an infectious burden through bacteria and their 
products which enter the systemic circulation. This burden may endanger overall 
health for example by causing atherosclerosis 8 and cardiovascular diseases 9• 
Circulating oral bacteria and lipopolysacharides are also able to stimulate hepa­
tocytes to secrete CRP 10•12 • Thus, high levels of CRP associated with periodontitis 
may be considered as a common pathway for both the inflammatory and infec­
tious burden posed by periodontitis. 
The high levels of CRP accompanying periodontitis, may lead to insulin resis­
tance and thereby to poor control of blood glucose in type 2 diabetes mellitus 
(DM2) and healthy subjects 13•1 6 resulting in increased levels of glycated haemo­
globin (HbA1c)17• 18 • Accordingly, high levels of CRP are correlated with increased 
HbA1c levels in DM2 patients 1 9. 2°. Furthermore, increased CRP levels have been 
associated with an increased risk of cardiovascular disease (CVD) in DM2 pa­
tients, the major cause of the increased mortality in DM2 patients 21 • 22• 
Given the importance of blood glucose control in preventing CVD in DM2 
patients, relatively few studies assessed whether periodontitis and CRP are pre­
dictors of HbA1c levels 23• 24• Furthermore, no study has investigated this issue in 
Indonesia. With 230 milion people, Indonesia is the 4th most populous country 
in the world, with 125 milion living on the island of Java. In Indonesia, the preva­
lence of DM in 2005 was 5.7%25, putting Indonesia in the top ten of countries 
with the highest prevalence of DM in the world. It has been estimated that by the 
year 2030, the prevalence of DM in Indonesia will be about 10%, corresponding 
with 20 million DM patients 26• In addiction to the huge number of DM patients 
in Indonesia, Indonesian DM2 patients have a prevalence of periodontitis of 72 
to 93% and an increased severity of periodontitis 27• Therefore, the aim of this 
study was to assess whether periodontitis severity and CRP predict HbA1c levels 
in healthy Indonesians and Indonesian DM2 patients. 
MATER IAL AN D M ETHODS 
The participants in this study were recruited from three different sites, namely 1) 
The Internal Medicine Department Dr. Sardjito Hospital, Yogyakarta 2) Prof. Soe­
domo Dental Hospital, Faculty of Dentistry, Gadjah Mada University, Yogyakarta 




Table 1. Characteristics of the partici pants. 
Variables Healthy controls DM2 p value 
Demography 
Age (yrs) mean (SD) 
Smoking (pack year) 
median (IQR)t 
BMI (kg/m2) mean (SD) 
Java origin n (%)* 
Gender n (%)* 
Male 
Female 




Hypertension n (%)* 
Laboratory serum markers 
HbA1c (%) Mean (SD) 
CRP (mg/1) Median (IQR)t 
*Result of Chi-square test 
(n=132) (n=IOI) 
47.9 (10.13) 54.4 (10.69) 
o.o (o.oo to o.oo) o.oo (o.oo to o.oo) 
24-4 (3.8) 25·5 (4.2) 
n9 (90%) 94 (93%) 
34 (26%) 40 (40%) 
98 (74%) 60 (60%) 
2.13 (0.77) 2.18 (0.79) 
24 (23%) 32 (24%) ) 
34 (34%) 51 (39%) 
43 (43%) 49 (37%) 
24 (18%) 26 (26%) 
5.5 (0.39) 8.9 (2.44) 










·,- result of Mann Whitney U-test, other results are the results of the independent samples t-test 
p: level of significance 
BMI: body mass index 
CRP: c-reactive protein 
DM2: diabetes mellitus type 2 
ESR: erythrocyte sedimentation rate 
HbA1c: glycated hemoglobin 
IQR: inter quartile range; n: number of participants 
SD: standard deviation 
Education: low: elementary & junior school, middle: high school, high: university 
yrs: year 
All participants, were aged � 18 years and had � 8 remaining teeth. This study was 
approved by the Ethical Committee for Research of the Medical Faculty of Gadjah 
Mada University, Yogyakarta, Indonesia. 
All participants completed a validated general health assessment question­
naire 28• 29 to check for other medical conditions that might be a risk factor for 
periodontitis. Information on age, gender, height and weight (for body mass in­
dex (BM I) calculation) , education and smoking were obtained from each partici­
pant. 
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Table 2. Periodonta l status of healthy controls and DM2 subjects. 
Variables Healthy controls DM2 (n=101) p value 
(n=132) 
Periodontal prevalence: n (%)* 
PPD >4mm & CAL >3mm 89 (67%) 89 (88%) <0.001 




869.3 (709.93 to 923-2 (725.65 to 
0.037 
1013.42) n99.71) 
PISA (mm2) 83.9 (35.21 to 206.41) 
170.4 (91.55 to 
<0.017 
392·59) 
CAL (mm) 1.8 (1.68 to 2.26) 2.4 (2.01 to 3.43) <0.001 
PPD (mm) 1.7 (1.60 to 1.93) 1.9 (1.72 to 2.35) <0.001 
Number of sites: median 
(IQR)t 
CAL > 3 mm 30.0 (17.00 to 47.00) 54.0 (32.50 to 74.50) <0.001 
CAL > 4 mm 5.0 (1.00 to 15.75) 25.0 (9.00 to 48.00) <0.001 
CAL > 5 mm 1.0 (o.oo to 4.75) 13 .0 (2.00 to 31.50) <0.001 
CAL > 6 mm o.o (oo to 1.00) 4.0 (o.oo to 19.50) <0.001 
PPD > 4 mm 2.0 (o.oo to 4.00) 6.o (2.00 to 18.00) <0.001 
PPD > 5 mm o.o (o.oo to 1.00) 2.0 (o.oo to 8.00) <0.001 
PPD > 6 mm o.o (o.oo to o.oo) 1.0 (o.oo to 3.00) 0.001 
BOP 9.0 (4.00 to 20.00) 




Plaquescore: 93 % (8.52) 91 % (7.89) 0.059 
Number of teeth 25.7 (4-72) 23.6  (6.24) 0.005 
* Result of Chi-square test 
t result of Mann Whitney U-test; other results are the results of the independent samples t-test; 
p: level of significance 
BOP: bleeding on probing 
CAL: clinical attachment loss 
DM2: diabetes mellitus type 2 
IQR: inter quartile range 
n: number of participants 
PESA: periodontal epithelial surface area 
PISA: periodontal inflamed surface area 
PPD: probing pocket depth 




All participants underwent a periodontal examination including periodontal 
probing pocket depth (PPD), gingival recession, plaque score and bleeding on 
probing (BOP) measurements. Measurements were performed on all teeth, on six 
sites per tooth using a manual periodontal colour coded standard probe (Dent­
sply, London, UK). Clinical attachment loss (CAL) was defined as the distance 
from the cemento enamel junction (CEJ)  to the bottom of the pocket/sulcus, and 
calculated as the mathematical sum of the PPD and gingival recession measure­
ments 30• Measurement were made in millimetres and were rounded of to the near­
est millimetre. BOP was recorded as either present or absent within 30 seconds of 
probing at 6 sites per tooth. Plaque score was defined as being present or absent at 
6 points on each tooth 31 . The number of missing teeth was also recorded. 
Periodontitis extent and severity were operationalized using a variety of meth­
ods, all of which are currently used in literature studying the association between 
periodontitis and other diseases. All measurements were calculated using con­
ventional clinical measurements obtained during the full mouth periodontal ex­
amination. The number of sites with probing pocket depth (PPD) �. �s and �6 
mm, the numbers of sites with clinical attachment loss (CAL) �3, �. �s and �6 
mm, mean PPD, mean CAL 32 and the percentage of sites with BOP were calcu­
lated using a freely accessible online Microsoft XL spreadsheet. Additionally, two 
recently introduced measures of periodontitis severity, the periodontal epithelial 
surface area (PESA) and the periodontal inflamed surface area (P ISA) 1 were cal­
culated, again using a freely downloadable spreadsheet (www.parsprototo.info; 
Microsoft Excel 2003 spreadsheet for Windows). PESA reflects the surface area of 
all pocket epithelium in square millimetres, whereas P ISA reflects the surface area 
of bleeding pocket epithelium in square millimetres. PESA and P ISA are calculated 
using conventional CAL, gingival recession and BOP measurements. P ISA quan­
tifies the amount of inflamed periodontal tissue, and it is suggested that PISA 
thereby quantifies the inflammatory burden posed by periodontitis 1 • 
Finally, all participants underwent a venapuncture to obtain a blood sample. 
Both blood glucose, determined by glucose oxidase enzymatic method, and gly­
cosilated/glycated hemoglobin (HbA1c) values, determined using low pressure 
cation ion exchange chromatography (DIASTAT™ , Bio-Rad, USA), were deter­
mined for all participants. Additionally, CRP, determined by chemiluminescent 
immunometris assay ( lmmulite 2000™ , Diagnostic Products Corp. , Los Angeles, 
CA, USA), was determined for all participants. 
Statistical analysis 
Differences in periodontitis severity between DM2 and healthy subjects were ana­
lyzed first using univariate analyses (independent sample t-test, Mann-Whitney 
U-test or Chi-square test as appropriate). Likewise, differences in potential predic-
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Table 3. Resu lts of mu ltip le  l i near regression ana lysis for healthy control group.  
Model predictors B p-value R1 95% confidence interval 
Model A 
PISA (mm2)* 0.0004 
Age (year) 0.0105 
Male/female (1/0) -0.1378 
Smoking(pack year) 0.0086 
CRP (mg/1) 0.0212 
Constant 4-9591 
of [) off �  
0.214 
<0.05 0.00004 to 0.00076 
0.001 0.00431 to 0.01674 
0.08 -0.29170 to 0.01595 
0.07 -0.00074 to 0.01805 
0.06 -0.00093 to 0.04343 
<0.001 4.62706 to 5.29121 
Other measures of periodontitis severity were not predictors of HbA1c 
Dependent variable HbA1c:glycated hemoglobin 1 Independent variables: PISA (Periodontal Inflammation Surface Area), age, sex, smoking/pack 
years CRP : C-reactive protein, Constant. 
p = probability, a p-value of so.05 was considered statistically significant 
f3: unstandardized coefficient. R2 = proportion of variability in data set that is accounted for by 
the statistical model 
tors of periodontitis (age, gender, body mass index (BMI), education, smoking, 
plaque score, number of teeth, ethnicity and other medical conditions) between 
DM2 patients and healthy subjects were tested for significance using univariate 
analyses. Since periodontitis severity was operationalized in 12 different ways, 
significance level a of 0.05 was corrected for multiple comparisons according to 
the Bonferroni-Holm method. 
To assess periodontitis and CRP as potential predictors of HbA1c in subjects 
with and without DM2, a multiple linear regression analysis was performed, us­
ing a backward stepwise method. HbA1c was the dependent variable. 
As independent variables, i.e. predictors of HbA1c: age, sex, BMI, pack years, 
education, CRP and all measures of periodontitis severity, the latter one by one, 
were introduced in the model. Statistics were calculated using SPSS 16.0. 
RESU LTS 
A total of 101 participants, treated for DM2, diagnosed according to WHO criteria 
33, were included; 40 men and 61 women, with a mean age of 54 years (Table 1, p72). 
Most of the participants were Javanese (93.0 %). The mean BM I in this group was 
25.5, labeling them as being overweight according to the World Health Organiza­
tion classification (overweight; BMI 23-27.5) 34• The DM2 patients had an average 




DM2 group was 8.9%. In addition, 132 healthy controls were enrol led, 34 men and 
98 women, with a mean age of 48 years. Again, the healthy subjects were mainly of 
Javanese origin (90.2%) and were on average overweight (BM I :  24.4). The healthy 
subjects had an average of 26 teeth and a mean plaque score of 93 %. By defini­
tion, the HbA1c was below 6.5%. The average HbA1c level of this group was 5. 5%. 
The severity of periodontitis was significantly higher in participants 
with DM2 when compared to controls, independent of the method used 
to operationalize periodontitis severity (table 2, p73). All applied meth­
ods showed to be significantly higher with the exception of PESA; p was 
smaller than 0.05, however not significant after correcting the signifi­
cance level using Benferroni-Holm (p=o.037; significance level p<o.025). 
In the DM2 patients, none of the measures of periodontitis severity predicted 
HbA1c. Only SES (� = -0.752, 95% Cl = -1.345 to -0.158) was a predictor of HbA1c, 
(r of 6.0%). By contrast, in healthy Indonesians, P ISA (-fs = 0.0004, 95% Cl = 
o.000045-0.000763) was a predictor of HbA1c together with age, sex, smoking 
and CRP, (r 2 = 21.4%) (Table 3, p75). 
DISCUSSION 
This study showed that P ISA is a predictor of HbA1c, in conjunction with CRP, 
age, sex and smoking, in healthy Indonesians. Thus, periodontitis may play a 
role in inducing impaired blood glucose control. Indeed there is evidence that 
periodontitis may induce insulin resistance 1 8 • I t  is thought that periodontitis 
poses an inflammatory and infectious burden as evidenced by increased levels 
of CRP 3• 5• 6 which may increase HbA1c levels 1 9• 20• 35• Accordingly, P ISA predicted 
HbA1c together with CRP. It is striking that out of the various methods to opera­
tionalize periodontitis severity, only the P ISA emerged as a predictor of HbA1c. 
The other methods for determining the severity and extent of periodontitis did 
not contribute significantly to a mod�I that predicts HbA1 c. It may be that the 
P ISA is a predictor of HbA1 c because it reflects the amount of inflamed peri­
odontal tissue, thereby predicting both infectious and inflammatory burdens 
more accurately than other methods used to operationalize periodontitis 1 • 1 8• 
I n  Indonesian DM2 patients, no measure for periodontitis severity predicted 
HbA1c. The observed differences between DM2 patients and healthy Indonesians 
could be explained as follows. First, most Indonesian DM2 patients used insu­
lin. Insulin is a potent blood glucose regulator, normally rerserved for DM type 
1, insulin dependant diabetes, patients 36• Use of insulin may mask an effect of 
periodontitis on the HbA1c level in DM2 patients. Second, DM2 patients may 
have dietary restrictions, e.g. avoiding sugar rich foods. Such a diet may impact 
blood sugar and may mask an affect of periodontitis on HbA1c level. 
Previously, a dose response relationship was observed between PISA and HbA1c 
in DM2 patients from Curacao 18• This finding appears to be in sharp contrast 
with the findings in this study, i.e. PISA is not a predictor of HbA1c in a group 
of Indonesian DM2 patients. The difference between these two studies could 
be explained by differences between the studied DM2 populations. First, many 
of the Indonesian DM2 patients used insulin, while few of the African-Ameri­
can DM2 patients used insulin. As stated above, effects of PISA on HbA1c may 
have been masked rn Indonesian DM2 patients by usage of insulin. Second, the 
average BMI of DM2 patients from Curacao was 31, while the average BMI of 
Indonesian DM2 patients was substantially lower, namely 25. BMI may be an 
effect modifier, i.e. increased BMI may increase the potential insulin resistance 
inducing effect of periodontitis in DM2 patients 37• 38• Third, there is the obvi­
ous difference in ethnicity between the two groups, i.e. one from Indonesia of 
Javanese origin and the other from Curacao of African-American origin. Possible 
differences in (health promoting) behavior, diet and genes, related to the differ­
ences in ethnicity, may be another explanation for these conflicting results 39• 40• 
In conclusion, P ISA was shown to be a predictor of HbA1c in healthy Indone­
sians in conjunction with CRP. This implies that periodontitis may contribute to 
insulin resistance through posing an inflammatory and infectious burden leading 
to DM2 establishment. However, once DM2 is established, the usage of insulin 
may be the most potent blood glucose (de)regulators, at least in an Indonesian 
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Dose-response relationship between Periodontal 
Inflamed Surface Area (PISA) and HbA1c in 




Background: A dose-response relationship between the amount of inflamed perio­
dontal tissue and HbA1c-level, might be indicative for a causal association be­
tween periodontitis and type 2 diabetes. 
Aim: To assess a dose-response relationship between the Periodontal Inflamed 
Surface Area (P ISA) , as a measure of the amount of inflamed periodontal tissue, 
and HbA1c-levels in type 2 diabetics. 
Materials and methods: 40 consecutive dentate type 2 diabetics attending their 
general practitioner for regular check-up, underwent full mouth probing pocket 
depth and bleeding on probing assessment. From these data P ISA was calculat­
ed. HbA1c-levels were retrieved from patients' medical files. The dose-response 
relationship between PISA and HbA1c-levels was assessed using multiple linear 
regression analyses, controlling for factors that might influence P ISA or HbA1c­
levels. 
Results: The higher the PISA of type 2 diabetics was, the higher their HbA1c-levels 
were. On a group level, an increase of P ISA with 333 mm2 was associated with a 
1 .0 percentage point increase of HbAic, independent of the influence of other 
factors. 
Conclusion: On a group level, there is a dose-response relationship between P ISA 
and HbA1c in type 2 diabetics. This might be an indication of a causal relationship 
between type 2 diabetes and periodontitis. 
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I NTRODUCTION 
I t  was estimated that 194 million people suffered from diabetes mellitus across the 
globe in 2003, equalling 5.1% of the world's population. This is estimated to increase 
to 333 million, or 6.3% of the world's population, in the year 2025 ( International Dia­
betes Federation 2003). Type 2 diabetes mellitus is the most prevalent type of the dis­
ease, occurring in 90-95% of all diabetic patients (Taylor 2001). Type 2 diabetes melli­
tus is characterised by insulin resistance, insensitivity to the effects of insulin, which 
results in elevated levels of blood glucose. As a consequence of prolonged elevated 
blood glucose levels (poor glycemic control), blood vessels sustain damage resulting 
in complications commonly associated with diabetes, namely: atherosclerosis, myo­
cardial infarction, retinopathy, nephropathy, neuropathy, delayed wound healing and 
an increased risk of infections ( International Diabetes Federation 2003). 
Inflammation has been postulated as an important factor initiating the onset of 
Diabetes mellitus type 2 (Pradhan et al. 2001; Hu et al. 2004). Furthermore, inflam­
mation has been shown to exert a negative effect on glycemic control in diabetics 
(Schmidt et al. 1999; Pradhan et al. 2001; Pradhan & Ridker 2002). When inflamma­
tory mediators as TNF-a, IL-6 and IL-1 enter the systemic circulation, they alter lipid 
and glucose metabolism ( Iacopino & Cutler 2000), and induce insulin resistance 
(Feingold & Grunfeld 1992; Grunfeld et al. 1990; Pickup et al. 1997). Since perio­
dontitis poses an inflammatory burden with, amongst others, TN F-a, I L-6 and I L-1 
entering the systemic circulation (Grossi & Genco 1998; Engebretson et al. 2007), 
periodontitis may induce insulin resistance. In accordance, it has been shown that 
periodontitis has a negative effect on glycemic control (Taylor et al. 1996; Collin et 
al. 1998; Saito et al. 2004). Moreover, diabetics with severe periodontitis had more 
diabetic complications than diabetics with mild or no periodontitis ( Finestone & 
Boorujy 1967; Thorstensson et al. 1996). Finally, treatment of periodontitis has been 
shown to improve glycemic control in type 2 diabetics (Grossi et al. 1997; Iwamoto 
et al. 2001; Stewart et al. 2001; Rodrigues et al. 2003; Kiran et al. 2005; Faria-Almeida 
et al. 2006; Navarro-Sanchez et al. 2007; O'Connell et al. 2008). 
While periodontitis may be a risk factor for development or deterioration of type 2 
diabetes, type 2 diabetes may also be a risk factor for the development of periodon­
titis. Patients with type 2 diabetes suffer from periodontitis more often and more 
severely than non-diabetics (Emrich et al. 1991; Collin et al. 1998; Tsai et al. 2002; 
Campus et al. 2005; De Silva et al. 2006; Struch et al. 2008). Hence, there may be 
a bilateral causal relationship between periodontitis and type 2 diabetes, with one 
influencing the other and vice versa. 
Establishing the potentially causal nature of the association between periodontitis 
and diabetes requires assessing dose-response relationships between the inflamma­
tory burden posed by periodontitis and glycemic control. A problem that needs to be 
resolved is that, in contrast to glycemic control (commonly assessed by measuring 
I 
I 
the percentage of haemoglobin that is glycated, HbA1c-level), there is as yet no 
common way to assess the inflammatory burden posed by periodontitis. 
The inflammatory burden, consisting of bacteria and inflammatory mediators 
entering the systemic circulation, is thought to be related to the amount of in­
flamed periodontal tissue. The greater the amount of inflamed periodontal tissue 
is, the greater the amount (and the chance) of bacteria and inflammatory me­
diators entering the systemic circulation is thought to be. Therefore, classifying 
periodontitis as a risk factor for other diseases should be done by a measure 
that quantifies the amount of inflamed periodontal tissue. Classifications of peri­
odontitis that are currently used, take mean Probing Pocket Depth (PPD), mean 
Clinical Attachment Level (CAL) or a particular cut-off point for PPD or CAL as a 
means to classify or define periodontitis. Neither PPD nor CAL are appropriate to 
assess dose-response relationships between periodontitis and HbA1c, because 
PPD and CAL are linear measures that do not quantify the amount of inflamed 
periodontal tissue. Therefore, a new measure of periodontitis as a risk factor for 
other diseases was developed, the Periodontal Inflamed Surface Area (P ISA) 
(Nesse et al. 2008). 
PISA reflects the surface area of bleeding pocket epithelium in square mil­
limetres. Since PISA quantifies the amount of inflamed periodontal tissue, it is 
assumed that PISA quantifies the inflammatory burden posed by periodontitis. 
The aim of this study was to assess a dose-response relationship between PISA 
and HbA1c-levels in type 2 diabetics. 
PATIENTS AN D M ETHODS 
Patients 
This study was performed on Curacao, an island that is part of the Netherlands 
Antilles. During a three month period, from September 2006 until November 
2006, dentate type 2 diabetics who came for regular check-ups to their general 
practitioner were asked to participate in this study. The following inclusion crite­
ria were used: 
1) Availability of at least 1 measurement of HbA1c-level in the past 3 
months, 
2) Having at least 8 remaining teeth, 
3) Not having used antibiotics in the past 3 months, 
4) Not having received periodontal treatment in the past 6 months. 
Since no data regarding the association between PISA and HbA1c exists, no for­
mal sample size calculation could be performed. Therefore a convenience sample 
was taken. During the inclusion period, a total of 40 diabetic patients met the 
inclusion criteria. All agreed to participate in this study. All participants signed an 
informed consent agreement. 
Table , .  Patients' characteristics 
Patient characteristics 
Sex: % (numbers) 
Male 17% (7) 
Female 83% (33) 
Age: mean (± sd) 58 (± 9.5) years 
Diagnosed with DM 2: median (IQR) 7.0 (2.3 to 12.0) years 
BMI: mean (± sd) 31.1 (± 4.6) kg/m2 
WHO BMI-classification: % (numbers) 
Healthy; BMI 18.5 < 25 kg/m2 10% (4) 
Overweight; BMI 25 < 30 kg/m2 27% (n) 
Obese; BMI �30 kg/m2 63% (25) 
Oral hygiene-classification: % (numbers) 
Good 40% (16) 
Moderate 32.5% (13) 
Bad 27.5% {II) 
Number of teeth: mean (± sd) 19 (5) 
SES-classification: % (numbers) 
High 17.5% (7) 
Middle 35% (14) 
Low 47.5% (19) 
Smoking: % (numbers) 
Smoker 5% (2) 
Non-smoker 95% (38) 
PISA: median (IQR) 151 (39 to 307) mm2 
HbArc: mean (± sd) 7.7 (±r.8)% 
List of abbreviations: 
SD = standard deviation, IQR= Inter Quartile Range, DM 2 = type 2 Diabetes Mellitus, 
BMI = Body Mass Index, WHO =World Health Organisation, SES = Socio-Economic Status, 
PISA = Periodontal Inflamed Surface Area, HbA1c = % of glycosylated hemoglobin 
All patients agreed to (1) disclose data in their medical file for research purpos­
es, (2) complete a questionnaire (assessing socio-economic status (SES), length 
and weight, smoking and oral hygiene practises), and (3) undergo a full mouth 
probing pocket depth (PPD) assessment. From the medical files, data regarding 
HbA1c-levels, number of years since diagnosed with type 2 diabetes mellitus, and 
the usage of medication were retrieved. 
M ETHODS 
On the basis of education, income and profession, patients were categorised 
into low, middle and high SES. Length and weight were used to calculate Body 




Patients were categorised into 4 BM I classes according to WHO classifications; 
underweight (BM I s18.5 kg/m2) ,  healthy weight (BM I 18.5 < 25 kg/m2) ,  overweight 
(BMI 25 < 30 kg/m2) and obesity (BMI �:30 kg/m2) (WHO 1995; WHO 2000). 
Full mouth PPD and bleeding on probing (BOP) data on six sites per tooth 
were obtained using a pocket probe (PCP106, Hu-Friedy®). Oral hygiene was as­
sessed using Silness and Loe's plaque-index (Loe 1967). Al l patients were in­
vestigated by one researcher (A.L.), then bachelor of dental surgery, who was 
trained during a special clinical course in periodontology. Data on PPD and BOP 
on six sites per tooth were entered in a spreadsheet to calculate the PISA for each 
patient (Nesse et al. 2008). This spreadsheet can be accessed via http://www. 
parsprototo.info/docs/PISA_CAL.xls and is free for use. PISA was calculated with 
this spreadsheet in four steps: 
1 .  After filling in Probing Pocket Depth (PPD) measurements at six sites per 
tooth, the computer calculates the mean PPD for each particular tooth. 
2. The mean PPD around a particular tooth is entered into formula that trans­
late this linear mean PPD into the Periodontal Epithelial Surface Area (PESA) 
for that specific tooth (Hujoel et al. 2001). The PESA for a particular tooth 
is the root surface area of that tooth (in mm2) that is covered with pocket 
epithelium. 
3. The PESA may consist of uninflamed pocket epithelium that does not pose 
an inflammatory burden. Therefore, the PESA for a particular tooth is subse­
quently multiplied by the proportion of sites around that tooth that was af­
fected by Bleeding On Probing (BOP). If, for example, three out of the maxi­
mum of six sites were affected by BOP, the PESA of that particular tooth was 
multiplied by 3/6, thereby rendering the Periodontal Inflamed Surface Area 
(PISA) for that specific tooth. 
4. The sum of Periodontal Inflamed Surface Areas around each individual tooth 
is calculated, amounting to the total P ISA within a patient's mouth. 
Please read the discussion section of this paper and the article entitled "PISA, 
quantifying inflammatory burden" in an earlier version of this journal (Nesse et 
al. 2008) for a more detailed explanation of PISA and it's calculation. 
Statistical analysis 
To analyse dose-response relationships between PISA and HbA1c-levels, multiple 
linear regression analyses were performed. The outcome variable was HbA1c and 
as potential predictors PISA, sex, oral hygiene (high versus low/middle), smoking 
(yes versus no), social economic status (SES; high/middle versus low), BMI and 
"the number of years since diagnosed with diabetes" were entered in the regression 
equation (method; stepwise backward). The significance of the contribution of the 
variables to the model was estimated and compared to the removal criterion (p = 
86 
Table 2. Resu lts from mu lt iple l i near regression ana lyses (models to predict H bA1 c) .  







SES high/middle -1.o55 
Years diagnosed with DM 2 0.048 
of B Interval of fi 
< 0.001 6.289 to 7.744 0.175 
0.001 0.001 to 0.005 
< 0.001 6.107 to 7.641 
< 0.001 0.002 to 0.005 0.367 -1.866 to -0.244 0.012 
0.093 -0.008 to 0.104 
Model A is the resulting model from the regression analysis of all patients. 
Model B is the resulting model from the regression analysis excluding one extreme outlier. 
Dependent variable: HbAic(%); Independent variables initially entered into the model: Sex, 
Oral Hygiene, Body Mass Index, Periodontal Inflamed Surface Area (PISA) 
SES= Socio-Economic Status, years since diagnosed with diabetes mellitus type 2 (DM 2) . 
p.=probability; a p. value of s 0.05 was considered statistically significant. 
� = Unstandardised coefficient. 
0.1). When a potential predictor met the removal criterion, it was removed from 
the regression model. The model was then reestimated for the remaining predictor 
variables, and the process was repeated until no further predictors met the removal 
criterion. The residuals of the last model were checked for normality. Residuals 
were standardized and analyzed. Statistics were calculated using SPSS 14.0. 
RESU LTS 
Patients' characteristics are summed up in table 1 (p85). Our study population 
consisted of mainly female type 2 diabetics (83%). Only 4 (10%) out of the 40 
included patients had a healthy weight, 90% was either overweight (n=l l ,  27%) 
or obese (n=25, 63%). HbA1c ranged from 4.9 to 14.2%, with 60% of the study 
population (n=24) having an HbA1c-level above the recommended 7.0%. The 
P ISA ranged from o to 1087 mm2, with a median of 151 mm2, and an inter quartile 
range of 39 to 307 mm2 • Only two patients smoked. 
In the multiple linear regression analysis it appeared that PISA (�=0.003, 95%CI  
=0.001 to 0.005) was the only predictor significantly associated with HbA1c-level 
with r2=17.5%. (Table 2; model A). However, when plotting standardised residuals 
we found one extreme outlier (Fig. 1, p88). For that case there was a large differ­
ence between the observed and predicted value of HbA1c. The outlier was deleted 
and the regression analysis was repeated (Table 2; model B), after which residuals 





















r2 1 inear Model A: 0 . 175 
r2 l inear Model B*: 0.367 
*excluding the outlier 
400 600 800 
PISA (mm2) 
1 .000 1 .200 
The results indicate that on a group level, an increase in PISA of 1 mm2 is asso­
ciated with a rise in HbA1c of 0.003% {Table 2, Fig. 1). This means that on a group 
level, an increase of P ISA of 333 mm2 is associated with an increase in HbA1c of 
1.0 percentage point. 
DI SCUSSI O N  
This study shows that a dose-response relationship exists between control of 
blood glucose levels over time {HbA1c) and the amount of inflamed periodontal 
tissue {P ISA) in type 2 diabetics. Namely, on a group level, an increase in PISA of 
333 mm2 is associated with an increase of HbA1c with 1.0 percent {Fig. 1, Table 2 
Model A). Similarly a decrease in PISA of 333 mm2 is associated with a decrease 
of HbA1c with 1.0 percent. This dose-response relationship appeared to be in­
dependent of factors as sex, oral hygiene, SES, BMI, smoking and the number 
of years since diagnosed with type 2 diabetes mellitus, when all patients were 
included in the analysis. 
When the analysis was repeated without the outlier with the unusually high 
standard residual, the � for P ISA was basically unchanged {Table 2, model B). 
However, SES and number of years since diagnosed with type 2 diabetes mellitus 
were added as predictors of HbA1c. The explained variance increased from 17.5% 
88 
(model A) to 36.7% (model B). Model B appeared to strengthen the notion of an 
association between P ISA and HbA1c, since the lower bound of the 95% confi­
dence interval went up from 0.001 (model A) to 0.002 (model B). 
Although a decrease of Hb1Ac with 1.0 percentage point seems to be minor 
at a first glance, it should be noted that a decrease of HbA1c with 1.0 percentage 
point is associated with a 10% reduction of the risk of dying from cardiovascular 
diseases (Balady et al. 2007). Since treatment of periodontitis has been shown 
to improve glycemic control in type 2 diabetics (Grossi et al. 1997; Iwamoto et al. 
2001; Stewart et al. 2001; Rodrigues et al. 2003; Ki ran et al. 2005; Faria-Almeida et 
al. 2006; Navarro-Sanchez et al. 2007; O'Connell et al. 2008) the potential benefit 
of reducing the PISA, in case of a causal association between P ISA and HbA1c, 
may be high. For example, 25% of our population has a PISA above 300 mm2, 
reducing these patients' P ISA might reduce HbA1c by up to 1 percentage point, 
thereby potentially reducing their risk of dying from cardiovascular diseases by up 
to 10% (Ba lady et al. 2007). However, since the effect of periodontal treatment on 
diabetic control and systemic inflammation are not proven beyond doubt, there 
is a need to perform large well designed randomized controlled clinical trials to 
establish the benefit of periodontal treatment to glycemic control in type 2 diabet­
ics (Kinane & Bouchard 2008). These studies could simultaneously elucidate the 
potential causal nature of the association between periodontitis and glycemic 
control. 
Type 2 diabetics suffer from periodontitis more often and more severely than 
non-diabetics (Emrich et al. 1991; Collin et al. 1998; Tsai et al. 2002; Cam pus et 
al. 2005; De Silva et al. 2006; Struch et al. 2008). The dose-response relationship 
between P ISA and HbA1c may also be explained in this light, i.e. type 2 diabetics 
with poor glycemic control (high HbA1c) might be more likely to develop severe 
periodontitis (high P ISA). Whether periodontitis deteriorates glycemic control or 
diabetes causes periodontitis, measures that safeguard periodontal health may 
need to become part of regular care of patients with poorly controlled type 2 dia­
betes, if it is proven that HbA1c is indeed causally related to PISA. 
Recently it was posed that P ISA predicts the probability of periodontitis to 
cause or deteriorate other diseases by quantifying the inflammatory burden posed 
by periodontitis (Nesse et al. 2008). This study revealed that P ISA indeed appears 
to be a valuable tool to assess dose-response relationships between the amount 
of inflamed periodontal tissue and a well defined disease activity parameter as 
HbA1c. However, further studies are needed to confirm that P ISA quantifies the 
inflammatory burden posed by periodontitis. This could be done by assessing 
dose-response relationships between PISA and blood levels of inflammatory me­
diators as TNF-a, IL-6 and IL-1. 




ics. Reservations should be held about generalising results from studies with 
a small sample size. Another limitation that could hinder generalisation of our 
results, is that all patients included in this study were of mixed black origin living 
in the Netherlands Antilles, go% of the study population was either overweight 
or obese, and 83% was female. Ethnicity could be an effect modifier in the rela­
tionship between P ISA and HbA1c, as could BMI and sex (although we controlled 
for the effects of the latter two). In other words, obese women of mixed black 
origin from the Netherlands Antilles might have a different dose-response re­
lationship between P ISA and HbA1c than male patients of different weight and 
ethnic origin. Regardless of the existence of effect modification, this study shows 
a clear dose-response relationship between PISA and HbA1c. Although this dose­
response relationship may differ depending on the presence of effect modifiers, 
given the large number of studies showing an association between diabetes and 
periodontitis across different populations, the dose-response relationship might 
be present in other populations as well. 
It should be noted that the original P ISA calculation using the online spread­
sheet (http://www.parsprototo.info/docs/P ISA_CAL.xls) requires CAL and re­
cession measurements to be filled in. Given the absence of data on recession 
measurements, for this study, we were forced to enter PPD measurements into 
the spreadsheet as CAL and enter recession measurements into the spreadsheet 
as zero. Using PPD instead of CAL measurements, i.e. ignoring the presence of 
recessions, may lead to a slight overestimation of true P ISA (Nesse et al. 2008) . 
However, this underestimation is likely small and can most probably be neglected. 
Moreover, the underestimation applies to the study population as a whole and 
thus unlikely effects the dose-response relationship between P ISA and HbA1c­
levels currently observed. 
I n  conclusion this study shows that there is a dose-response relationship be­
tween HbA1c-levels and PISA, in type 2 diabetics. Namely, on a group level, an 
increase in P ISA with 333 mm2 is associated with an increase of HbA1c with 1 .0 
percentage point. This dose-response relationship might be an indication of a 
causal relationship between PISA and HbA1c. Additional studies are needed to 
confirm that there is indeed a causal nature underlying the observed association 
between PISA and HbA1c. Furthermore, this study suggests that P ISA is a useful 
tool to assess dose-response relationships between the amount of inflamed peri­
odontal tissue and HbA1c. However, studies still have to confirm that P ISA does 
indeed quantify the inflammatory burden posed by periodontitis. 
go 
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Treatment of periodontitis in rheumatoid 
arthritis patients 
reduces rheumatoid arthritis 




Background: Periodontitis is a chronic inflam mation of the tissues anchoring 
teeth within the jaws. It is suggested that rheumatoid arthritis (RA) increases 
the risk of periodontitis. Additionally, treatment of periodontitis is suggested to 
reduce RA disease activity. 
Aim: To systematically review the evidence on prevalence and severity of peri­
odontitis in RA patients as compared to healthy controls, and the potential of 
treatment of periodontitis to reduce RA disease activity. 
Methods: Sensitive search strategies were designed aimed at including all rel­
evant studies published from 1968 till 10-10-2010. Relevant studies performed in 
humans and published in the English language were included. The methodologi­
cal quality of each study was graded as good, meeting all criteria appropriate for 
study design, fair, meeting a selection of key criteria guaranteeing fair validity, 
or poor, missing one or more key criteria. Studies with fair or good quality were 
included in a meta-analysis. 
Results: Out of 798 articles initially retrieved, 9 case control studies and 2 random­
ized controlled trials had fair quality and were included in meta-analyses. Results 
of meta-analyses indicated that RA-associated odds ratios (95% confidence in­
tervals) of periodontitis range from 8.o (3.1 to 20.9) to 13.2 (3.7 to 47.2) depend­
ing on the measure of periodontitis used. Moreover, treatment of periodontitis 
reduces DAS28 by 1.2 (0.6-1.7). 
Conclusion: Prevention and treatment of periodontitis in RA patients may be 
needed to safeguard oral health and may additionally reduce RA disease activity. 
However, there is a need for well-designed studies to confirm these findings. 
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I NTRODUCTION 
The periodontium is the tissue that surrounds, supports and anchors teeth within 
the jaws. Periodontitis is a chronic inflammation of the periodontium that causes 
loss of the anchoring connective tissue and jaw bone. Periodontitis is a major 
cause of tooth loss and negatively impacts quality of life [1-7]. 
Periodontitis may be associated with rheumatoid arthritis (RA). The first an­
ecdotal 'case report' of this association was written by Hippocrates, around 400 
BC. He described a patient with 'rheumatism' being cured after extraction of a 
single tooth [8]. Over the past decades, dozens of studies have appeared on the 
association between periodontitis and RA. These studies can roughly be divided 
into four series. The first series of studies deals with the epidemiologic associa­
tions between periodontitis and RA. Some studies suggest periodontitis may be 
more prevalent among RA patients, when compared to healthy controls and vice 
versa [9-19]. Additionally, more severe RA may be associated with more severe 
periodontitis and vice versa [20-22]. 
A second series of studies deals with similarities in disease pathogenesis be­
tween periodontitis and RA. Both diseases share a genetic predisposition for a 
pro-inflammatory response (H LA-DR4)[20,23], resulting in the secretion of the 
same catabolic cytokines and inflammatory mediators [24]. In both diseases, 
drugs inhibiting the activity of matrix metalloproteases, responsible for the even­
tual destruction of connective tissue and bone that is a hallmark of both diseases, 
reduce disease severity and bone loss [25,26]. 
A third series of studies hypothesizes on a role of periodontitis as inducer of 
anti citrullinated protein antibody (ACPA) production [22,27]. ACPAs are thought 
to play an important role in the aetiology of RA. Since both citrullinated proteins 
and auto-reactive plasma cells are present in periodontitis tissue [28,29], anti 
citrullinated protein antibody formation might be initiated in periodontal tissue. 
A fourth series of recently published studies indicate that treatment of pe­
riodontitis may reduce disease activity of RA. Treatment of periodontitis was 
shown to reduce CRP, erythrocyte sedimentation rate, number of swollen and 
tender joints counts, visual analog scale scores for general health and, thus, di­
sease activity score (DAS) 28 [30-32]. 
If periodontitis is more prevalent in RA patients and plays a role in the etiology 
of RA, prevention and treatment of periodontitis in RA patients may be needed to 
improve oral health, preserve teeth, and consequently improve quality of life. Fur­
thermore, if periodontitis treatment is able to reduce RA disease activity, prevention 
and treatment of periodontitis may need to become a part of RA treatment. Con­
sequently, the aim of this study was to systematically review the available evidence 
on periodontitis prevalence and severity in RA patients as compared to healthy 




M ATER IALS AN D M ETHODS 
Sensitive search strategies were designed aiming to include all potentially relevant 
studies, limited to studies on humans and published in the English language. 
Search strategies were performed in Medline using PubMed: "Periodontitis"[MeSHJ 
OR periodontitis OR periodont10') AND ("Arthritis, Rheumatoid"[MeSHJ OR rheuma­
toid arthritis OR rheumat*) limit eng hum, in Embase and Medline using Embase: 
('periodontitis'/syn OR periodont-1') AND (rheumatoid AND 'arthritis'/syn OR rheu­
mat*) AND [english]/lim AND [humans]/lim, and in the Cochrane Library: peri­
odont-1, AND rheumat-1,. Studies published from 1968 till , 0-10-2010 were included 
in this study. 
Studies potentially relevant to the focussed research questions were selected by 
excluding irrelevant studies in a stepwise fashion (Fig. 1, p99). Duplicate studies, 
non-systematic reviews, case reports, case series, and studies that were irrelevant 
to the research question were excluded. Cohen's kappas and overall agreement 
were calculated to check the level of inter-observer agreement at each step. 
The level of evidence was graded as is commonly performed on the basis 
of study design. How well the study design was executed, was graded as either 
"good", "fair" or "poor" [33]. For this purpose, a list of 1 8  criteria for study design 
of observational studies was created for the specific purpose of this review, as 
on prelimanary exploration of the literature most studies appeared to be obser­
vational studies [34,35]. A study meeting all 18 criteria appropriate for the study 
design was judged as "good". Eight items were thought to constitue a set of key 
criteria guaranteeing at least fair validity. For the 1 8  criteria and and a justifica­
tion of the choice of 8 key items guaranteeing at least fair validity, see table 1 
(p100-102). The 8 key items consisted of: adequate description of the number 
of subjects, mean age and sex distribution (item no 1), valid measurements to 
assess periodontitis presence, absence and RA presence (resp. item no 3, 4 and 
6), and adequate control for confounding by oral hygiene, smoking, gender and 
age (resp. item no 9, 10, 1 3  and 14). A "fair" study did not meet all 1 8  criteria, but 
met the set of 8 key criteria. If any of the 8 key criteria was not met, the study was 
considered to have major flaws and "poor" validity. In case any of the key items 
were judged differently by both authors (e.g. EB scored o while WN scored 1 ), 
a meeting was called to reach a consensus. Studies that were, either directly or 
after consensus meeting, unanimously judged as "fair" or "good" were included 
in meta-analyses. Studies with "poor" validity were excluded. 
As the 18 criteria checklist was designed to judge the validity of observational 
studies, included randomized controlled clinical trials were additionally judged 
using an unmodified Cochrane checklist for judging the validity of randomized 
controlled clinical trials [36]. However, the key criteria on the checklist of obser­
vational studies were also considered to guarantee fair validity of randomized 
98 
controlled trials (RCT; see table 1 p100) RCTs that didn't meet the key criteria were 
considered to have poor validity and were excluded. 
Meta-analyses were performed using a statistical software programme (Com­
prehensive Meta-Analysis, Biostat, Englewood, USA) and aimed to answer the 
following research questions: I) is periodontitis prevalence and severity increased 
in RA patients as compared to healthy controls and I I) does treatment of perio­
dontitis reduce RA disease activity? Meta-analyses were performed separately for 
e�ch type of periodontitis disease measure in order to reduce clinical heterogene­
ity. Both fixed models, assuming only within study variance, and random models, 
additionally assuming between study variance, were calculated. 
Finally, potential threats to generalizability of results from meta-analyses were 
explored by exploring sources of clinical heterogeneity. Studies were compared 
on: exclusion criteria, age, sex, nationality, numbers of teeth, oral hygiene level 
(plaque scores) and percentage of smokers, measures used for periodontitis, 
DAS28, RA disease duration, drugs used, and, for RCTs only, on the treatment 
of periodontitis that was administered. Finally, possible publication bias was as­





Identification of relevant and valid articles in a stepwise fashion 
Medline: Em base: Cochrane: 
345 records identified 713  records identified 10 records identified 
1068 records retrieved from 3 databases 
798 records screened for relevance 
56 full-text articles assessed for validity 
Total of 1 1  articles, in groups of2 to 5, 
included in quantitative synthesis 
99 
270 duplicates removed 
742 articles excluded because 
of irrelevance to topic 
43 full-text articles excluded 
because of insufficient validity, 
3 studies dealt with 1 original 





T a b l e  1 .  S e t  o f 1 8  i t e m s  j u d g i n g  q u a l i t y  o f  p a p e r s  
-
I .  





5 .  
6 .  
7
.  
D e s c r i p t i o n  o f  i t e m :  
A )  N u m b e r  o f  s u b j e c t s  g i v e n ,  a n d  
B )  M e a n  ( m o d u s  o r  m e d i a n )  a g e  g i v e n ,  a n d  
C )  N u m b e r  ( o r % )  o f  m a l e s  a n d  fe m a l e s  g i v e n .  
A  a n d  B  a n d  C  =  r  p o i n t  
A )  C l i n i c a l  s e t ti n g  w h e r e  p a ti e n t s  w e r e  a p p r o a c h e d  g i v e n ,  a n d  
B )  I n c l u s i o n  c r i t e r i a  s t a t e d  w i th  r a t e  o f  i n c l u s i o n ,  a n d  e i t h e r  
C )  R a n d o m  s e l e c t i o n  o f  p a ti e n t s ,  o r  
D )  S e l e c ti o n  o f  R A  o r  p e r i o p a t i e n t s  p e r f o r m e d  w i t h o u t  p r i o r  k n o w l ­
e d g e  o f  p e r i o  o r  R A  p r e s e n c e ,  r e s p e c ti v e l y .  
A  a n d  B ,  a n d  ( C  o r  D )  =  r  p o i n t  
R e g a r d i n g  p e r i o d o n ti t i s  c a s e s :  
A )  M e a s u r e m e n t  o f  P P D  o r  C A L  o n  � 6  t e e t h ,  a t  4 - 6  s i t e s  p e r  t o o t h ,  o r  
B )  M e a s u r e m e n t  o f  r a d i o g r a p h i c  a l v e o l a r  b o n e  o n  � 6  t e e th ,  o r  
C )  M e a s u r e m e n t  o f  C P I T N  o n  a l l  t e e t h  a t  4 - 6  s i t e s  p e r  t o o th .  
A  o r  B  o r  C  =  r  p o i n t  
R e g a r d i n g  N o n - P e r i o d o n t i ti s  c o n tr o l s :  
A )  M e a s u r e m e n t  o f  P P D  o r  C A L  o n  � 6  t e e t h ,  a t  4 - 6  s i t e s  p e r  t o o t h ,  o r  
B )  M e a s u r e m e n t  o f  r a d i o g r a p h i c  a l v e o l a r  b o n e  o n  � 6  t e e t h ,  o r  
C )  M e a s u r e m e n t  o f  C P I T N  o n  a l l  t e e t h  a t  4 - 6  s i t e s  p e r  t o o t h .  
A  o r  B  o r  C  =  r  p o i n t  
P e r i o d o n t i ti s  d i s e a s e  a c ti v i t y :  
A )  B O P  m e a s u r e m e n t  o n  � 6  t e e t h  a t  4 - 6  s i t e s  p e r  t o o t h ,  a n d  
B )  r e tr i e v a b l e  a s  t o t a l  n u m b e r  o r  p r o p o r ti o n  o f  t e e t h  w i th  B O P .  
A  a n d  B  =  I  p o i n t  
I s  R A  a s s e s s e d  a c c o r d i n g  t o  1 9 8 7  A C R  c r i t e r i a  i n  c a s e s ?  
Y e s =  I  p o i n t  
N o n - R A  c o n tr o l s  w i t h o u t  c u r r e n t  o r  p a s t  p r o b l e m s  o f  m u l ti p l e  s y m ­
m e t r i c a l  ( l e ft  a n d  r i g h t )  j o i n t s ?  
Y e s =  r  p o i n t  
I n - o r  e x c l u s i o n  o f  i t e m  i n  k e y  c r i t e r i a  s e t :  
K e y  c ri t e ri o n  1 ;  b a s i c  d a t a  o n  n u m b e r  o f  i n c l u d e d  p a t i e n t s ,  a g e  a n d  
s e x  m u s t  b e  p r o v i d e d .  
E x c l u d e d  fr o m  k e y  c r i t e r i a  s e t ;  m o s t  o ft e n  p e r i o d o n t i ti s  p r e s e n c e  
c o u l d  r e a s o n a b l y  b e  a s s u m e d  t o  b e  u n k n o w n  t o  b o t h  p a r ti c i p a n t s  
a n d  r e s e a r c h e r s  p r i o r  t o  d e c i s i o n  o n  p a r ti c i p a ti n g  i n  s t u d y .  
K e y  c ri t e ri o n  2 ;  s u ffi c i e n t l y  v a l i d  m e a s u r e m e n t s  m u s t  b e  p e r f o r m e d  
t o  e s t a b l i s h  p e r i o d o n ti t i s  p r e s e n c e .  
K e y  c ri t e ri o n  3 ;  s u ffi c i e n tl y  v a l i d  m e a s u r e m e n t s  m u s t  b e  p e r f o r m e d  
t o  e s t a b l i s h  p e r i o d o n ti ti s  a b s e n c e .  
E x c l u d e d  fr o m  k e y  c r i t e r i a  s e t ;  p r e s e n c e  o f  p e r i o d o n ti ti s  w a s  d e e m e d  
m o r e  r e l e v a n t  t h a n  s e v e r i t y ,  m o r e o v e r  P P D  a n d  C A L  a r e  m o r e  v a l i d  
m e a s u r e s  o f  p e r i o d o n ti ti s  t h a n  B O P ,  t h e  l a t t e r  r e f l e c ti n g  i n fl a m m a ­
t i o n  w i th o u t  t h e  n e e d  fo r  p e r i o d o n ti t i s  p r e s e n c e .  
K e y  c ri t e ri o n  4 ;  a  v a l i d  d e fi n i ti o n  a n d  d i a g n o s i s  o f  RA  m u s t  b e  e s ­
t a b l i s h e d  i n  R A  p a ti e n t s .  
E x c l u d e d  fr o m  k e y  c r i t e r i a  s e t ;  g i v e n  th e  l o w  p r e v al e n c e  o f  R A  a n d  
t h e  i n t e r e s t  i n  R A  p a ti e n t s  a s  c a s e  g r o u p ,  i t  i s  u n l i k e l y  R A  p a ti e n t s  




g II.  
12. 
13. 
RA disease activity measured according to 
A) ACR criteria for RA disease activity or 
B )  According to Disease Activity Score 28 or 44? 
A or B = r point 
Assessment of dental plaque presence: 
A) Plaque index per sextant scored, and 
B) Plaque levels not significantly different between cases and controls 
or, if significantly different, 
C) Plaque levels were included in a multivariate analysis. 
A and (B or C) = r point 
A) Proportion of smokers within cases and controls given, 
B) Proportion of smokers does not differ significantly between cases 
and controls, or, if significantly different, 
C) Smoking was included in a multivariate analysis. 
A and (B or C) = 1 point 
A) Use of medication was assessed in all patients, and 
B) A stratified analysis for the use of medication was performed, or 
C) The use of medication was included in a multivariate analysis. 
A and (B or C) = 1 point 
A) Presence of other medical conditions was assessed, and 
B) Prevalence of these diseases did not differ significantly between 
cases and controls or, if significantly different, 
C) The prevalence of these diseases was included in a multivariate 
analysis. 
A and (B or C) = r point 
A) Gender distribution did not differ significantly between cases and 
controls or, if it differed significantly, 
B) Gender was included in a multivariate analysis. 
A or B = r point 
lliifi 
Excluded from key criteria set; the presence of RA was deemed more 
relevant than the activity of RA. Exclusion of studies that established 
presence, but not activity of RA was deemed unwanted. 
Key criterion 5; dental plaque is the major etiologic factor causing 
periodontitis. Since RA patients may have decreased hand function­
ing and thus decreased ability to maintain proper oral hygiene levels, 
this may confound an association between periodontitis and RA. 
Key criterion 6; smoking is a major risk factor for both periodontitis 
and RA and may thus confound an association between periodonti­
tis and RA. 
Excluded from key criteria set; obviously RA patients use different 
medication as healthy controls. Although this may influence perio­
dontitis to some extend, excluding articles for not meeting this item 
was deemed to strict. 
Excluded from key criteria set; although both RA and periodontitis 
are associated with other diseases, the potential effect of such associ­
ations on the association between periodontitis and RA was deemed 
insufficiently profound to justify exclusion of articles. 
Key criterion 7; female sex is obviously associated with a highly 




1 4 ·  
1 5 .  
1 6 .  
1 7 .  
1 8 .  
A )  C a s e s  a n d  c o n tr o l s  d i d  n o t  d i ff e r  s i g n i fi c a n tl y  w i t h  r e s p e c t  t o  a g e  
o r ,  i f  s i g n i fi c a n t l y  d i ff e r e n t ,  
B )  A g e  w a s  i n c l u d e d  i n  a  m u l ti v a r i a t e  a n a l y s i s .  
A  o r  B  =  r  p o i n t  
A )  T e s ti n g  fo r  a  s i g n i fi c a n t  d i ff e r e n c e s  b e t w e e n  g r o u p s  i n  n o m i n a l  
d a t a  ( d i s e a s e  p r e s e n c e  o r  a b s e n c e )  w a s  d o n e  u s i n g  a n  a p p r o p r i a t e  t e s t  
( e . g .  C h i  s q u a r e  o r  F i s c h e r ' s  e x a c t  t e s t ) ,  a n d / o r  
B )  T e s ti n g  fo r  t h e  i n f l u e n c e  o f  m u l ti p l e  i n d e p e n d e n t  v a r i a b l e s  o n  a  
d e p e n d e n t  v a r i a b l e  w a s  p e r fo r m e d  u s i n g  m u l ti p l e  l o g i s ti c a l  r e g r e s s i o n  
a n a l y s i s .  
A  a n d / o r  B  =  r  p o i n t  
A )  A  m e a s u r e  o f  e ff e c t  i s  g i v e n ,  a n d  
B )  A  c o n fi d e n c e  i n t e r v a l  ( C I )  i s  g i v e n ,  o r  
C )  T h e  C I  c a n  b e  r e tr i e v e d  fr o m  t h e  d a t a  g i v e n  i n  t h e  a r ti c l e .  
A  a n d  ( B  o r  C )  =  r  p o i n t  
A )  S o u r c e s  o f  fu n d i n g  o r  s p o n s o r s h i p  a r e  e x p l i c i tl y  m e n ti o n e d ,  a n d  
B )  I t  c a n  r e a s o n a b l y  b e  a s s u m e d  t h a t  t h e s e  s o u r c e s  h a v e  n o t  e n d a n ­
g e r e d  th e  fulfillm e n t  o f  a u th o r s '  i m p a r ti a l  s c i e n ti fi c  d u ti e s .  
A  a n d  B  =  r  p o i n t  
W a s  p e r i o d o n t a l  s t a t u s  a s s e s s e d  w i th o u t  kn o w l e d g e  o f  RA  p r e s e n c e ?  
Y e s =  r  p o i n t  
K e y  c ri t e ri o n  8 ;  i n c r e a s i n g  a g e  i s  o b v i o u s l y  a s s o c i a t e d  w i th  a n  i n ­
c r e a s e d  r i s k  o f  p e r i o d o n t i ti s .  S t u d i e s  s h o u l d  a c c o u n t  fo r  t h i s .  
E x c l u d e d  fr o m  k e y  c r i t e r i a  s e t ;  r e l e v a n t ,  b u t  s i n c e  r a w  d a t a  o n  n u m ­
b e r s  o f  p a ti e n t s  w e r e  e n t e r e d  i n  t h e  m e t a - a n a l y s i s ,  n o t  j u s tifi e d  a s  
e x c l u s i o n  c r i t e r i o n .  
E x c l u d e d  fr o m  k e y  c r i t e r i a  s e t ;  a l th o u g h  l o g i c a l  t o  a s s e s s ,  h a r d l y  
d i ff e r e n ti a ti n g .  
E x c l u d e d  fr o m  k e y  c r i t e r i a  s e t ;  E i t h e r  s t a n d a r d l y  m e n ti o n e d  o r  s t a n ­
d a r d l y  l e ft  u n m e n ti o n e d  i n  c e r t a i n  j o u rn a l s .  
E x c l u d e d  f r o m  k e y  c r i t e r i a  s e t ;  S i n c e  b l i n d i n g  a p p e a r s  h a r d  t o  
a c h i e v e  i n  p r a c ti c e ,  e x c h a n g i n g  a  h a n d s h a k e  o r  h a v i n g  a  l o o k  a t  
p a ti e n t s '  h a n d s  c o u l d  e a s i l y  r e v e a l  R A  d i s e a s e  s t a t u s  p r i o r  t o  a  p e r i ­
o d o n t a l  s c r e e n i n g .  P e r i o d o n ti ti s  m e a s u r e m e n t s  a r e  fa i r l y  o b j e c ti v e  
( m e a s u r e m e n t  o f  s p a c e  b e t w e e n  t e e t h  a n d  g u m  e x p r e s s e d  i n  m m ) .  
A n  i nfl u e n c e  o f  o b s e r v e r  b i a s  w a s  d e e m e d  r e l e v a n t  t o  a s s e s s ,  b u t  
i n s u ffi c i e n tl y  p r o fo u n d  t o  j u s tify  e x c l u s i o n  o f  a r ti c l e s .  
Figure 2 Treatment of periodontitis reduces rheumatoid arthritis disease activity: DAS28 
(abbreviations: Cl: confidence interval, DAS28: Disease Activity Score-28) . 
m .. 
0 

















en QI r- 0 0 0 ·- 0 g 0 en ii 0 0 :::- 0 
� 
a. 
g: r- .,,. r- r-co 0 
ta ii "" ,r, "" "" 
C: � 
":' '? ; -r 
<C i, .t:: 
r- a, IC) lC> 
cr, tg .,,. .,.,. a. E '.0 (0 
� 
a. =  9 9 0 0 
ta 
:::, 
� . .  � "" r-g 0) 
Cl) 
� E CD r- r-
QI o ::  � "7 "7 "7 ...I :e .E � N � ,r., � .. r-u ; N 0 "' � 0 
� > 
'O * .,.,. ..,. .. ... '.0 r- r-"' 0  ..,. N N 
'O ... 0 0 
C ,._ a .  
QI "'  0 � co co U C � C nl 
� i  "7 "7 "7 "7 � = 
� 
C 
.x g 0 0 0  0 0 













M i l li  
A  
B l e e d i n g  o n  p r o b i n g  ( a b b r e v i a t i o n s :  B O P :  b l e e d i n g  o n  p r o b i n g ,  C l :  c o n fi d e n c e  i n t e r v a l ,  R A :  r h e u m a t o i d  a r t h r i t i s )  
M o d e l  S t u d y  n a m e  E t h n i c i ty  S m o k i n g  %  
S t a t i s t i c s  f o r  e a c h  s t u d y  
O d d s  L o w e r  U p p e r  
r a t i o  l i m i t  l i m i t  Z - V a l u e  p - V a l u e  
F i x e d  
R a n d o m  
A b o u - R a y a  A  E g y p t  0  0 0 0  
A b e u - R a y a  S  E g y p t  0 , 0 0 0  
K a s s e r  
M e r c a d o  
8 1 y 1 k o g l u  
G e r m a n  2 0 . 0 0 0  
A u s t r a l i a n  1 1 , 0 0 0  
T u r k i s h  2 2 , 0 0 0  
1 1 , 9 6 5  
2 9 , 5 7 1  
2 . 4 1 6  
1 . 0 0 0  
2 4 , 8 8 9  
3 . 6 8 7  
6 . 4 5 3  
4 , 2 8 7  3 3 , 3 9 7  4 , 7 3 9  
0 , 0 0 0  
9 , 7 3 5  8 9 , 8 2 4  5 . 9 7 5  0 , 0 0 0  
1 , 1 9 4  4 , 8 8 7  
2 . 4 5 4  0 , 0 1 4  
0 . 4 7 5  2 , 1 0 6  0 , 0 0 0  
1 , 0 0 0  
2 , 7 9 4  2 2 1 , 7 1 1  2 , 8 8 1  
0 , 0 0 4  
2 . 4 3 3  5 , 5 8 7  6 . 1 5 1  
0 , 0 0 0  
1 , 7 3 7  2 3 , 9 6 5  2 , 7 8 5  0 , 0 0 5  
O d d s  r a t i o  a n d  9 5 %  C l  
- ·  
0 , 0 1  0 , 1  1  1 0  1 0 0  
F a v o u r s  A  F a v o u r s  B  
B  C l i n i c a l  a t t a c h m e n t  l o s s  ( a b b r e v i a t i o n s :  C A L :  c l i n i c a l  a t t a c h m e n t  l o s s ,  C l :  c o n fi d e n c e  i n t e r v a l ,  R A :  r h e u m a t o i d  a r t h r i t i s )  
M o d e l  
F i x e d  
R a n d o m  
S t u d y  n a m e  E t h n i c i ty  S m o k i n g  
A b e u  R a y a  A  E q y p t  
0 %  
A b e u  R a y a  S  E g y p t  0 %  
P 1 s c h o n  
G e r m a n  2 1  %  
O d d s  
r a t i o  
6 2 , 3 6 4  
1 4 , 4 6 2  
5 , 0 8 1  
1 0 , 3 7 3  
1 3 , 2 0 0  
S t a t i s t i c s  f o r  e a c h  s t u d y  O d d s  r a t i o  a n d  9 5 %  C i  
L o w e r  U p p e r  
l i m i t  l i m i t  
Z - V a l u e  p - V a l u e  
7 , 9 7 2  4 8 7 , 8 8 7  3 , 9 3 8  0 , 0 0 0  
3 , 9 7 2  5 2 , 6 5 6  
4 , 0 5 2  0 , 0 0 0  
1 , 7 4 2  1 4 , 8 2 0  
2 , 9 7 6  0 , 0 0 3  
4 , 8 2 6  2 2 , 2 9 7  
5 , 9 9 2  0 , 0 0 0  
3 , 6 9 0  
4 7 , 2 1 7  3 , 9 6 8  0 , 0 0 0  
-fl  
0 , 0 1  
0 , 1  1 0  1 0 0  
F a v o u r s  A  F a v o u r s  B  






























Study name Ethnicity Smoking 
Abeu Raya A Eqypt 0 %  
Abeu Raya S Egypt 0 %  




4, 1 95 
7,538 
6,982 
8,0 1 4  
Statistics for each study Odds ratio and 95% Cl 
Lower Upper 
llmlt llmlt Z-Value p-Value 
5,924 79,007 4,652 0.000 
1 ,8 1 0  9,728 3,342 0,001 
2,070 27.457 3,063 0,002 
3,759 1 2,967 6, 1 52 0 ,000 
3,066 20,945 4,246 0 ,000 ½ 
0,01 0,1 10 1 00 




Selection of relevant studies with at least fair validity 
After removal of duplicates, a total of 798 studies was retrieved from PubMed 
(Medline), Embase (Medline & Embase) and the Cochrane Library (Fig. 1, p99). 
Of these, 56 studies were deemed potentially relevant to answering the research 
questions (non-systematic reviews or case reports were excluded; Cohen's Kappa 
0.93 and overall agreement 97%). Out of the 56 remaining studies, 14 studies 
were deemed to have at least "fair" validity and were therefore included in meta­
analyses (Cohen's Kappa 0.64, overall agreement 82%). 
However, of these 14, 3 studies reported identical data on periodontitis and RA 
from an identical population [14, 18, 37]. These 3 studies were treated as 1 study 
[18], yielding a total of 12. From the remaining 12 studies, 3 RCTs analysed the ef­
fect of treating periodontitis on RA disease activity [30-32]. All three RCTs met the 
8 key criteria set guaranteeing "fair" validity. However, when using the Cochrane 
checklist for the validity of RCTs, one of the three RCTs was considered to have 
poor validity [32], i.e. insufficient information was presented on randomization 
procedures to assure adequate randomization had taken place. The other two ran­
domized controlled clinical trials were deemed to have "fair" validity and were, 
therefore, included in the meta-analysis. 
Thus 1 1  studies, 2 randomized clinical trials [30, 31], 7 original case control stud­
ies on periodontitis prevalence and severity in RA patients [9, 18, 21, 38-41], and 2 
case control studies on the effect of anti-TN Fa treatment on the periodontium of 
RA patients [42, 43] were included in meta-analyses. 
The effect of periodontitis treatment on DAS28 
Two randomized controlled clinical trials with fair quality (level I-fair evidence) could 
be combined to analyse the effect of periodontal treatment on DAS28 [30,31]. A re­
duction in DAS28 of 1.2 (o.6 to 1.7) was observed in RA patients treated for perio­
dontitis versus RA patients who were not treated for periodontitis ( Fig. 2, p103). 
Periodontitis prevalence and severity in RA patients versus healthy controls 
None of the case control studies met all 18 criteria for internal validity. All of the 
included studies showed a higher periodontitis prevalence in RA patients com­
pared to non-RA controls. Thus qualitatively, there appears to be level ll-2-fair evi­
dence of an RA-associated increased prevalence of periodontitis. Quantitatively, 
five studies could be combined to calculate the odds ratio (OR) of bleeding on 
probing (BOP) associated with RA, yielding an OR of 6.4 (1.7 to 24.0; Fig. 3a, 
p104)[18, 21, 38-40]. Three studies could be combined to calculate OR of clinical 
attachment level (CAL; Fig. 3b, p104 and probing pocket depth (PPD; Fig. 3c, 
p105) of > 4mm in RA patients, yielding ORs (95% confidence interval) of respec-
106 
tively 13-2 (3.7 to 47-2) and 8.o (3.1 to 20.9) [9,38,40]. 
Four studies could be combined to calculate mean difference in CAL and PPD  
(respectively, Fig. 4a and 4b, p108) [9,18,39,41]. All but one [41] study showed an 
increased periodontitis severity in RA patients versus healthy controls. This was 
the only study performed in an Asian population of RA patients. When including 
this study, no significant increased severity of periodontitis in RA patients was 
observed (in fixed models, a significant decreased severity of periodontitis was 
observed). When excluding this study, an increase in mean CAL of 1 .6mm (0.9 
to 2.3mm) and an increase in mean PPD of 0.7mm (0.5 to 1.0mm) in RA versus 
non-RA controls was found (Fig. 4c and 4d, p109). 
The effect of anti-TN Fa on the periodontium of RA patients 
None of the two included case control studies met all 18 criteria for internal valid­
ity [42,43]. Both studies showed a reduction in PPD and CAL associated with anti­
TNFa treatment. Thus qualitatively, there is level ll-2-fair evidence of anti-TN Fa 
treatment decreasing PPD and CAL. Quantatively, results of meta-analyses show 
anti-TN Fa treatment reduces CAL and PPD by resp. o.8 (0.7 to 1.0) and 0.5 (0.1 
to o.9)mm (Fig. 5a and 5b, p110). 
One of the case control studies [43] additionally included a follow-up study. Nine 
RA patients underwent periodontal screening prior to start and 9 months after 
treatment with infliximab. The follow-up study showed an increase in gingival in­
flammation (evidenced by increase in BOP), stable PPD values, and decreased CAL 
after infliximab treatment. This indicates infliximab appears to increase gingival 
inflammation, while decreasing attachment loss (progression of periodontitis). 
Generalizability of results 
The studies of Ortiz et al [30] and Al Katma [31] were the only two RCTs that could be 
combined in the meta-analysis. There was no appearant heterogeneity; i.e. identi­
cal RA definition and fairly identical RA disease activity (DAS28 ranging from 4.3 to 
5), drugs used, periodontitis treatment, oral hygiene levels, nationality (American, 
although Al Katma [31] included mainly patients with African-American ethnicity), 
sex distributions (88% female), age (55 years), and exclusion of smokers, preg­
nant women, patients with xerostomia, other systemic diseases (e.g. diabetes), 
or recent use of antibiotics. 
All included case control studies on RA asscociated periodontitis prevalence 
and severity had fairly identical populations, i.e. identical: RA definition and fairly 
identical RA disease durations, drugs used, oral hygiene levels, sex distributions, 
age, and the presence of other diseases (table 2, p112). Differences in study popu­







C l i n i c a l  a t t a c h m e n t  l o s s  
(
a b b r e v i a t i o n s :  C A L :  c l i n i c a l  a t t a c h m e n t  l o s s ,  C l :  c o n fi d e n c e  i n t e r v a l ,  R A :  r h e u m a t o i d  a r t h r i t i s )  
M o d e l  S t u d y  n a m e  S m o k i n g  'lo  
S t a t i s ti c s  f o r  e a c h  s t u d y  
D i ff e r e n c e  I n  m e a n s  a n d  9 5 %  C l  
D i f f e r e n c e  S t a n d a r d  
L o w e r  U p p e r  
i n  m e a n s  e r r o r  
V a r i a n c e  l i m i t  
l l m l t  Z - V a l u e  p - V a l u e  
B  y 1 k o g l 1 .1  T u • k 1 s h  2 0  0 0 0  2  2 0 0  0  1 9 0  0  0 1 6  1  8 2 9  
2  5 7 1  1 1  6 0 9  
0  0 0 0  
. c[  
K a s s e r  G e r m a n  2 0  0 0 0  
1  6 5 0  0 1 %  
0  0 3 8  1  2 6 7  2  0 1 1  
8  4 3 6  0  0 0 0  
P 1 s c h o n  G e r m a n  2 1  0 0 0  0  9 7 0  0  2 1 5  0  0 4 6  0  5 "1 8  
1  3 9 2  4  5 0 3  0 0 0 0  
K o b a y a s h i  J a p a r. e s e 7  0 00  - 0  3 0 0  0  0 3 0  
0 0 0 1  - 0  3 5 9  
- 0  2 4 1  - 9  8 8 5  0  0 00  
F i x e d  - 0  1 7 3  0  0 2 9  0  0 0 1  - 0  2 3 0  
- 0  1 1 5  - 5  8 8 1  0  0 0 0  
R a n d o m  
1  1 2 4  
0  7 0 9  0  5 0 3  - 0  2 6 6  2 . 5 1 4  
1  5 8 5  
0  1 1 3  
- 4 , 0 0  - 2 , 0 0  
0 , 0 0  2 , 0 0  4 , 0 0  
F a v o u r s  A  
F a v o u r s  B  
B  
P r o b i n g  p o c k e t  d e p t h  
(
a b b r e v i a t i o n s :  C l :  c o n fi d e n c e  i n t e r v a l ,  P P D :  p r o b i n g  p o c k e t  d e p t h ,  R A :  r h e u m a t o i d  a r t h r i t i s )  
�  S tu d y n a m e  S m o k i n g  
S t a t i s ti c s  T o r  e a c h  s t u d y  
D i ff e r e n c e  i n  m e a n s  a n d  9 5 %  C l  
D i ff e r e n c e  S t a n d a r d  L o w e r  U p p e r  
I n  m e a n s  e r r o r  V a r i a n c e  l i m i t  l i m i t  
Z - V a l u e  p - V a l u e  
B 1 y 1 k o g l u  T u r k i s h  2 0  0 0 0  1  0 0 0  
0  1 3 7  0  0 1 9  0  7 3 2  1  2 6 8  7  3 1 6  0  0 0 0  
i:  
K a s s e r  G e r m a n  2 0  0 0 0  0  6 0 0  
0  0 9 7  0  0 1 0  0  4 0 9  0  7 9 1  6  1 5 5  0  0 0 0  
P 1 s c h o n  G e r m a n  2 1  0 0 0  
0  5 5 0  0  1 2 7  0  0 1 6  0  3 0 1  0  7 9 9  4  3 2 7  0  0 0 0  
K o b a y a s h i  J a p a n e s e 7 . 0 0 0  
- 0  3 0 0  0  0 3 0  0  0 0 1  - 0  3 5 9  - 0  2 � 1  
- 9  8 8 5  0  0 0 0  
F , x e d  
- 0  1 3 4  0  0 2 8  0 0 0 1  · O  1 8 8  
- 0  0 8 0  · 4  8 4 2  0  0 0 0  
R a n d o m  0  4 5 6  
0  3 4 5  0  1 1 9  - 0  2 2 0  1  1 3 2  1  3 2 2  0  1 8 6  
- 4 . 0 0  
- 2 , 0 0  0 , 0 0  2 , 0 0  
4 , 0 0  
F a v o u r s  A  F a v o u r s  B  
"T1  


































C Clinical attachment loss (abbreviations: CAL: clinical attachment loss, C l :  confidence interval, RA: rheumatoid arthritis) 






Turkish 20 000 
German 20 000 
German 21 000 
Difference Standard 
In means error 
2 200 0 190 
1 650 0 196 
0 970 0 215 
1 659 0 1 15 
1 613 0 350 





















Difference In means and 96% Cl 
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D Probing pocket depth (abbreviations: C l :  confidence interval, PPD: probing pocket depth, RA: rheumatoid arthritis) 
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Regarding disease activity, DAS28 differed from 5.4 (high disease activity) to 3.2 
(low disease activity). Unfortunately, DAS28 could not be retrieved or calculated 
from the data in 2 of the 7 included case control studies [21, 39]. Of the three case 
control studies showing a significant increase in CAL and PPD, the lowest mean 
reported difference in CAL and PDD between RA patients and controls was ob­
served in patients with the lowest RA disease activity (with DAS28 3.2 to 3.4) [9]. 
Additionally, the one study that showed no significant difference in CAL and PPD 
contained 28 RA patients with a low disease activity (DAS28 <3.2), 48 RA patients 
with intermediate disease activity (DAS28 <5.1), while only 8 patients had high 
disease activity (DAS28 >5.1) [41]. 
Regarding nationality, studies in Egyptian and Turkish RA patients yielded 
a considerably higher RA-associated periodontitis risk than studies in European 
(German) and Australian RA patients, when BOP was used as a measure of peri­
odontitis. The influence of ethnicity was inconsistent for RA-associated increased 
risk of PPD and CAL. As stated earlier, the one that did not show an increased 
severity of periodontitis in RA patients was the only study performed on an Asian 
(Japanese) population [41]. 
Regarding smoking as a source of heterogeneity, smoking was excluded in 
the two studies from Egypt, while the other studies were relatively homogeneous 
with percentages of smokers of 7, 11, 20, 21 and 22%. The influence of smoking 
on the observed results was inconsistent. 
Sources of heterogeneity for the two included case control studies on the 
effect of anti-TN Fa treatment on the periodontium of RA patients pertained to 
disease activity (DAS28 3.4 vs. 4.9) and outcome regarding BOP (increased vs. 
decreased in infliximab treated RA patients, table 3, p1 1 4) [42,43]. Study popula­
tions were otherwise homogeneous. 
D I SCUSS ION 
Although numerous well-written narrative reviews have appeared on this issue 
[44-51], this is the first time a meta-analysis was performed summarizing the best 
available evidence on the association between periodontitis and RA. The assess­
ment of the methodological quality of available evidence in a non-biased, repro­
ducible manner and summarizing the available evidence quantitatively, as per­
formed in this review, carries substantial advantages over these reviews. 
This study showed there is level I -fair evidence of periodontitis treatment re­
ducing RA disease activity. Moreover, there is level l l -2-fair evidence of an RA-as­
sociated increased periodontitis prevalence as compared to healthy controls. Ad­
ditionally, this study showed severity of periodontitis was increased in RA patients 
versus healthy controls only when excluding Japanese RA patients. When Japanese 
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observed. Finally, there is level l l -2-fair evidence of anti-TN Fa treatment reducing 
periodontitis severity in RA patients. 
Since RA patients suffer from periodontitis more often than healthy controls, 
despite anti-TN Fa treatment and independent of smoking status, oral hygiene, 
age and sex differences, RA appears to be associated with periodontitis develop­
ment. Prevention and treatment of periodontitis in RA patients may thus be need­
ed to safeguard oral health and improve quality of life. Perhaps more interestingly, 
periodontitis may also predipose to RA and/or an increased RA disease activity, as 
periodontitis treatment may decrease RA disease activity. 
Notwithstanding these findings, there is a need to further strengthen the evi­
dence on the association between RA and periodontitis. The results of this meta­
analysis were based on a limited number of studies, which has probably resulted in 
wide confidence intervals around the calculated ORs for RA-associated periodon­
titis risk. Meta-analyses may give rise to spurious results caused by residual bias 
and confounding. In general, positive results from case control studies and small 
trials are far more likely to get published than negative results. The created funnel 
plots did not hint towards the presence of such publication bias (data not shown). 
However, since only small groups of studies could be included in the analyses, the 
value of funnel plots may be limited. Thus, there is a need to confirm these findings 
by more and larger observational and intervention studies that deal with at least 
some of the issues that potentially harm the validity of the present results. 
One issue potentially harming validity of studies performed on the RA-perio­
dontitis link is selection bias. As periodontitis is a major cause of tooth loss, RA­
associated periodontitis may cause early loss of teeth in RA patients. RA patients 
with too few teeth for evaluation of periodontitis presence were excluded, having 
potentially led to an underestimation of 'true' periodontitis prevalence and sever­
ity in RA patients. Thus, RA-associated increased periodontitis prevalence and sever­
ity may be higher than presently reported. 
One study selected dental professionals as healthy controls, potentially having 
better oral health than the general population [39]. Since it were these controls 
to which RA patients were compared, RA-associated periodontitis severity might 
have been overestimated. Accordingly, Biyikoglu et al. [39] found the highest RA­
associated increase in periodontitis severity (Fig. 4, p108,109). Finally, the effect 
of selection bias resulting from (sub)conscious choices on study participation, 
made by researchers and participants alike, are considered small, as it may rea­
sonably be assumed that most patients and certainly clinicians were unaware of 
periodontal status at the time of selection. 
Two additional issues potentially harming validity of studies on RA and peri­
odontitis are observer bias and placebo effects. In RCTs, the effect of periodon­
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fa s a l a z i n e ,  h y d r o x y c h l o r o q u i n e  
D A S 2 8 : :  d i s e a s e  a c ti v i t y  s c o r e  2 8 ,  M TX ;  m e t o t r e x a t e ,  N S A I D S ;  n o n - s t e r i o d  a n t i  i n fl a m m a t o r y  d r u g s ,  R A ;  r h e u m a t o i d  a r t h r i ti s ,  S D ;  s t a n d a r d  d e v i a t i o n  
groups simply received no treatment). One might argue these flaws to be fatal, 
yielding poor instead of fair quality evidence. 
However, RCTs reported decrease in tender and swollen joint counts, CRP, ery­
throcyte sedimentation rate and visual analog scores (VAS), of which only the first 
0oint counts) and the last (VAS) were deemed sensitive to respectively observer 
bias (lack of blinding) and placebo effects. 
Furthermore, establishing placebo periodontitis treatment may be difficult to 
achieve. Still, observer bias and placebo effects may have lead to an overestima­
tion of the effect of periodontitis treatment on reducing RA disease activity. 
Like RCTs, case control studies included in the analyses often did not report 
whether periodontitis presence was assessed blinded for the presence of RA. 
Again, one might argue these flaws to be fatal, yielding poor instead of fair quality 
evidence. The main reason why blinding was not included in the key criteria set 
guaranteeing at least fair validity, was that periodontitis measurements are fairly 
objective (measurement of space between teeth and gum expressed in mm). Mo­
reover, screening for periodontitis presence was most often performed in a simi­
lar fashion for all study participants. Thus, although observer bias may have lead 
to an over-estimation of RA-associated periodontitis risk, lack of blinding was 
presumed not to harm validity to such an extend, as to qualify evidence as poor. 
Apart from these qualification issues, there is an obvious need to strengthen 
the evidence on the association between RA and periodontitis. To improve the 
strength of evidence some specific recommendations can be made. Future case 
control studies should 1) randomly select patients (including edentulous RA pa­
tients), 2) report inclusion rates, 3) blind clinicians evaluating periodontal status 
to RA disease status and 4) use uniform continuous measures for periodontitis, 
like the recently developed periodontal inflamed surface area [52]. Future RCTs 
should 1 )  randomly allocate RA patients either to periodontitis treatment or to 
some form of placebo treatment that does not counter periodontitis (e.g. rinsing 
the mouth with a placebo solution) and 2) blind both the clinician evaluating RA 
disease activity, as well as the person performing statistical analyses, for periodon­
titis treatment status. 
A final threat to validity of studies on RA and periodontitis may be confounding. 
Only studies adequately adjusting for confounding by sex, age, smoking and oral 
hygiene were included in this meta-analysis. Residual confounding by medication 
use and concomittent diseases may have occured. However, medication used in 
RA has been shown to exert anti-inflammatory effects on periodontitis [53-55]. This 
is also evidenced by our results showing anti-TN Fa treatment reduces periodonti­
tis severity. Thus, if any confounding by drug use exists, this has most likely led to 
an underestimation of RA-associated periodontitis risk and severity. Since conco-
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mittent diseases that may predispose to periodontitis (e.g. diabetes) were always 
excluded from the studies included in this meta-analysis (except [9]), this type of 
confoudinding poses little threat to the observed association. 
Due to the many common characteristics of study populations, little threat to 
generalizability of the results of this meta-analysis may be assumed. The two in­
cluded RCTs exhibited no appearant heterogeneity. However, this may simply be 
due to the fact that only two studies were included. In contrast, heterogeneity was 
evident in case control studies and pertained to RA disease activity, nationality and 
smoking (table 2 p112). The study reporting the lowest mean difference in CAL and 
PPD between RA cases and controls also had lowest RA disease activity [9]. The 
one study that showed no significant difference in CAL and PPD contained only 8 
(out of 84) RA patients with DAS28 >5.1 [41]. Thus, increased RA disease activity 
may be associated with increased severity of periodontitis and vice versa. 
Studies in Egyptian and Turkish RA patients yielded a considerably higher RA­
associated risk of BOP than studies in European and Australian RA patients. How­
ever, BOP is a measure of inflammation not necessarily indicative for the presence 
of periodontitis. 
The influence of ethnicity was inconsistent for RA-associated increased risk of 
PPD and CAL, more valid periodontitis measures. Finally, the one study that did 
not show an increased severity of periodontitis in RA patients was the only study 
performed on an Asian (Japanese) population [41]. Thus, RA-associated risk of 
BOP and RA-associated increased severity of periodontitis may be influenced by 
differences in environmental, life style and genetic factors associated with differ­
ences in nationality. In contrast to disease activity and nationality, smoking did not 
exert clear and consistent influences on RA-associated periodontitis risk. 
The two case control studies on the effect of anti-TN Fa treatment on the perio­
dontium of RA patients differed in RA disease activity and their results regarding 
BOP (table 3). Pers et al. [43] (DAS28 around 3.5) found only a small reduction in 
PPD and CAL associated with anti-TN Fa treatment, while Mayer et al. [42] (DAS28 
around 5) found rather large reductions. Thus, anti-TN Fa treatment reduces peri­
odontitis severity, but patients with more active RA may benefit more from such a 
reduction than RA patients with less active disease. As RA patients with less active 
disease also appear to have less severe periodontitis (see above), this appears logi­
cal. Given these results, the fact that included RA patients received anti-TN Fa treat­
ment may explain why two of the case control studies [9, 41] respectively reported 
the lowest and a non-significant increase in periodontitis severity (table 2, p112, fig. 
4a,b p108). 
The increased risk of BOP associated with anti-TN Fa treatment in Pers et al. 's 
study [43], versus the decreased risk of BOP in Mayer et al.'s study [42], may well 
be explained by the fact that the former expressed BOP risk as an index score 
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(papillary bleeding index) while the latter expressed BOP as the percentage of sites 
actually bleeding after probing. These different dimensions of the same phenom­
enum are difficult to compare, emphasizing the need for using uniform measures 
of periodontitis. 
Notwithstanding the need for additional studies to strengthen the evidence, 
there appears to be a RA-associated increased periodontitis risk that is independ­
ent of confounding by oral hygiene levels, smoking, sex and age. Moreover, perio­
dontitis may play a role in the etiology of RA or contribute to increased RA disease 
activity, as treatment of periodontitis appears to reduce RA disease activity. 
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The periodontium of periodontitis patients 
contains citrullinated proteins which may play a 




Objective: Anti citrullinated protein antibodies (ACPAs) may play a role in the 
etiology of rheumatoid arthritis (RA). Periodontitis, an inflammation of the tis­
sues surrounding and anchoring the tooth roots, contains all of the ingredients 
necessary to induce ACPA formation. However, whether citrullinated proteins are 
present in periodontitis tissue is currently unknown. 
Methods: Periodontal tissue samples of 15 randomly selected periodontitis pa­
tients and 6 non-periodontitis controls, both without any other known diseases, 
were stained for the presence of citrullinated proteins using polyclonal (Ab5612) 
and monoclonal (F95) antibodies. Synovial tissue samples of four RA patients 
and buccal mucosal swabs of three healthy controls were used as control tis­
sues. 
Results: In stroma, increased citrullinated protein presence (80%) was observed 
in periodontitis tissue as compared to control tissue (33%). In control tissue, cit­
rullinated protein presence in stroma was associated with inflammation of non­
periodontitis origin. Periodontal epithel ium in periodontitis tissue always stained 
positive for Ab5612 and F95, while control periodontal epithelial tissue stained 
positive for Ab5612 only. Three out of 4 synovial tissue samples and all buccal 
mucosal swabs stained positive for both Ab5612 and F95. 
Conclusion: Within the periodontal stroma, citrullinated protein formation ap­
pears to be an inflammation-depended process. In periodontal epithelium, in­
flammation may lead to the formation of different types of citrullinated proteins 
than the types of citrullinated protein present in non-inflamed periodontal epi­
thelium. In the presence of H LA DRB1 shared epitope and smoking, citrullinated 




Hippocrates was probably the first (400 BCE) to report on the association between 
oral health and 'rheumatism' by reporting a case of joint pain being successfully 
treated after extraction of a single tooth (1). More recently, evidence from epi­
demiologic studies has pointed out that patients with rheumatoid arthritis (RA) 
have a significantly increased prevalence of periodontitis, an inflammation of the 
structures surrounding and anchoring the teeth that leads to destruction of these 
tissues (2-8). Moreover, disease severity of the one (RA or periodontitis) seems to 
be related to disease severity of the other (9-11). To prove that Hippocrates' state­
ment might not have been far from the truth, recent intervention studies pointed 
towards a beneficial effect of treating periodontitis on RA disease activity; i.e. a 
reduction in number of tender and swollen joints, CRP, ESR, VAS-scores, and 
consequently DAS28, was observed after treating periodontitis (12-14). 
Anti citrullinated protein antibodies (ACPA) are highly specific for RA and are 
suspected of playing a role in the etiology of RA (15-17). The discovery of ACPA in 
1964, then called anti-perinuclear factor, was made on buccal epithelial cells (18). 
In addition to the presence of citrullinated proteins in buccal epithelium from 
within the oral cavity, the periodontal epithelium may also contain citrullinated 
proteins. In fact, periodontitis, a chronic inflammation of the structures anchor­
ing the teeth within the jaws, that arises in response to infection of these tissues, 
has been hypothesized as being an inducer of anti citrullinated protein antibody 
(ACPA) formation (19). In support of this hypothesis, the presence of periodon­
titis in RA has recently been shown to be associated with ACPA positivity (20). 
There are further lines of evidence in support of periodontitis as inducer of ACPA 
formation. First, both periodontitis and ACPA formation share the same envi­
ronmental and genetic risk factors, viz. smoking (21 ,22) and HLA-DR4 shared 
epitope (23). Second, Porphyromas gingivalis, a major pathogen in periodontitis, 
is the only known bacterium to contain a peptidyl arginine deiminase (PAD) en­
zyme (24). The formation of citrullinated proteins is catalyzed by PAD enzymes. 
Therefore, PAD formed by P. gingivalis may cause citrullinated protein formation, 
which may in turn elicit an antibody response to these proteins, i.e. lead to ACPA 
formation. Furthermore, citrullinated a-enolase peptide 1, is considered to be a 
major auto-antigen in RA. This immunodominant peptide showed 82% homol­
ogy with citrullinated enolase from P. gingivalis. Thus, ACPA response to syno­
vial citrullinated a-enolase may be induced by P. gingivalis produced citrullinated 
enolase in the periodontium (25). Moreover, antibody titers to P. gingivalis are 
correlated with ACPA titers of RA patients (26). This implies that P. gingivalis, 
either through PAD, citrullinated enolase or otherwise, contributes to inducing 
ACPA formation. A third line of evidence implicating periodontitis as an inducer 




Figure 1 Hypothetical model: periodontitis initiates ACPA formation. 
Periodontitis, together with exposure to tobacco smoke and PAD enzymes from P.gingivalis (a 
major pathogen causing periodontitis) may cause citrullination of joint-specific proteins, i.e. 
auto-antigens implicated in RA. In conjunction with the H LA-DRB1 shared epitope and expo­
sure to tobacco smoke, an ACPA response could be initiated in the periodontium. Abbreviations: 
ACPAs: anti citrullinated protein antibodies; H LA-D R B1 se: human leukocyte antigen complex 
encoding for the peptide binding pocket of the DRB1 molecule; PAD: peptidyl arginine deiminase; 
P.gingivalis: Porphyromonas gingiva/is; RA: rheumatoid arthritis. 
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occurs in periodontitis. Strikingly, the auto-antibodies produced in periodontitis 
mainly target collagen (27). Furthermore, citrullination is known for its ability to 
break immunological tolerance (28)1 and ACPAs are known for recognizing two 
or more different citrullinated peptides (29). Therefore, an auto-antibody (ACPA) 
response against citrullinated collagen initiated in the periodontium, might cross 
react with citrullinated collagen in the synovium. 
In summary, ACPAs are thought to play an important role in the aetiology of 
RA and periodontitis might, for more than one good reason, be involved in the 
initiation of ACPA formation (fig 1). However, the presence of citrullinated pro­
teins is a necessary ingredient for ACPA formation. As yet, it is unknown whether 
citrullinated proteins are present in periodontitis tissue. Therefore, this study 
was designed to assess the presence and localisation (stromal vs. epithelial) of 
citrullinated proteins in periodontitis tissue as compared to non-periodontitis 
controls. The periodontal epithelium might be expected to contain citrullinated 
proteins, while their presence in stroma is uncertain. Another reason for compar­
ing periodontal epithelium with periodontal stroma, is that the latter contains 
plasma- and many other infiltrating inflammatory cells, whereas the periodontal 
epithelium contains only a few inflammatory cells. 
M ETHODS 
Patients and tissue samples 
Patients with chronic persistent periodontitis, not responding to initial therapy, 
are routinely subjected to surgical excision of the inflamed part of their periodon­
tium. Periodontal tissue samples of 15 randomly selected periodontitis patients, 
without any other known medical condition (including RA), undergoing such sur­
gical excision were obtained. Information on age, sex, smoking (pack years) and 
periodontitis severity was obtained from patients' dental records, in which these 
data were routinely recorded. Clinically non-inflamed periodontal tissue samples 
(no bleeding on probing, no periodontal pockets � 4mm) were obtained from 
6 patients undergoing prophylactic removal of impacted third molars (wisdom 
teeth). Synovial tissue samples of 4 RA patients, previously obtained during joint 
replacing surgery, and buccal mucosa I cell swabs of 3 healthy persons, were used 
as positive control tissues for citrullinated protein staining. Informed consent 
was obtained from all patients and the institutional review board approved this 
study. 
Processing the tissue samples 
After excision, periodontal tissue samples of periodontitis patients were symmetri­
cally dissected. Immediately thereafter, half of the sample was frozen using liquid 




Figure 2 Citrullinated proteins are present in periodontium of periodontitis patients and in 
synovium of RA patients using rabbit anti-citrullinated protein polyclonal antibody 
Ab561 2, magnification 10ox. 
A. Synovium of RA patient (blanc) : No false positive staining for citrullinated proteins 
was shown using a rabbit lgG control followed by secondary antibody staining. 
B. Synovium of RA patient: Brown staining indicates the presence of citrullinated pro­
teins using a rabbit anti-citrullinated protein polyclonal antibody (Ab561 2) followed by 
secondary antibody staining. 
C. Periodontium of periodontitis patient (blanc) :  No false positive staining for citrulli­
nated proteins was shown using a rabbit lgG control followed by secondary antibody 
staining. 
D. Periodontium of periodontitis patient: Brown staining indicates the presence of 
citrullinated proteins using a rabbit anti-citrullinated protein polyclonal antibody 
(Ab5612) followed by secondary antibody staining. 
fin. Cryostat sections were fixated in acetone and endogenous peroxidase was 




) in phophate buffered saline (PBS). 
Then cryostat sections were incubated with either of two primary antibodies: 1) 
anti-citrullinated protein rabbit polyclonal antibody (Ab5612, Millipore, Massa­
chusetts, USA) diluted 1:100 in PBS + 1% bovine serum albumin (BSA), and 2) 
mouse anti-citrullinated protein lgM monoclonal antibody (F95, kindly provided 
by AP. Nicholas, University of Alabama, Birmingham, USA) diluted 1:1000 in 




, the cryostat sections 
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were blocked with 10% pool serum in PBS when F95 was used. Finally, detection 
of primary antibodies was performed using respectively 1) a goat anti-Rabbit. 
(Dako, Glostrup, Denmark) diluted 1:50 in PBS + 1% BSA for Ab5612 and 2) a goat 
anti-Mouse lgM-HRP (Southern Biotech, Alabama, USA) diluted 1:500 in PBS + 
1% AB serum for F95, followed by using a DAB kit (Dako, K3467). 
Cryostat sections of 6 clinically non-inflamed periodontal tissue samples and 
4 synovial tissue samples of RA patients were stained for citrullinated proteins 
in a similar manner as periodontal tissue samples from periodontitis patients. 
Likewise, the buccal mucosal swabs, fixated in acetone, were stained. All tissue 
samples were hematoxylin and eosin (HE) stained. As control for false positive 
staining, all tissues were additionally stained using control primary antibodies 
(a mouse lgM isotype control for F95 (Southern Biotech, clone 11 E10, 1:1000 in 
PBS) and rabbit lgG control for Ab5612 (Southern Biotech, nr. om-01 , 1 : 100 in 
PBS + 1% BSA)), followed by identical detection procedures. Finally, the presence 
of citrullinated proteins in periodontitis tissue and synovium was analysed quali­
tatively, i.e. either present or absent. 
To obtain information on cell types involved in the inflammatory periodontitis 
lesions, paraffin sections of periodontitis tissues were stained for CD3 (Monosan, 
Uden, Netherlands, clone PS1, 1:20; T-cells), CD20 (Dako, Glostrup, Denmark, 
clone L-26, 1:200; B-cells), CD138 ( IQ Products, Groningen, The Netherlands, 
clone B-A38, 1 :80; plasma cells), CD68 ( Dako, clone KP, ,  1:100; macrophages), 
CD1a ( lmmunotech, Marseille, France, clone 010, R.T.U.; dendritic cells), CD31 
(Dako, clone JC  70A, 1 :40; endothelial cells) and toluidine blue (mast cells). Stain­
ing with antibodies was performed using standard methods as described by the 
manufacturers. 
Analysis of the periodontitis tissue samples 
All positive cells were counted in 10 adjacent fields with a 4ox objective (mag­
nification 4oox) per periodontitis tissue sample, after which medians and inter­
quartile ranges of cell numbers were calculated for each cell type. 
Statistical analysis 
To explore factors possibly linked to the formation of citrullinated proteins in 
the periodontium, periodontitis patients whose periodontal tissue samples did 
and did not contain citrullinated proteins were compared with respect to age, 
sex, smoking, periodontitis severity (probing pocket depth) and the amounts of 
inflammatory cell types, using student t-test, Mann-Whitney U- and Chi-square 
tests as appropriate. Significance level a was set at 0.05 and subsequently cor­




Figure 3 Citrullinated proteins are present in periodontium of periodontitis patients and in 
synovium of RA patients using mouse anti-citrullinated protein monoclonal antibody 
F95, magnification 10ox. 
A. Synovium of RA patient (blanc) :  No false positive staining for citrullinated proteins 
was shown using mouse lgM isotype control followed by secondary antibody stain­
ing. 
B. Synovium of RA patient: Brown staining indicates the presence of citrullinated pro­
teins using mouse anti-citrulline antibody (F95) followed by secondary antibody stain­
ing. 
C. Periodontium of periodontitis patient (blanc) :  No false positive staining for citrulli­
nated proteins was shown using mouse lgM isotype control followed by secondary 
antibody staining. 
D. Periodontium of periodontitis patient: Brown staining indicates the presence of cit­
rullinated proteins using anti-citrulline antibody (F95) followed by secondary antibody 
staining. 
R ES U LTS 
In stroma, citrullinated proteins were detected in 53% (n=8) , 67% (n=10) and 
80% (n=12) of periodontitis tissue samples using, respectively, Ab5612, F95, or 
either antibody (figure 2 & 3, p126 & p128) . Out of 6 control periodontal tissue 
samples, 2 tissue samples were from persons that had complained of pain and 
swelling in the previous weeks, although not clinically evident at the time of sur­
gery. Citrullinated proteins were detected in stroma of these 2 controls only. In 1 
of these 2 controls this was apparently associated with an inflammatory infiltrate. 
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Thus, citrullinated proteins were detected in stroma of 33% (2 in 6) of control tis­
sue samples. Citrullinated proteins were detected in 3 and 4 out of 4 synovial tis­
sue samples of RA patients using Ab561 2 or F95 respectively. The buccal mucosal 
cell swabs were positive for both antibodies (fig 4, only F95 shown, p130). 
Only 3 out of 15 periodontitis patients were negative for citrullinated proteins, 
i.e. neither AB5612 nor F95 was positive in stroma. For these 3 patients, there 
were no macrophages (CD68) per visible field. In contrast, in citrulline positive 
patients (n=12) median number of macrophages per visual field was 2.0 with an 
interquartile range of o to 4.5 (p=o.01 1 ). This difference was not significant after 
correcting significance level a with Bonferroni-Holm correction for multiple com­
parisons, probably due to small numbers. 
Likewise, there were no statistically significant differences in age, sex, smoking 
(current and pack years) and periodontitis severity between periodontitis patients 
whose stroma contained citrullinated proteins (using Ab5612, F95, or either anti­
body) and those whose periodontium did not. 
In epithelium, citrullinated proteins were detected in periodontitis and control 
tissue samples whenever using Ab5612. In contrast, when using F95, epithelium 
stained positive in periodontitis tissue samples only. 
DISCUSSION 
To the best of our knowledge, this was the first study that showed citrullinated 
proteins are present in periodontal tissue (30) and this is the first full paper on 
this issue. Increased citrullinated protein presence (80%) was observed in stro­
ma of periodontitis tissue compared to control tissue (33%) when considering 
either antibody (Ab5612 or F95) to be positive. Recently, our results have been 
confirmed by others in an abstract, i.e. showing citrullinated protein presence 
in 80% of periodontitis patients and in 40% of healthy controls (31 ). In control 
periodontal tissue, citrullinated protein presence appeared to be associated with 
inflammation of non-periodontitis origin. Thus, citrullinated protein formation 
within the periodontal stroma appears to be an inflammation-depended process. 
This is in agreement with previous studies showing that the formation of citrulli­
nated proteins in other sites of the human body is inflammation-driven (32). 
Periodontal epithelium, whether inflamed or not, stained positive for Ab5612. 
Citrullinated protein detection in epithelium of periodontitis tissue samples could 
have been expected. In fact, the discovery of ACPA in 1 964, then named anti­
perinuclear factor for perinuclear staining pattern, was made on buccal mucosa! 
cells (18). Filaggrin, a keratin binding protein abundantly present in epithelium, 
is known to bind ACPA (33). Citrullinated proteins have also been shown to be 
present in the epidermis (34). It has even been posed that citrullination plays an 




Figure 4 Citrullinated proteins are present in buccal epithelial cells of healthy subjects and in 
periodontal epithelium of a periodontitis patient using mouse anti-citrullinated pro­
tein monoclonal antibody (F95) . 
A. Buccal epithelial cells of healthy subjects: The speckled cytoplasmic, perinuclear and 
nuclear brown staining, as originally described by N ienhuis and Mandema in 1 964, 
indicates presence of citrullinated proteins (F95. magnification 4oox) . 
B. Periodontal epithelium of a periodontitis patient: Brown staining indicates presence 
of citrullinated proteins (F95. magnification 20ox) . 
of keratin filaments. I n  other words, citrullinated proteins naturally occur in epi­
thelial tissues. This study is the first to show the presence of citrullinated proteins 
in epithelium of periodontitis tissue samples. In periodontal epithelium, inflam­
mation may lead to the formation of different types of citrullinated proteins (tar­
geted by F95 and Ab5612} than the types of citrullinated proteins naturally present 
in (non-inflamed) periodontal epithelium (targeted by Ab5612 only). 
While positive staining for F95 appears to be restricted to inflamed periodontal 
epithelium, buccal epithelial cells of selected healthy controls also stained posi­
tive for F95. Buccal and sulcus epithelium constitute different epithelial types and 
are exposed to differencent local environmental influences within the oral cavity 
which may explain the observed differences in staining for F95. When using the 
swab technique to collect buccal cells, losely attached terminally differentiated 
apoptotic cells are collected. Citrullination is known to occur in apatotic cells. 
Apoptosis may explain the staining of F95 on buccal mucosa! cells obtained via 
swab technique. Thus, the presence of citrullinated proteins targeted by F95 in 
buccal mucosa! cells is most likely physiologic and unrelated to ACPA associated 
aetiology of RA (35, 36). 
I n  contrast, the finding of citrullinated proteins in periodontitis tissue may be 
of particular relevance to solving the issues of how ACPA formation is initiated, 
and why ACPAs specifically target joints (fig. 1, p124). ACPA production shares ge­
netic and environmental risk factors with periodontitis, namely H LA-DRB1 shared 
epitope and smoking (21 -23). Auto-antibody production is a common event in 
periodontitis and can be found locally as well as in serum of periodontitis patients 
(27). The periodontium contains many of the cellular and structural components 
of a joint, in fact it is a fibrous joint called ghomphosis. Where other fibrous joints 
are only composed of bones and fibrous connective tissue, the periodontium is 
additionally composed of joint space (gingival sulcus or pocket) filled with fluid 
(gingival crevicular fluid) that is partially surrounded by epithelium. Thus, the 
periodontium is a fibrous joint that shares structural similarities with synovial 
joints. The periodontium contain collagens, proteoglycans and hyaluronic acid, 
major constituents of cartilage (37). When these extra-cellular matrix components 
are degraded by the activity of matrix metalloproteases and subsequently phago­
cytized by macrophages, as is the case in both RA and periodontitis, an auto­
antibody response may be initiated in the periodontium targeting the same com­
ponents in joints. In this respect it is striking that the number of macrophages in 
stroma of periodontitis tissue samples without detectable citrullinated proteins 
(n=3) is consistently zero, whereas their numbers are small, but almost consist­
ently higher in stroma of periodontitis tissue containing citrullinated proteins. 
The presence of macrophages thus appears to be associated with citrullinated 
protein formation in periodontitis stroma, indicating the potential importance of 
macrophages in the formation of citrullinated proteins. 
No significant differences were found with regards to any of the other investi­
gated parameters between citrullinated protein positive and negative periodon­
titis stroma (i.e. age, severity of periodontitis, sex, and smoking). However, this 
may be due to the small number of patients. Many of the major auto-antigens 
targeted by ACPA in RA can be found within the periodontium. The periodontal 
epithelium contains keratin and filaggrin, and periodontal fibroblasts express vi­
mentin. Although not examined in this study, these proteins might get citrullinat­
ed in periodontitis tissue, thus stimulating or initiating ACPA formation against 
these major auto-antigens in RA. 
Citrullinated a-enolase is considered to be another major autoantigen in RA. 
ACPA response to synovial citrullinated a-enolase may be induced by P. gingivalis 
produced citrullinated enolase in the periodontium, since both share a largely 
identical immunodominant epitope (24,25). Moreover, antibody titers to P. gin­
givalis are correlated with ACPA titers of RA patients (26). Thus, P. gingivalis may, 
either through PAD, citrullinated enolase or otherwise, contribute to inducing 
ACPA formation. 
Although this study is the first to show citrullinated protein presence in peri­
odontitis tissue (30), ACPA presence and local ACPA formation in periodontitis 
tissue and peripheral blood were not assessed. Neither was P. gingivalis presence 
assessed. Thus, the most important focus of future studies should be on poten-
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tial ACPA formation within periodontitis tissue. Other factors related to ACPA for­
mation in periodontitis should also be assessed in studies with a larger sample 
size, i.e. smoking habits, the types of citrullinated proteins present as well as the 
specific role of P. gingivalis, the presence of H LA DR B1 shared epitope alleles and 
the role of auto-antibody producing plasma cells and collagen auto-immunity. 
In conclusion, citrullinated protein formation within the periodontal stroma 
appears to be an inflammation-depended process. In periodontal epithelium, in­
flammation may lead to the formation of different types of citrullinated proteins 
(targeted by F95) in addition to those naturally present in non-inflamed periodon­
tal epithelium (targeted by Ab5612 only). Periodontitis is a chronic inflammation 
of tissue containing many of the structural components of joints, including col­
lagen, and all the major auto-antigens targeted by ACPA (fig. 1). Furthermore, 
periodontitis is associated with auto-antibody producing B-cells. Thus, in the pres­
ence of H LA-DR B1 shared epitope and exposure to tobacco smoke, periodontitis 
is postulated to provide an environment capable of the initiation of an ACPA 
response that might specifically target citrullinated proteins in joints. 
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In the introduction (chapter 1) a brief history is described of research within the 
field of periodontal medicine, the field that is concerned with the link between 
periodontal and overall health. Although the thought of a link between oral and 
overall health is at least thousands of years old, the concept of the mouth pos­
ing an infectious burden endangering overall health is from a more recent date. 
Around 1 goo, extraction of teeth potentially posing an infectious burden was pro­
posed to treat and prevent a great variety of diseases. However, in the fol lowing 
decades, it became apparent that extraction of teeth was an ineffective cure for 
most diseases. Thereupon the concept of the mouth posing an infectious burden 
endangering overall health was dropped for about half a century. In 1989, this 
concept gained new interest by studies showing a link between periodontitis and 
an increased risk for cardiovascular diseases. Although no longer considered a 
major cause of diseases, the chronic low-grade infection and inflammation, as­
sociated with periodontitis are now thought to contribute to the rise and deterio­
ration of a variety of other diseases. Currently, most evidence exists for periodon­
titis as a risk factor for diabetes mellitus type-2. Randomized control led clinical 
trials and meta-analyses of these trails have shown that periodontitis treatment 
reduces the percentage of glycosylated haemoglobin (HbA1c). However, since 
several challenges as yet remain, whether periodontitis is a risk factor for diabetes 
is still not completely beyond doubt. 
Challenges in establishing whether periodontitis should be considered as a 
risk factor for other diseases formed the inspiration for the studies described in 
this thesis. The overal l aim of the studies described in this thesis was to assess 
the effects of the inflammatory burden posed by periodontitis on overall health, 
and more specifical ly on overall-health of diabetes type-2 and rheumatoid arthri­
tis patients. 
Associations between periodontitis and cardiovascular and autoimmune diseas­
es are most often assessed in patients with a particular cardiovascular or autoim­
mune disease. This approach carries the risk of selection bias, i.e. selected sam­
ples do not represent the general population and, therefore, observed associations 
cannot be generalized to the population as a whole. Furthermore, the magnitude 
of associations between periodontitis and cardiovascular and autoimmune dis­
eases appears to differ between studies performed in different geographical loca­
tions, probably coinciding with differences associated with ethnicity. 
The study presented in chapter 2 assessed the existence of associations be­
tween periodontitis and cardiovascular and autoimmune diseases in a random 
sample of patients attending a dental or periodontal c linic in the North of the 
Netherlands, while controlling for the most important confounders. Data were 
collected from 1276 randomly selected dental records from patients attending a 
dental (n=588) or periodontal (n=688) clinic. Data on the prevalence of cardio­
vascular and autoimmune diseases were obtained from a validated health ques­
tionnaire. Data on the presence of periodontitis were taken from patients' dental 
records. In uncontrolled analyses, the prevalence of hypertension, diabetes mel­
litus (DM) and rheumatoid arthritis (RA) was significantly increased in periodon­
titis patients. Controlled for confounding, periodontitis was associated with DM, 
with an odds ratio of 4.0 (1.03-15.3), in the dental clinic. DM was not associated 
with periodontitis in periodontal clinics. Hypertension did not appear to be as­
sociated with periodontitis when controlling for confounders. Periodontitis was 
associated with RA in both clinic types. From this study it was concluded that the 
increased prevalence of cardiovascular and autoimmune diseases among peri­
odontitis patients attending dental or periodontal clinics appeared to be, at least 
in part, influenced by confounding. However, the increased prevalence of DM and 
RA in periodontitis patients could not be explained for by confounding. 
The great variation in classifications of periodontitis and the lack of a measure 
that adequately assesses the inflammatory burden posed by periodontitis, is a 
major drawback of the studies published on the periodontal inflammation - sys­
temic disease interaction. The study presented in chapter 3 describes the devel­
opment of a new measuring tool quantifying the inflammatory burden posed by 
periodontitis; the periodontal inflamed surface area (PISA). The more inflamed 
periodontal tissue there is, the higher the inflammatory burden is assumed to be. 
Therefore, a literature search was conducted to look for a classification of peri­
odontitis that quantified the amount of inflamed periodontal tissue. A classifica­
tion that calculated the root surface area affected by attachment loss was found. 
By using tooth specific formula, linear clinical attachment loss (CAL) measure­
ments of any given tooth could be transformed into the root surface area affected 
by attachment loss for that specific tooth. After calculation of the root surface 
area affected by attachment loss for a particular tooth, the PISA for that tooth 
can be calculated in three steps. First, recession measurements instead of CAL 
are entered into the formula, to calculate the root surface area affected by attach­
ment loss. Second, subtracting the root surface area affected by recession from 
the root surface area affected by attachment loss, renders the root surface area 
covered with pocket epithelium. Third, as bleeding on probing (BOP) represents 
inflamed ulcerative pocket epithelium, multiplying the root surface area covered 
with pocket epithelium by the proportion of sites around each particular tooth 
that is affected by bleeding, renders the root surface area covered with inflamed 
pocket epithelium, the P ISA. Finally, simply adding up the PISA for each tooth 
renders the total PISA within a patient's mouth. PISA reflects the surface area of 




of inflamed periodontal tissue and the inflammatory burden. A Microsoft Excel 
spreadsheet was developed in order to aid in the calculation of P ISA. By simply 
filling in CAL, recession and BOP measurements, P ISA is automatically calculat­
ed. Because this spreadsheet is available online for free (www.parsprototo.info), 
P ISA can be easily calculated and broadly applied. 
Using different periodontitis definitions may lead to differences in study results 
on the association between periodontitis and other diseases. The study presen­
ted in chapter 4 compared prevalence and severity of periodontitis in O M  type 
2 (DM2) patients to healthy controls, using different periodontitis definitions, 
including the newly developed P ISA. No study had yet assessed the association 
between periodontitis and DM2 in Indonesia, while Indonesia is the 4th most 
populous country in the world and is in the top ten of countries with the highest 
number of O M  patients in the world. Seventy eight DM2 patients and 76 he­
althy subjects underwent a full mouth periodontal screening, assessing probing 
pocket depth, gingival recession, plaque index and bleeding on probing. Using 
these measurements, periodontitis prevalence and severity were operationalized 
in various ways. Differences in periodontitis prevalence and severity between 
DM2 patients and healthy subjects were analyzed using univariate analyses. In  
regression analyses, periodontitis prevalence and severity were predicted on the 
basis of DM2 presence, controlling for confounders and effect modification. The 
results of this study showed that Indonesians with DM2 suffered from periodon­
titis more often and more severely than Indonesian healthy subjects. I t  may be 
concluded that the association between periodontitis and DM2 is robust, i.e. 
independent of confounding factors or the methods used to operationalize pe­
riodontitis. Furthermore, P ISA proved to be significantly greater in Indonesians 
with than Indonesians without DM2. 
To assess the potential of P ISA to predict the inflammatory burden posed by 
periodontitis in DM2 patients, a dose-response relationship between P ISA and 
HbA1c-levels was assessed in chapters 5 and 6. In the study presented in chapter 
5, 132 healthy I ndonesians and 101 I ndonesians treated for DM2 were subjected 
to a full mouth periodontal examination including probing pocket depth, gingival 
recession, plaque index and bleeding on probing. In addition, HbA1c, glucose, 
c-reactive protein (CRP) and erythrocyte sedimentation rates (ESR) were asses­
sed. A standardized questionnaire was used to assess smoking, body mass index 
(BMI), education and medical conditions. In regression analyses, it was assessed 
whether HbA1c was predicted by periodontitis severity, operationalized in various 
ways, and CRP, controlling for confounding and effect modification. The results 
of this study showed that P ISA was the only measure of periodontitis severity 
that predicted HbA1c together with CRP, age, sex and smoking in healthy Indone­
sians. In Indonesians treated for DM2, P ISA did not predict HbA1c. It may thus 
be concluded that periodontitis may impair blood glucose regulation in healthy 
Indonesians through posing an inflam matory burden, as evidenced by the fact 
that P ISA predicts HbA1c in conjunction with CRP. It may also be concluded that 
P ISA reflects the inflammatory burden better than other measures of periodonti­
tis severity, as several measures of periodontitis severity were used, and P ISA was 
the only significant predictor of HbA1c. The potential effect of periodontitis on 
glucose control in DM2 patients may be masked by DM2 treatment. 
In the study presented in chapter 6, 40 consecutive dentate African-Americans 
with DM2 attending their general practitioner for regular check-up, underwent full 
mouth probing pocket depth and bleeding on probing assessment. From these 
data P ISA was calculated. HbA1c-levels were retrieved from patients' medical fi­
les. The dose-response relationship between P ISA and HbA1c-levels was asses­
sed using multiple linear regression analyses, controlling for factors that might 
influence P ISA or HbA1c-levels. Results showed that on a group level, an increase 
of P ISA with 333 m m2 was associated with a 1.0 percentage point increase of 
HbA1c, independent of the influence of other factors. Although a 1.0 percentage 
point HbA1c increase may appear small, this is associated with a 10% increase in 
the risk of dying of cardiovascular diseases, the major source of increased mor­
tality associated with DM2. The observed dose response relationship between 
P ISA and HbA1c may be an indication of a causal association between increasing 
severity of periodontitis and worsening of blood glucose control in DM2 patients. 
Furthermore, it may be an indication of the potential of P ISA to predict the inflam­
matory burden posed by periodontitis. 
The study presented in chapter 2 pointed out an association between periodonti­
tis and RA. Several other studies have also suggested that patients with RA have 
an increased prevalence and severity of periodontitis. Moreover, few studies even 
pointed out that treatment of periodontitis in RA patients might reduce RA disease 
activity. Therefore, the study presented in chapter 7 aimed to systematically review 
the available evidence on the prevalence and severity of periodontitis in RA patients 
and the potential of periodontitis treatment to reduce RA disease activity. Sensitive 
search strategies were designed aimed at including all relevant studies published 
from 1968 till 10-10-2010. Relevant studies performed in humans and published in 
the English language were included. The methodological quality of each study was 
graded as good, meeting all criteria appropriate for study design, fair, meeting a 
selection of key criteria guaranteeing fair validity, or poor, missing one or more key 
criteria. Studies with fair or good quality were included in a meta-analysis. Out of 
798 articles initially retrieved, 9 case control studies and 2 randomized controlled 
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trials had fair quality and were included in meta-analyses. Results of meta-analyses 
indicated that RA-associated odds ratios (95% confidence interval) of periodon­
titis range from 8.o (3.1 to 20.9) to 13.2 (3.7 to 47.2) depending on the measure 
of periodontitis used. Moreover, treatment of periodontitis reduces DAS28 by 1 .2 
(95% confidence interval: o.6 to 1.7). Thus, prevention and treatment of periodon­
titis in RA patients may be needed to safeguard oral health and may additionally 
reduce RA disease activity. However, given the lack of blinding in most studies and 
the large confidence intervals reported in our meta-analyses, there is a need for 
well-designed studies to confirm these findings. 
Anti citrullinated protein antibodies (ACPAs) may play a role in the aetiology of 
RA. Periodontitis has been implicated as playing a role in the etiology of RA by 
causing ACPA formation, since the inflamed periodontium contains all of the 
ingredients necessary to induce ACPA formation. However, whether citrullinated 
proteins, the key ingredients, were present in periodontitis tissue was yet un­
known. Therefore the study presented in chapter 8 aimed to assess the presence 
of citrullinated proteins in periodontitis tissue, as compared to their presence 
in control tissues. Thereto, periodontal tissue samples of 15 randomly selected 
periodontitis patients and 6 non-periodontitis controls, both without any other 
known diseases, were stained for the presence of citrullinated proteins using 
polyclonal (Ab5612) and monoclonal (F95) antibodies. Synovial tissue samples 
of four RA patients and buccal mucosa! swabs of three healthy controls were 
used as control tissues. The results of this study indicated an increased citrul­
linated protein presence (80%) in periodontitis stroma as compared to control 
stroma (33%). In control tissue, citrullinated protein presence in stroma was as­
sociated with inflammation of non-periodontitis origin. Periodontal epithelium 
in periodontitis tissue always stained positive for Ab5612 and F95, while control 
periodontal epithelial tissue stained positive for Ab5612 only. Three out of 4 sy­
novial tissue samples of RA patients and all buccal mucosa! swabs of healthy 
volunteers, stained positive for both Ab5612 and F95. 
From this study it may be concluded that citrullinated protein formation wit­
hin the periodontal stroma appears to be an inflammation depended process. 
In periodontal epithelium, inflammation may lead to the formation of different 
types of citrullinated proteins than the types of citrullinated protein present in 
non-inflamed periodontal epithelium. In the presence of H LA-DRB1 shared epi­
tope and smoking, citrullinated proteins formed in association with periodontal 
inflammation may play a role in ACPA formation. 
In chapter 10 the implications of the various studies performed are discussed 
and perspectives for future research are given. 
CHAPTER 9 




In de inleiding (hoofdstuk 1) wordt kort de geschiedenis beschreven van onder­
zoek binnen de parodontale geneeskunde, het vakgebied dat zich bezighoudt 
met de relatie tussen de parodontale en de algehele gezondheid. Hoewel de notie 
van een verband tussen mondgezondheid en de algehele gezondheid minstens 
duizenden jaren oud is, is de kennis dat de mond een infectie- en ontstekingslast 
veroorzaakt die de gezondheid in gevaar brengt van een meer recente datum. 
Rond , goo werd het trekken van tanden, die een bron van infectie konden vor­
men, gepropageerd om een breed scala aan ziekten te behandelen en te voor­
komen. In de daaropvolgende decennia werd echter duidelijk dat het extraheren 
van tanden een ineffectieve remedie voor de meeste ziekten bood. Daarop werd 
de gedachte dat de mond een infectielast veroorzaakt die gezondheid in gevaar 
brengt een halve eeuw ter zijde geschoven, tot in 1989 twee studies verschenen 
waarin een verband tussen parodontitis en een verhoogd risico op hart- en vaat­
ziekten werd aangetoond. 
Hoewel de mond niet langer wordt beschouwd als de belangrijkste oorzaak 
van ziekten, wordt verondersteld dat de chronische infectie- en ontstekingslast 
die wordt veroorzaakt door parodontitis kan bijdragen aan het ontstaan en/of 
verergeren van verscheidene andere ziekten. Momenteel bestaat het meeste be­
wijs voor parodontitis als een risicofactor voor diabetes mellitus type-2 (DM2). 
Uit meta-analyses van gerandomiseerde, gecontroleerde klinische trials bleek 
dat behandeling van parodontitis het percentage geglycosyleerd hemoglobine 
(HbA1c) verlaagt. Echter, de kracht van het bewijs is nog niet optimaal. Zo werd 
parodontitis vaak verschillend gedefinieerd en werd het effect van parodontitis 
behandeling veelal inadequaat geanalyseerd. Kortom, de relatie tussen parodon­
titis en DM2 moest nog verder onderzocht worden in studies waarin parodontitis 
en parodontitis behandeling op dusdanige wijze in kaart worden gebracht dat het 
aansluit bij de manier waarop parodontitis wordt geacht de gezondheid parten te 
spelen, namelijk door het veroorzaken van een infectie- of ontstekingslast. 
Het overkoepelende doel van de studies beschreven in dit proefschrift was om 
de effecten van de infectie- en ontstekingslast als gevolg van parodontitis op de 
algehele gezondheid te beoordelen, in het bijzonder bij patienten met DM2 en bij 
patienten met reumato'ide artritis (RA). 
Onderzoek naar de verbanden tussen hart- en vaatziekten en parodontitis en auto­
immuunziekten en parodontitis wordt veelal verricht binnen een specifieke popula­
tie van patienten met een van deze cardiovasculaire of auto-immuunziekten. Deze 
aanpak draagt het risico van selectie bias in zich, dat wil zeggen dat geselecteerde 
groepen niet de algemene bevolking vertegenwoordigen. Hierdoor kunnen waar­
genomen verbanden tussen parodontitis en andere ziekten niet automatisch wor­
den gegeneraliseerd naar de bevolking als geheel. Daarnaast verschilt de sterkte 
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van het verband tussen parodontitis en cardiovasculaire en auto-immuunziekten 
tussen de studies, al naar gelang die zijn uitgevoerd in verschi llende geografische 
locaties. Waarschijnl ijk hangen deze verschil len in de sterkte van het verband tus­
sen parodontitis en andere ziekten (deels) samen met het verschil in etniciteit 
(genen, dieet, gedrag) tussen de diverse onderzochte populaties. 
In hoofdstuk 2 wordt een studie beschreven waarin het bestaan van verbanden 
tussen parodontitis en cardiovasculaire en auto-immuunziekten is onderzocht 
in een aselecte steekproef van patienten die een a lgemene tandartspraktijk of 
kl iniek voor parodontologie in Nederland bezoeken. Gegevens werden verzameld 
uit  1276 wil lekeurig geselecteerde tandheelkundige dossiers van patienten uit  een 
tandartspraktijk (n = 588) en twee klinieken voor parodontologie (n = 688). Ge­
gevens over de prevalentie van cardiovasculaire en auto-immuunziekten werden 
verkregen middels analyse van een gevalideerde gezondheidvragenlijst die in 
a l le praktijken standaard werd gehanteerd. Gegevens over de aanwezigheid van 
parodontitis werden verkregen door analyse van de tandheelkundige status van 
patienten. 
In ongecontroleerde analyses was de prevalentie van hypertensie, DM en RA 
significant hoger bij parodontitis patienten t.o.v. de controle groep zonder pa­
rodontitis. Gecontroleerd voor de invloed van mogel ijke verstorende variabelen 
(leeftijd, roken en geslacht) bleek parodontitis geassocieerd met DM, met een 
odds ratio van 4,0 (95% betrouwbaarheidsinterval :  1,03 tot 15.3) in de tandarts­
praktijk. DM bleek niet geassocieerd met parodontitis in de kl inieken voor paro­
dontologie. Ook hypertensie bleek niet !anger geassocieerd te zijn met parodon­
titis na correctie voor verstorende variabelen. Parodontitis leek, ook na correctie 
voor de invloed van verstorende variabelen, geassocieerd te zijn met RA in beide 
soorten klinieken. Uit deze studie werd geconcludeerd dat de toegenomen pre­
valentie van cardiovasculaire en auto-immuunziekten bij parodontitis patienten 
deels kan worden verklaard uit de invloed van verstorende variabelen. Toch kan 
de toegenomen prevalentie van DM en RA bij parodontitis patienten in Neder­
land niet geheel worden verklaard door de invloed van verstorende variabelen. 
De grote variatie in de classificatie van parodontitis en het ontbreken van een maat 
die de ontstekingslast die parodontitis veroorzaakt kwantificeert, is een groot na­
deel van de studies die tot nu toe zijn gepubliceerd. De uitkomsten van de diverse 
studies zijn daardoor moeilijk met elkaar te vergel i jken en lastig te interpreteren. 
In hoofdstuk 3 wordt een nieuw meetinstrument ge"introduceerd waarmee het mo­
gelijk is om de ontstekingslast die wordt veroorzaakt door parodontitis te kwan­
tificeren, als het parodontale ontstoken weefseloppervlak, ofwel 'the Periodontal 




Hoe meer ontstoken parodontaal weefsel er is, hoe hoger de ontstekingslast 
wordt verondersteld te zijn. Met behulp van tandspecifieke formules worden li­
neaire sondeermetingen rond een element omgezet in het worteloppervlak van 
dat element dat betrokken is bij parodontitis. Dit gebeurd in vier stappen door 
gebruik te maken van metingen van de aanhechtingsverlies, de gingiva recessie 
en het bloeden van het tandvlees na sonderen (BOP; maximaal zes bloedingen 
rond een element). Eerst (stap 1) worden klinisch aanhechtingsverlies metingen 
(CAL) ingevoerd in de formule, waardoor het worteloppervlak dat aangedaan is 
door aanhechtongsverlies voor die tand wordt berekend. Daarna (stap 2) worden 
recessie metingen ingevoerd in de formule, waardoor het worteloppervlak aan­
gedaan is door aanhechtingsverlies voor die tand wordt berekend. Vervolgens 
(stap 3) wordt het worteloppervlak dat bloot ligt t.g.v. recessie afgetrokken van 
het worteloppervlak dat getroffen is door klinisch aanhechtingsverlies. Op deze 
wijze kan het worteloppervlak dat bedekt is met pocketepitheel worden berekend. 
Tenslotte (stap 4) wordt het worteloppervlak dat bedekt is met pocket epitheel 
vermenigvuldigd met het aantal bloedingen rond een element gedeeld door zes, 
deze breuk geeft namelijk de verhouding weer tussen ontstoken en niet ontsto­
ken pocketepitheel. Op deze wijze wordt het worteloppervlak dat bedekt wordt 
met ontstoken pocketepitheel (PISA) voor een bepaald element berekend. Door 
het optel len van de P ISA van elke tand kan de totale P ISA voor een patient worden 
berekend. 
P ISA weerspiegelt dus het oppervlak van bloedend pocketepitheel en geeft 
dat oppervlak weer in vierkante millimeter. Daardoor kwantificeert P ISA de hoe­
veelheid ontstoken parodontaal weefsel en daarmee de ontstekingslast. Door 
simpelweg CAL, recessie en BOP metingen in te vullen in een Microsoft Excel­
spreadsheet wordt P ISA automatisch berekend. Deze spreadsheet is online en 
gratis beschikbaar (www.mondgezondheid.info), waardoor P ISA gemakkelijk en 
op grote schaal kan worden toegepast. 
Het gebruik van verschil lende classificaties voor parodontitis kan leiden tot ver­
schillen in studieresultaten voor wat betreft het verband tussen parodontitis en 
andere ziekten. In de studie die in hoofdstuk 4 beschreven staat de prevalentie 
en ernst van parodontitis vergeleken tussen DM2 patienten en controles zonder 
DM2. Daarbij werd gebruik gemaakt van verschillende classificaties voor paro­
dontitis, inclusief P ISA. Voor lndonesie werd gekozen, omdat tot op heden geen 
enkele studie het verband tussen parodontitis en DM2 in dit land had onder­
zocht, terwij l lndonesie het op 4 na meest bevolkte land ter wereld is en in de 
top tien van landen staat met het hoogste aantal DM patienten in de wereld. 
Achtenzeventig DM2 patienten en 76 gezonde proefpersonen ondergingen een 
vol ledig parodontaal onderzoek, waarbij pocketdiepte, gingiva recessie, plaque 
index en BOP in kaart werden gebracht. Met behulp van deze metingen werden 
de prevalentie en ernst van parodontitis op verschillende wijzen geclassificeerd. 
Verschillen in prevalentie en ernst van parodontitis tussen de DM2 patienten en 
gezonde proefpersonen werden geanalyseerd met behulp van univariate analyses. 
In regressie analyses werden de prevalentie en ernst van parodontitis voorspeld 
op basis van het al dan niet aanwezig zijn van DM2, waarbij gecorrigeerd werd 
voor mogelijke verstorende of effect be·invloedende variabelen. De resultaten van 
deze studie toonde aan dat lndonesiers met DM2 vaker en ernstiger parodontitis 
hadden dan de lndonesische gezonde proefpersonen, onafhankelijk van de wijze 
waarop parodontitis werd geclassificeerd. Er kan worden geconcludeerd dat de 
associatie tussen parodontitis en DM2 robuust is, dat wil zeggen onafhankelijk 
van verstorende variabelen of de gebruikte methoden om parodontitis te clas­
sificeren. Tevens bleek PISA significant groter in lndonesiers met DM2 dan bij 
gezonde lndonesische proefpersonen. 
Om te bepalen of PISA de ontstekingslast veroorzaakt door parodontitis en de 
gevolgen die deze met zich meebrengt voor de algehele gezondheid adequaat 
voorspelt, werd een dosis-respons relatie tussen PISA en HbA1c-niveaus bij D M2 
patienten bepaald (hoofdstukken 5 en 6). In de studie gepresenteerd in hoofd­
stuk 5, ondergingen 132 gezonde lndonesiers en 101 lndonesiers met DM2 een 
volledig parodontaal onderzoek, waarbij pocketdiepte, gingiva recessie, plaque 
index en BOP in kaart werden gebracht. Daarnaast werden bij elk van de deelne­
mers de serumconcentraties HbA1c, glucose en C-reactief proterne (CRP), en de 
bloedbezinking (BSE) bepaald. Een gestandaardiseerde vragenlijst werd gebruikt 
om roken, body mass index (BMI), sociaaleconomische status en medische aan­
doeningen vast te leggen. In regressie-analyses werd nagegaan of HbA1c werd 
voorspeld door de ernst van parodontitis CRP, gecorrigeerd voor verstorende of 
effect be·invloedende variabelen. De resultaten van deze studie toonden aan dat 
PISA de enige classificatie van de ernst van parodontitis was die de HbA1c bij ge­
zonde lndonesiers voorspelde, tezamen met CRP, leeftijd, geslacht en roken. In 
lndonesiers die werden behandeld voor DM2 voorspelde PISA HbA1c niet. M.a.w. 
parodontitis lijkt de bloedglucoseregulatie bij gezonde lndonesiers negatief te 
be"invloeden middels een ontstekingslast, zoals blijkt uit het feit dat de PISA de 
HbA1c waarde voorspelt in combinatie met CRP. Het potentiele effect van paro­
dontitis op de glucose controle bij DM2 patienten leek te worden gemaskeerd 
door DM2 behandeling (gebruik van insuline). 
In de studie gepresenteerd in hoofdstuk 6, ondergingen 40 opeenvolgende 
dentate Afro-Amerikanen met DM2, die hun huisarts bezochten voor een regu­
liere controle, een volledig parodontaal onderzoek, waarbij pocketdiepte, gingiva 




P ISA berekend. HbA, c-niveaus werden verkregen uit de medische dossiers van 
patienten. De dosis-respons relatie tussen PISA en HbA1c-niveaus werd geanaly­
seerd met behulp van lineaire regressie analyses, waarbij werd gecorrigeerd voor 
verstorende of effect be"invloedende variabelen. De resultaten van dit onderzoek 
toonden aan dat op groepsniveau, een stijging van P ISA met 333 mm2 bleek te 
zijn geassocieerd met een 1 ,0 procentpunt stijging van de HbA1c, onafhankelijk 
van de invloed van andere factoren. Alhoewel een 1 ,o procentpunt stijging van 
de HbA,c niet veel lijkt, is deze stijging bij DM2 patienten geassocieerd met een 
toename van het risico op het overlijden aan hart- en vaatziekten van 10%. Een 
dergelijke dosis-respons relatie tussen P ISA en HbA,c is een indicatie van een 
causaal verband tussen toenemende ernst van parodontitis en het verergeren van 
bloedglucoseregulatie bij DM2 patienten. 
In de studie die beschreven is in hoofdstuk 2 wordt al gewezen op een mogelijk 
verband tussen parodontitis en RA, evenals dat behandeling van parodontitis 
de ziekteactiviteit van RA zou kunnen verminderen. In de studie die wordt be­
schreven in hoofdstuk 7 is, middels het verrichten van een systematisch litera­
tuur onderzoek, vastgesteld wat de prevalentie en de ernst van parodontitis bij 
RA-patienten is en wat het effect is van behandeling van parodontitis op de ziek­
teactiviteit van RA. Daartoe werden alle mogelijke relevante studies die tussen 
1968 en oktober 201 0 in de internationale Engelstalige literatuur waren gepu­
bliceerd opgespoord. Vervolgens werd de relevantie voor het onderwerp en de 
methodologische kwaliteit van gevonden studies beoordeeld. Relevantie studies 
met een redelijke tot goede methodologische kwaliteit werden opgenomen in een 
meta-analyse. Van de aanvankelijk gevonden 798 artikelen, konden uiteindelijk 9 
case-control studies en 2 gerandomiseerde gecontroleerde studies worden opge­
nomen in meta-analyses. 
De resultaten van meta-analyses toonden aan dat het aan RA gerelateerde 
toegenomen risico op parodontitis odds ratio's (95% betrouwbaarheidsinterval) 
met een bereik van 8,o (3.1 tot 20.9) tot 13,2 (3,7 tot 47.2) kent, afhankelijk van 
de maat die voor de aanwezigheid of de ernst van parodontitis werd gebruikt. 
Behandeling van parodontitis bleek de DAS28, een samengestelde maat van de 
ziekte activiteit bij RA, met 1 ,2 (95% betrouwbaarheidsinterval: o,6 tot 1 ,7) te ver­
minderen. Kortom, preventie en behandeling van parodontitis bij RA patienten 
is nodig om de mondgezondheid te bevorderen en kan de ziekteactiviteit van RA 
verminderen. Echter, gezien het ontbreken van blindering in de meeste studies 
en de grote betrouwbaarheidsintervallen, bestaat behoefte aan goed opgezette 
studies om deze bevindingen te bevestigen. 
Anti-gecitrullineerde eiwit antilichamen (ACPA) spelen vermoedelijk een rol in 
de etiologie van RA. Omdat ontstoken parodontium alle ingredienten bevat die 
nodig zijn om de vorming van ACPA te induceren, zou parodontitis betrokken 
kunnen zijn bij het ontstaan van RA. Of gecitrullineerde eiwitten aanwezig zijn in 
parodontaal weefsel was tot nu toe nog onbekend. In de studie die in hoofdstuk 8 
wordt beschreven werd nagegaan of gecitrullineerde eiwitten in parodontaal weef­
sel voorkomen. Daartoe werden parodontale weefselmonsters van 15 willekeurig 
geselecteerde patienten met parodontitis en 6 gezonde controles getest op de 
aanwezigheid van gecitrullineerde eiwitten met behulp van polyklonale (Ab5612) 
en monoklonale (F95) anti-gecitrullineerde eiwit antilichamen. Synoviale weef­
selmonsters van vier patienten met RA en uitstrijkjes van het wangslijmvlies van 
drie gezonde controles werden gebruikt als controle. 
In het parodontaal stroma van patienten met parodontitis bleken gecitrulli­
neerde eiwitten vaker (bij 80% ) aanwezig te zijn dan in het stroma van gezonde 
proefpersonen (bij 33%). Bovendien bleek dat de aanwezigheid van gecitrulli ­
neerde eiwitten in het stroma van gezonde proefpersonen verband hield met een 
ontsteking van het parodontium die niet door parodontitis werd veroorzaakt. 
In het parodontaal epitheel van patienten met parodontitis kleurde Ab5612 en 
F95 altijd positief aan, terwijl parodontaal epitheel van gezonde controles alleen 
positief aankleurde met Ab5612. Drie van de 4 synoviale weefsel monsters van 
patienten met RA en alle uitstrijkjes van het wangslijmvlies van gezonde vrijwil­
ligers, kleurden positief aan voor zowel Ab5612 als F95. 
De vorming van gecitrullineerde eiwitten binnen het parodontale stroma lijkt 
ontstekingsafhankelijk. In parodontaal epitheel kan de ontsteking leiden tot de 
vorming van additionale soorten gecitrullineerde eiwitten, naast de gecitrullineer­
de eiwitten die van nature reeds voor lijken te komen in parodontaal epitheel. 
In aanwezigheid van een genetische predispositie (HLA-DRB1se) voor een pro­
inflammatoire respons en roken, zouden de tijdens het parontaal verval geprodu­
ceerde gecitrullineerde eiwitten een rol kunnen spelen bij de vorming van ACPA. 
In hoofdstuk 10 worden de implicaties van de bevindingen uit het onderhavige 








Chapter 1 describes how the past has shown that extraction of teeth was an ineffec­
tive measure to cure diseases. Although extraction of teeth affected by periodon­
titis might still be necessary in preventing potentially life threatening situations 
in a small and particular group of patients, e.g. patients whose immune system 
is severely comprised, these cases are the exceptions to the rule. Findings in this 
thesis should in no way be seen as promoting teeth extraction to benefit overall 
health, turning the clock back to the beginning of the 1 goos. The chronic low grade 
infection and inflammation through which periodontitis may contribute to the de­
velopment and deterioration of cardiovascular and auto-immune diseases should 
be seen in a different light. Increased awareness among dentists, doctors and the 
public at large of the potential of periodontitis to pose a chronic inflammatory bur­
den that may contribute to the development of cardiovascular and auto-immune 
diseases, accompanied by simple preventive measures as maintaining proper oral 
hygiene, appear a far more sensible way of promoting overall and oral health than 
extraction of teeth. 
Associations have been reported between periodontitis and a large spectrum of 
other diseases. These associations are at least in part based on the fact that fac­
tors like lifestyle and genes cluster together and exert a negative effect on oral as 
well as overall health. Therefore, causality should not be automatically assumed. 
However, observed epidemiological associations can and should not directly be 
thought to be non-causal in nature either. These obvious facts are stated here, as 
often a division is encountered among professionals. This division separates the 
believers from the non-believers, the former believing periodontitis may pose a 
threat to overall health, while the latter do not. With the threat of again stating the 
obvious, science is not concerned with belief and should not be. Rather, careful 
exploration of the existence and nature of associations between periodontitis and 
other diseases should take place. 
Ideally, a large prospective cohort study of a representative sample of the gen­
eral population would follow-up progress (incidence) of periodontitis and other 
diseases, while at the same time recording potential risk factors to oral and overall 
health (e.g. genes, socioeconomic status, smoking, oral hygiene levels, diet, age 
and sex). The fact that conducting such studies is no utopia is evidenced by the 
"Lifelines" study currently conducted by the University Medical Center Gronin­
gen. The "Lifelines" study will follow-up three generations of people living in the 
North of the Netherlands for up to thirty years in order to identify factors involved 
in the initiation and progression of diseases. This study provides a unique oppor­
tunity to elucidate the nature of the associations between periodontitis and other 
diseases by simply including oral health data. 
In chapter 2, association were observed between periodontitis and diabetes, 
rheumatoid arthritis, hypertension and stroke, in a sample of the population 
in the North of the Netherlands. Even if these associations are the result of 
confounding, periodontitis should at least be considered as a risk indicator of 
diabetes, rheumatoid arthritis, hypertension and stroke. Recognizing periodon­
titis as a risk indicator could aid in the prevention and treatment of diabetes, 
rheumatoid arthritis, hypertension and stroke, and may thereby promote both 
oral and overall health of our patients. While associations with hypertension 
and stroke appear to be non-causal in nature, periodontitis might be causally 
associated with OM and RA. OM and RA patients may be at increased risk of 
periodontitis development, or of developing more severe periodontitis. Alter­
natively, periodontitis may be a risk factor for development or deterioration of 
OM and RA. 
When performing the study described in chapter 2 and looking at the literature, 
it quickly became apparent that a large variety of methods was used to define 
periodontitis as a risk factor for other diseases. None of the measures quanti­
fied the amount of inflamed periodontal tissue, while the inflamed periodon­
tal tissue is assumed to pose an inflammatory burden. Thus, the higher the 
amount of inflamed periodontitis tissue is, the higher the inflammatory burden 
is thought to be. 
Therefore, a measure quantifying the amount of inflamed periodontal tis­
sue was created in the study presented in chapter 3. The periodontal inflamed 
surface area (PISA) quantifies the amount of inflamed periodontal tissue as the 
surface area of bleeding pocket epithelium. P ISA is easily calculated by filling in 
common clinical measures of periodontitis in a freely available online spread­
sheet. PISA is thought to be to best tool yet available to quantify the inflamma­
tory burden posed by periodontitis. Broad application of PISA within the field 
of periodontal medicine could solve the problems of the incomparability of re­
search results and may thus provide decisive conclusions on periodontitis as a 
risk factor for other diseases. An additional advantage of the PISA is that it can 
be retrospectively calculated using existing research data containing CAL, reces­
sion and BOP measurements. 
However, PISA should not be considered as a panacea, i .e. an ideal measure 
that solves all problems associated with defining periodontitis as a risk factor 
for other diseases. To begin with, PISA may not precisely represent the amount 
of inflamed periodontitis tissue due to measurement errors, usage of popula­
tion based mean values of root surface areas, and the fact that periodontitis is 
a three dimensional, rather than two dimensional process. Apart from these 
quantification issues, the premise that more inflamed periodontal tissue equals 




inflammation may for example be more important in causing other diseases than 
the amount of inflamed periodontal tissue (P ISA). Certain cells, proteins (e.g. cit­
rullinated proteins!) or inflammatory mediators might play a key role in causing 
other diseases. Furthermore, certain oral microorganisms (e.g. p.gingivalis) might 
play a key role in causing other diseases. Future studies should assess the role of 
specific inflammatory mediators or microorganisms in causing other diseases. Fi­
nally, future studies should analyse construct validity by means of correlating PISA 
with measures of the activity, severity or presence of other diseases. 
In addition to research purposes, P ISA has found it's way into clinical practise. 
The fact that periodontitis often goes unnoticed may play a role in patients' lack of 
motivation to seek or comply with periodontitis prevention and treatment. PISA 
can be used to illustrate the gravity of periodontitis to patients, by simply pointing 
out the size of the wound that lies hidden beneath their gums. In the Netherlands, 
P ISA is already integrated into Exquise, Vista- and Novadent, software programmes 
commonly used by dentists to organize daily patient care. When recording perio­
dontal measurements in these programmes, P ISA is automatically calculated. 
The study presented in chapter 4 assessed prevalence and severity of periodontitis 
in Indonesian DM type 2 (DM2) patients as compared to healthy controls, using 
different periodontitis definitions, including P ISA. No study had yet assessed the 
association between periodontitis and DM2 in Indonesia, while Indonesia is the 
4th most populous country in the world and is in the top ten of countries with 
the highest number of DM patients in the world. Asians constitute approximately 
60% of the world's current population. As the world is becoming a global village, 
migration will increasingly cause communities to be composed of a mixture of 
ethnic groups. As our patients will increasingly be of different ethnic origins, eth­
nicity associated differences in health and disease will become relevant to us all. 
Indonesians with DM2 suffered from periodontitis more often and more severely 
than Indonesian healthy subjects, independent of confounding factors or of the 
definition used for periodontitis. Thus, the association between periodontitis and 
DM2 in Indonesia appears to be robust. 
As a proof of concept of the potential of P ISA to predict the inflammatory burden 
posed by periodontitis, a dose-response relationship between P ISA and HbA1c­
levels was assessed in two studies presented in chapters 5 and 6. In chapter 5, 
P ISA was the only measure of periodontitis severity that predicted H bA1 c together 
with CRP, age, sex and smoking in healthy Indonesians. Thus, periodontitis may 
impair blood glucose regulation in healthy Indonesians through posing an inflam­
matory burden, since PISA predicts HbA, c in conjunction with CRP. Furthermore, 
PISA reflects the inflammatory burden better than other measures of periodontitis 
severity, as several measures of periodontitis severity were used, and PISA was 
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the only significant predictor of HbA,c. In Indonesians with DM2, PISA did not 
predict HbA1c, nor did any other measure of periodontitis severity. 
In chapter 6 a decrease of PISA with 333 mm2 was associated with a 1.0 
percentage point decrease of HbA1c, in a group of 40 African-American DM2 
patients from Curacao. A 1.0 percentage point decrease of HbA,c may appear 
small, however such a decrease in DM2 patients has reportedly been associated 
with a 10% reduction of DM2 associated early mortality. Since the observed as­
sociation appeared to be independent of the influence of confounding factors, 
the dose response relationship between P ISA and HbA1c may be an indication 
of causality. However, our results may also imply type-2 diabetics with poor gly­
cemic control (high HbA,c) might be more likely to develop severe periodonti­
tis (high PISA). Whether periodontitis deteriorates glycemic control or diabetes 
causes periodontitis (or both), measures that safeguard periodontal health may 
need to become part of regular care of patients with poorly controlled type-2 
diabetes. Moreover, PISA appears to be a valuable tool to assess dose-response 
relationships between the amount of inflamed periodontal tissue and a well 
defined disease measure as HbA1c. 
The results of chapter 5, showing PISA does not predict HbA,c in Indonesians 
with DM2, appear to be in sharp contrast with the results of chapter 6, showing 
PISA does predict HbA1c in African-Americans with DM2. It appears that other 
factors may influence the potential effect of P ISA on HbA1c. First, many of the 
Indonesian DM2 patients used insulin, while few of the African-American DM2 
patients used insulin. As insulin is a potent blood glucose regulator, normally 
reserved for treatment of OM type-, , effects of PISA on HbA1c may have been 
masked in Indonesian DM2 patients. Second, the average BMI of DM2 patients 
from Curacao was 31, while the average BMI of Indonesian DM2 patients was 
substantially lower, namely 25. A higher BM I may increase the potential insulin 
resistance inducing effect of periodontitis in DM2 patients. Third, there is the 
obvious difference in ethnicity between the two groups, i.e. one of Javanese 
origin and the other of African-American origin. Possible differences in (health 
promoting) behaviour, diet and genes, related to the differences in ethnicity, 
may explain these conflicting results. Future studies should assess the role of 
effect modifiers like medication, BM I and ethnicity on the association between 
periodontitis and DM2. 
With the mounting evidence of a causal association between periodontitis 
and poor blood glucose control, large randomized placebo controlled clinical 
trials should establish the benefit of periodontal treatment (reducing PISA) to 
glycemic control (reducing HbA1c) in DM2 patients. In addition, studies are 
needed to confirm that PISA quantifies the inflammatory burden posed by perio­




els of inflammatory mediators as TNF-a, I L-6 and I L-1. Finally, a program may have 
to be developed that prevents (ideally) or treats (if necessary) periodontitis in DM2 
patients. Future studies should explore costs and benefits of such a program. 
In addition to DM2, the study presented in chapter 2 pointed out an association 
between periodontitis and RA. Since other studies had also suggested that RA 
patients have an increased prevalence and severity of periodontitis, and periodon­
titis treatment may reduce RA disease activity, the study presented in chapter 7 
systematically reviewed the available evidence on associations between periodon­
titis and rheumatoid arthritis. There is fair evidence of an RA associated increased 
periodontitis prevalence compared to healthy controls. Moreover, there is fair 
evidence of periodontitis treatment reducing RA disease activity. Fair evidence in­
dicates not all criteria appropriate for study design were met by studies included 
in the meta-analysis, however no criteria guaranteeing at least fair validity were 
missed. However, a lack of reporting inclusion rates and more importantly, a lack 
of blinding, was observed in many of the included studies. Since selection of study 
participants may be assumed to have taken place without prior knowledge of peri­
odontal status, thus avoiding selection bias, this was not considered a threat to 
the validity of our results. However, even though measuring probing pocket depth 
is a pretty straightforward procedure, lack of blinding to rheumatic status in clini­
cians assessing probing pocket depth could have lead to observer bias. Therefore, 
whether the evidence from our meta-analysis should strictly be taken as fair or 
poor is debatable. 
Regardless of these evidence classification issues, there appears to be a lot of 
room to improve the strength of the evidence on the association between perio­
dontitis and rheumatoid arthritis. Future case control studies should 1 )  include all 
rheumatoid arthritis patients (including edentulous patients), 2) report inclusion 
rates, 3) blind the clinician evaluating periodontal status to rheumatoid arthritis 
disease status and 4) use uniform continuous measures for periodontitis, like 
PISA. Future randomized controlled clinical trails should 1 )  blind both the clinician 
evaluating rheumatoid arthritis disease activity, as well as the person performing 
statistical analyses, for periodontitis treatment status, and 2) try to include some 
form of placebo treatment that does not counter periodontitis (e.g. rinsing the 
mouth with a placebo solution). 
Notwithstanding the need for additional studies and some residual biases that 
carry risks of both over- and underestimating the present results, our systematic 
review revealed that there appears to be a need to prevent and treat periodonti­
tis in RA patients to improve and preserve oral health. Additionally, periodontitis 
treatment caries the potential to reduce RA disease activity. 
Antibodies targeting citrullinated proteins, ACPA, are highly specific for rheuma-
toid arthritis and are suspected of playing a role in the etiology of rheumatoid ar­
thritis. To further explore the potential underlying mechanism of the observed as­
sociation between periodontitis and RA, the study presented in chapter 8 sought 
to assess the presence of citrullinated proteins in periodontitis tissue. To the best 
of our knowledge, the study presented in chapter 8 was the first that showed cit­
rullinated proteins are present in periodontal tissue. Citrullinated proteins natu­
rally occur in epithelial tissues. In periodontitis affected epithelium, inflammation 
may lead to the formation of different types of citrullinated proteins (targeted by 
F95) in addition to those naturally present in non-inflamed periodontal epithelium 
(targeted by Ab5612 only). The formation of citrullinated proteins within the peri­
odontal stroma, appears to be strictly inflammation depended. 
The finding of citrullinated proteins within periodontitis tissue is of particu­
lar relevance as it might be ACPA formation is initiated in periodontitis tissue, 
thus implicating periodontitis in the etiology of RA. Periodontitis is a chronic 
inflammation of tissue containing many of the structural components of joints, 
including collagen, and all the major auto-antigens targeted by ACPA; i.e. the 
periodontal epithelium contains keratin and filaggrin, and periodontal fibroblasts 
express vimentin. Although not examined in this study, these proteins might get 
citrullinated in periodontitis tissue, thus stimulating or initiating ACPA formation 
against these major auto-antigens in RA. Furthermore, periodontitis is associated 
with auto-antibody producing B-cells. Thus, in the presence of H LA-DRB1 shared 
epitope and exposure to tobacco smoke, periodontitis is postulated to provide an 
environment capable of the initiation of an ACPA response that might specifically 
target citrullinated proteins in joints. 
However many issues as yet remain unresolved. First, although ACPA forma­
tion occurs years before the clinical onset of RA and ACPA presence signifies a 
more destructive arthritis, the exact role of ACPAs in the etiology of RA remains to 
be determined. ACPA formation may be an epiphenomenon, i.e. coinciding with 
the true underlying cause of RA. Although almost all patients with ACPAs have or 
will develop RA, a substantial proportion of RA patients goes without detectable 
ACPA formation. Thus, ACPA formation is no conditio sine qua non in the devel­
opment of RA. Second, although it is postulated that periodontitis may be the best 
candidate to elicit ACPA formation, no evidence of local ACPA formation has yet 
been presented. Thus, local ACPA production within periodontitis tissue should 
be the main focus of future research. Other factors related to ACPA formation 
in periodontitis tissue should also be assessed; i.e. smoking habits, the types of 
citrullinated proteins present as well as the specific role of P. gingivalis, the pres­
ence of HLA-DRB1 shared epitope alleles and the role of auto-antibody producing 






I n  many ways periodontitis is a unique form of infection. A mineralized structure 
(the tooth) pierces through epithelium into the oral cavity, exposing part of the 
tooth to outside influences, while another part is embedded in connective tissue. 
Bacteria colonize the tooth surface. Unlike epithelial surface areas of the human 
body, no shedding of the surface takes place, making the tooth a stable surface 
area. The tooth surface knows no blood supply, hindering an adequate defense 
against microorganisms. To make matters worse, bacteria that colonize the tooth 
surface are organized in a biofilm, a microenvironment that promotes accumula­
tion and proliferation of bacteria. The biofilm is fairly insensitive to external influ­
ences. This biofilm in turn stands in direct contact with the periodontal pocket 
epithelium. Thus, periodontitis is a form of chronic infection and inflammation 
that may be particularly suited to contribute to the development or deterioration 
of other diseases. 
Since it is the chronic low-grade infection and inflammation associated with 
periodontitis that is thought to pose a threat to overall health, the periodontal in­
flamed surface area (PISA) appears the best way to define and quantify periodonti­
tis as a risk factor for other diseases. It's usage additionally carries the advantages 
of being able to show patients the size of the wound that lies hidden beneath their 
gums, thus potentially aiding in treatment motivation. 
Most diseases have a multifactorial etiology, meaning that there is more than 
one cause for the emergence of the disease. Although periodontitis should not 
be regarded as the main cause of other physical ailments, the chronic low-grade 
infection and inflammation associated with periodontitis are thought to constitute 
a risk factor for overall health, at least for patients with DM2 and potentially for 
patients with RA. 
Part of the observed association between periodontitis and other diseases may 
be the result of confounding. Rather than a risk factor, periodontitis should be 
considered as a risk indicator of such diseases. It is important to recognize that 
diseases cluster together, interact and share common risk factors. Such pattern 
recognition can aid in the prevention and cure of diseases and may promote both 
oral and overall health of our patients. In an age of increasing super specialization 
of both dentists and physicians, we should not loose sight of the forest called pa­
tient in favour of the trees, branches and leaves. The mouth is an integral part of 
the human body and the strict demarcation between the work of medical doctors 
and dentists in this context is unfortunate. The future could see an intensive col­
laboration between medical doctors and dentists taking place, although for some 




" Wie aan de men sen geen dank betoont, betoont geen dank aan God" . 
-Profeet Mohamed-
Voor wie in mij geloofden toen het geloof mij in mezelf ontbrak 
En die naar mijn voeten keken, als mijn hoofd weer in de wolken stak. 
Wauw, hier zit ik dan te typen, hier is dan het moment. Ongelofelijk maar waar, 
het zit erop, het is achter de rug, het is gebeurd, yes! Godzijdank, het proefschrift 
is af ! 
Dit boekje was er nooit gekomen als ik niet de hulp en steun had gehad van 
vele mensen die ik hier allen wil bedanken (ook als ze hier niet bij naam zijn 
genoemd, vergeef mij). Niet alleen wil ik de mensen bedanken voor hun hulp en 
steun, oak voor hun gezelschap en de manier waarop we deze route samen heb­
ben bewandeld. Soms vind je onderweg iets mooiers dan je reisdoel, ik ben blij 
dat ik jullie gevonden heb. 
Geachte prof. dr. Vissink, beste Arjan, betrouwbare, hardwerkende en zacht­
moedige 1 e  promotor, dank voor alles! Zonder jou geen proefschrift. Je mailt snel­
ler dan je schaduw, legde de lat hoog, maar gaf oak het duwtje om me eroverheen 
te helpen. Je bent een absolute top onderzoeker, dito onderzoeksbegeleider en 
een integer, fijn mens. Het zou mooi zijn om samen te kunnen blijven werken, 
maar nu eerst even genieten van dit moment. . .  
Geachte prof. dr. Abbas, beste Frank, aimabele 2e promotor. J ij stand aan de 
basis van dit proefschrift. We hebben naast een schitterend verblijf in lndonesie, 
ook vele gesprekken over niet onderzoeksgerelateerde zaken met elkaar gedeeld 
en vaak gelachen. Ook verdroeg je mijn aanhoudend gedram over de definitie 
van parodontitis als risicofactor voor ander ziekten. Je sprak in reactie daarop 
de magische woorden 'wat jij zoekt is eigenlijk een oppervlaktemaat, daarover is 
weleens iets gepubliceerd', waarna P ISA was geboren. Naast de promovendus, 
is dus ook de professor 'entitled to some suffering'. Dank voor jouw geloof en 
vertrouwen in mij! 
Geachte prof. dr. Dijkstra, beste Pieter, onmisbare 3e promotor. Naast je input 
op het vlak van de statistiek, methodologie, en het schrijven, vond ik in jou een 
vriend. We hebben, soms vergezeld door Bernarda en Heleen, gesurft, pannen­
koeken en een wokschotel met zelfgemaakte sambal gegeten, en veel gepraat. 
Misschien wel meer nag dan tijdens die sociale activiteiten, hebben we gelachen 
en plezier gemaakt tijdens het werk, desondanks hebben we kwalitatief en kwan­
titatief fl ink gepiekt. BMW & rctR rule! 
Geachte dr. Spijkervet, beste Fred, managing co-promotor. Met jouw kennis en 
kunde op gebied van de parodontitis en oral medicine was je natuurlijk de ideale 
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co-promoter bij dit project. Daarnaast heb ik geprofiteerd van jouw managers­
kwaliteiten. Dank voor je steun en het feit dat je me op koers wist te houden. 
Geachte prof. dr. de Bont, zonder u niet alleen geen proefschrift, maar ook 
voor mij vermoedelijk geen studie Tandheelkunde, en geen opleiding tot kaak­
chirurg. lk ben u zondermeer veel dank verschuldigd. U heeft een afdeling vorm 
gegeven met toppers op klinisch-, onderzoeks- en onderwijsgebied. Daarnaast 
heeft u ervoor gezorgd dat er een prettige sfeer heerst, waarin mensen zichzelf 
kunnen zijn en zich slechts hoeven te conformeren aan het feit dat zij in dit vak­
gebied hun stinkende best doen om bij te top te blijven horen. 
Drg Susanto, Dear Hendri, I am happy to have met you! You've managed to 
find the switch to "Dutch mode" and we've worked together succesfully on many 
papers. I am happy to hear you'll soon be defending your PhD-thesis. Best of 
wishes for you and your family, we'll stay in touch! 
Prof. Widowati & dr. Agustina, Dear Bu Bundi and Bu Dewi and the oral me­
dicine department of Gadjah Mada University, thank you all for your kindness, 
hospitality and collaboration! 
Geachte dr. Brouwer, beste Liesbeth, fijn dat je het zag zitten om met het toch 
wat vreemde onderwerp van de link tussen parodontitis en reumato'ide artritis 
samen aan de slag te gaan. Dank voor je kennis en kunde, je bedachtzame overwe­
gingen en de bijzonder fijne samenwerking. Heel veel succes met het onderzoek! 
Geachte dr. Westra, beste Hannie, het is fijn om in een team van denkers ook 
een denker te hebben die doet, die weet door te pakken. Dank voor de berg werk 
die je hebt verzet, je doortastendheid en de fijne samenwerking. Ook jij veel suc­
ces met het onderzoek! 
Geachte dr Huddleston Slater, beste James, dank voor je sympathieke onbaat­
zuchtige hulp bij het aan de praat krijgen van CMA en voor je adviezen bij het 
schrijven van de meta-analyse. 
Geachte dr. Van der Wal, beste Jacqueline, dank voor je expertise op patho­
logisch vlak. Het was vaak nuttig en gezellig achter de microscoop, zelfs als we 
letterlijk en figuurlijk volledig waren uitgeteld. 
Beste Berber, hartstikke fijn dat je zoveel van het labwerk voor je rekening het 
genomen, super! 
Geachte dr. Stokman, beste Monique, bedankt voor de gezelligheid en de fijne 
samenwerking. Beste Carla, jij natuurlijk evenzo bedankt! Jullie vormden een fijn 
duo om mee samen te werken op het gebied van parodontitis en Sjogren, een 
publicatie die wellicht nog in het verschiet licht. Wij zien elkaar nog! 
Geachte drs. Stijger, beste Astrid, dank dat we de vruchten mochten plukken 
van jouw nauwgezette protocollaire manier van werken door bij elke patient stan­
daard een DPS I  en gezondheidsvragenlijst te hanteren. Dank ben ik ook verschul­
digd aan je collegae die het verzamelen van de gegevens vergemakkelijkten. 
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Geachte dr. Tromp en dr. van Dijk, beste Jan en Johan, en natuurlijk alle andere 
PPG-ers, dank voor de fijne samenwerking! Jullie puike gestructureerde wijze van 
werken en het feit dat ik met mijn laptopje altijd welkom was, hebben eraan bijge­
dragen dat we een schat aan onderzoeksinformatie konden verzamelen en, zij het 
wat later dan gepland, ook nog een mooie studie wisten te pub liceren. 
Geachte collegae Hoedemaker en Huijser van Reenen, beste Eef en Yf, dank 
voor al jullie werk. Jullie waren een stel geweldige ambassadrices ter bevordering 
van de samenwerking met lndonesie. 
Ids van der Ploeg, Annemiek Linde, Karin Prins, Marjan Oldenburger, Kim 
Veenbrink, Korien van der Burg en Andy Laaning: dank voor jullie bijdragen aan 
het verzamelen van de vele onderzoeksgegevens in dit proefschrift, het schrijven 
van scripties en de prettige samenwerking. 
Prof. Taylor, dear George and dr. Iwasaki, dear Masanori, Thank you very much 
for your emails and the request for a collaboration. An honour which we really 
enjoyed! 
Geachte prof. dr. Kallenberg en prof. dr. Loos, dank voor het plaatsnemen in 
de leescommissie, erg fijn. 
Geachte prof. dr. van Winkelhoff, beste Arie Jan, dank voor het plaatsnemen in 
de leescommissie en de prettige samenwerking. Heel veel succes met het voort­
zetten van de parodontitis en reumato"ide artritis onderzoekslijn! 
Beste Menke, ik wens jou veel succes en plezier toe bij het verder voortzetten 
van de parodontitis en reumato"ide artritis onderzoekslijn. 
Anne, jij kan als geen ander zo heerlijk droog uit de hoek komen. Ook op het 
voetbalveld ken ik je inmiddels als betrouwbare wat stokijnse voetballer die met 
een hard droog schot kan scoren. Veel succes met de laatste loodjes, ik hoop nog 
lang met je samen te mogen werken! 
Madelon, kopjes koffie, bijpraten over de kids en een beetje filosoferen over 
het leven, om daarna weer met frisse energie aan het werk te gaan. Jammer dat 
we nu geen kamer meer zullen delen. Maar we zien elkaar nu gelukkig weer be­
neden. 
Prof. dr. Roodenburg, u stond aan de wieg van mijn opleiding doordat ik bij 
u mijn scriptie mocht schrijven. Dank voor uw vertrouwen, uw immer luisterend 
oor en uw vaderlijke adviezen. 
Beste Aarnoud, dank dat jij mijn scriptie wilde begeleiden en voor het voor 
mij ongeevenaarde succes dat we kenden doordat ons artikel zonder een enkele 
wijziging werd geaccepteerd (geen punt of komma). Misschien dat we nog eens 
serieus moeten kijken naar de relatie parodontitis en slaapapneu ... 
Prof. dr. Bos, beste Ruud, jouw enthousiasme tijdens een van de colleges tij­
dens mijn Geneeskunde studie was mede aanleiding om het vak van kaakchirurg 
serieus te overwegen, ik hoop dat je nog veel mensen zal enthousiasmeren. 
Jan en Jeroen de Graaf. Dank voor jullie steun voor wat betreft het opzetten en 
onderhouden van de website www.parsprototo.info / www.mondgezondheid.info 
die van over de hele wereld bezoekers trekt! 
Beste Saar, dank dat je hier een mooi boekje van hebt weten te maken. 
Harrie, Lisa, Karin en Nienke, ontzettend bedankt voor alle gezelligheid, alle 
hulp en ondersteuning op gebied van organisatie en ICT. lk blijf bij jullie langs 
lopen met de vraag: "kun jij voor mij .. .?" of gewoon voor een gezellig gesprek. 
Alie medeonderzoekers, maar in het bijzonder Susan, Rodney-a.k.a. King of 
Prussia a.k.a. the research pimp, Petra, Nico, Lucas, Sebastiaan, Ferdinant, be­
dankt voor de gezelligheid en de team spirit. 
Geachte dr. Schepman en dr. Jansma, Beste Kees-Pieter en Johan, dank dat 
jullie de start van mijn opleiding tot kaakchirurg wilde begeleiden. Jullie zijn een 
stel sympathieke, benaderbare opleiders. 
Geachte prof. dr. Stegenga, beste Boudewijn. Dank voor jouw vermogens op te 
leiden, te beschouwen en te relativeren. Dank voor je steun. 
Michiel Doff, met je volslagen ongepaste grappen arsenaal lagen we vaak in 
een deuk van het lachen. Fijne bijkomstigheid is dat jij bijna net zo hard om je 
eigen grappen kunt lachen als ik. lk hoop dat we in de toekomst verder samen 
mogen werken. 
Geachte Dr. Schortinghuis, Beste Jurjen, dank voor de tijd in Emmen! 
Gijs, Kristien, Roderick, Rutger, Alies, Maaike en alle andere collega's dank 
voor de gezelligheid en de wiChirpedia functie die jullie vervullen. 
Jurrijn-making a mountain look small- Kleinbergen en Jolanda-Kammie- Kam­
stra. Jullie spelen er een grote rol in dat mijn start aan de specialisatie tot kaakchi­
rurg met zoveel plezier gepaard is gegaan. Let's keep rocking! 
Geachte dr. Giel kens en dr. Krabbe, beste Pep en Chris, als directe voorgangers 
waren jullie ook voorbeelden waaraan wij ons konden spiegelen. Dank voor jullie 
adviezen en steun. 
Geachte dr. van Minnen, beste Baucke, jouw woorden in de trant van "ach dat 
heb ik ook weleens gehad, komt allemaal goed", stelden mij vaak gerust en heb­
ben me erg geholpen. 
Beste mensen van ' beneden'; het management, de administratie en last but 
not least alle assistenten, bedankt voor de fijne werksfeer! 
Beste Geert, Menno, Tjalling, Jules en Jurjan, mooi om nog een club van de 
middelbare school te hebben waarmee we tenminste eens per jaar elkaar probe­
ren van het bord te rammen met risk, schaak, en onderwijl vernemen hoe het de 
ander is vergaan het afgelopen jaar (minder belangrijk dan winnen). 
Beste dr. Stoutenbeek, Remco en dr. Sjauw, Krischan (meeegic) en Alex, tijd 
verspelen krijgt bij jullie een geheel andere dimensie. Het was een genoegen om 
samen vele potjes magic te spelen, nu ook ik straks hopelijk dr. zal zijn kunnen 
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we het spel wellicht naar nieuwe hoogten tillen. 
Beste Rienk "Pienkeman" en Frikke "Brussel-Catania!", als studievrienden heb­
ben jullie veel te lijden gehad onder het schrijven van dit proefschrift. Mannen, 
vergeef mij. Het wordt tijd om weer wat meer samen te ondernemen. 
Beste Salih, Elias, Hamid, Said, Khalid en Fouad. Om naast ons werk en onze 
gezinnen nog tijd te vinden om in deze tijd een moskee met 30 nationaliteiten te 
besturen, was geen sinecure. Toch ben ik trots op wat we hebben bereikt en dat ik 
dit werk samen met jullie mocht doen. Hier ligt het excuus voor mijn afwezigheid 
de laatste maanden. Het wordt tijd om weer eens wat gezelligs te doen. 
Geachte dr. Meijer, Lieve Jiska, als jonge dokters begonnen wij aan de studie 
Tandheelkunde. Kijk ons nu, arts, tandarts, en doctor (tenminste, als alles goed 
gaat). Wij hebben samen veel plezier gedeeld en als het even pittig werd, samen 
ook de last gedragen. Nu nog samen kaakchirurg worden! l k  ben blij dat jij van­
daag mijn paranimf wilt zijn. 
Lieve Erik, van de Drait, het Drachtster Lyceum en de RuG, tot werkende man­
nen. Als je elkaar vanaf de basisschool tot nu kent, dan kun je in elkaar zien waar 
de jongen van toen tot uitgegroeid is, en waar hij jongen is gebleven. Jij bent een 
echte vriend! 
Lieve Wobbe, Jacinta, Job en Adam, het is heerlijk om met gelijkgestemden zo 
af en toe een week een vakantiehuisje te bemannen en te doen waar je zin in hebt. 
Ook van een half dagje laden wij onze batterij weer helemaal op. 
Lieve hajj Omar, dank voor al je moeite om ons allen mensen te maken die 
zich vredig overgeven aan God. Dank voor je zachtmoedige leiding en je vriend­
schap. 
Dear Gafoor. Thank you for your faith, your wisdom, your love and your gui­
dance. 
Lieve familie, Daphne, Marian, Marita, Co, Wieb, Anneke, Barend, Froukje, 
Patrick, Bart, Martha, Bram, Helene, Peter, Zor, Yara en Finn, ik had het slechter 
kunnen treffen (da's Gronings voor: jullie zijn fantastisch!) 
Lieve Cor, als broers groeiden we op in de zelfde buik en onder hetzelfde dak, 
werden we op dezelfde instituten geschoold en hielden we van dezelfde voetbal­
club (dat laatste is vooral samen huilen op het moment, want 'ze staan in het 
rechter rijtje' ). Broertje, ik ben zo trots op jou en ben blij dat jij mij, als broer, 
psycholoog en paranimf bij wilt staan. 
Lieve Paula, als schoonmama was je een onverzettelijke bron van hulp, met 
Moesa is dat bepaald niet minder geworden. Je bent een super lieve (schoon) 
moeder en een geweldige oma, ik hoop dat we nog lang van elkaar mogen ge­
nieten. 
Lieve papa en mama. Zonder jullie zou ik niet bestaan. Voor jullie onvoorwaar­
delijke liefde kan ik jullie nooit genoeg bedanken. Hoe jullie leefden heeft mij 
opgevoed. Nu ik zelf vader ben, heb ik nog meer respect voor jullie. Het is een 
voorrecht om jullie wekelijks als opa en oma te zien opereren. lk houd van jullie. 
Liefste Heleen, liefde van mijn leven. Bij wie anders voel ik me zo thuis, op wie 
anders zou ik telkens weer opnieuw verliefd kunnen worden en wie anders zou ik 
de schuld moeten geven als ik zelf weer eens iets kwijt heb gemaakt? Misschien 
ben jij wel meer opgelucht dan ik dat dit boekje nu eindelijk af is. Heleen, mijn 
mooiste cadeautje van Allah, jij bent met recht mijn liefste, ik kan niet wachten 
tot we 7 mei gaan trouwen. 
Lieve Moesa. Jongen wat zijn papa en mama blij met jou; warm, vrolijk, cha­
rismatisch, dominant, slim en mooi mannetje. Je bent een wonder, een geschenk 
voor ons en een aanwinst voor deze wereld. Papa houdt zoveel van jou. 
Lieve God, bedankt voor het leven en voor alle lieve mensen om mij heen. 
Vergeef ons, leid ons en maak ons leven makkelijk. 
I 
Samenva tting  voor leken 
Er i s  steeds meer reden om aan te nemen dat parodontitis (tandvleesontsteking) , 
naast de mondgezondheid, ook de algehele gezondheid negatief kan be"invloeden. Pa­
rodontitis vormt een zwerend wondoppervlak dat de wortel s  van de tanden volgt. Hoe 
groter het door parodontitis veroorzaakte wondoppervlak i s ,  hoe groter de kans dat 
bacterien en ontsteki ngsmediatoren d ie  bij parodontit is betrokken zij n ,  de bloedbaan 
betreden en elders i n  het l ichaam voor gezondheidsproblemen zorgen. 
De belangrij kste bevind ingen in  d it proefsch rift wijzen erop d at parodontitis patienten 
vaker d iabetes mel l itus (su ikerziekte, DM) en reumato'ide a rtritis (gewrichts reuma, 
RA) hebben dan mensen zonder parodontit is . Om de ontstekingslast die door pa­
rodontit is wordt veroorzaakt i n  kaart te brengen, werd een methode ontwikkeld d ie  
als eerste de grootte van het door parodontitis veroorzaakte wondoppervlak i n  kaart 
brengt, het 'periodonta l i nflamed surface a rea' (P ISA) . Bij toepass ing h iervan in een 
drietal stud ies in d it proefsch rift bleek dat DM patienten een grotere P I SA hebben en 
dat een grotere P ISA gerelateerd is  aan hogere bloedsu i kersp iegels .  Kortom, hoe ern­
stiger de parodontitis ,  hoe slechter de b loedsu ikerregu latie. Tot s lot bleek u it een twee­
tal stud ies dat patienten met RA 6 tot 13 keer vaker parodontiti s hebben dan mensen 
zonder RA, dat behandel ing van parodontitis de ziekte activiteit van RA kan verlagen 
en dat bij parodontitis gecitru l l i neerde eiwitten worden gevormd die mogel ij k  een ro l 
kunnen spelen i n  de etiologie van RA. 
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